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ABSTRACT
Malignant mesothelioma (MM) is a rare tumor associated with occupational
exposure to asbestos with no effective treatment regime. Evaluation of mitochondrial
function in human MM cell lines revealed a common tumor phenotype: in comparison to
immortalized or primary human mesothelial cells, MM tumor cells displayed a more
oxidized mitochondrial environment, increased expression of mitochondrial antioxidant
enzymes, and altered mitochondrial metabolism. Earlier work by our laboratory indicated
that increases in mitochondrial reactive oxygen species (mROS) in MM cell lines
supports expression of FOXM1, an oncogenic transcription factor that contributes to
increased cell proliferation and chemoresistance. These studies sought to investigate
targeting of mitochondrial structure and function as a therapeutic avenue in MM.
MM cells have reduced mitochondrial reserve capacity, a redox vulnerability
exploitable by pro-oxidant therapeutics. Targeting of the mitochondrial peroxidase
peroxiredoxin 3 (PRX3) with the anti-cancer compound thiostrepton (TS) induces
irreversible modifications to PRX3 protein, increased mROS, and selective MM cell
death. Mass spectrometry showed TS targets conserved cysteine residues in PRX3. In
vitro and in MM cells, TS failed to modify human PRX3 harboring mutations to Cys108,
Cys127 or Cys229. Pre-incubation of MM cells with dimedone blocked cysteine
adduction of PRX3 by TS, suggesting adduction requires an active PRX3 catalytic cycle.
Studies with immortalized and primary human mesothelial cells showed adduction of
PRX3 by TS occurred at a much lower rate in normal cells than MM cells, and this
difference correlated with markedly decreased cytotoxicity. Moreover, MM cells
transduced with shRNA to PRX3 grew more slowly and were less sensitive to TS than
their wild type counterparts, indicating PRX3 is a major target of TS in MM cells.
Studies with a xenoplant mouse model of MM showed TS alone or in combination with
the TRX2 inhibitor gentian violet significantly reduced tumor volume.
Tumor cell mitochondria have an increased mitochondrial membrane potential,
therefore numerous drugs have been developed that selectively accumulatte into
energized mitochondria to enhance drug efficacy and specificity. Here two
mitochondrial-targeted nitroxides, Mito-carboxy-proxyl (MCP) and Mito-TEMPOL
(MT), were investigated for their anti-cancer effects. Treatment of MM cells with MCP
or MT led to rapid disruption of the mitochondrial reticulum, increased oxidant levels,
and reduced FOXM1 and PRX3 protein expression. Immunostaining revealed a pool of
cytoplasmic FOXM1 associated with PRX3 in mitochondria, suggesting PRX3
participates in regulating FOXM1 expression. Combination of MCP or MT with TS led
to synergistic effects on MM cell viability.
Upregulation of mitochondrial antioxidant enzymes is an adaptive response that
ameliorates mitochondrial oxidative stress and supports tumor cell survival. Studies here
indicate that enhanced dependency on the PRX3 catalytic cycle in tumor cells promotes
inactivation of PRX3 by TS, providing a therapeutic window dependent on a
mitochondrial phenotype common to many human tumor types. Therefore TS, alone or
in combination with other agents, may prove useful in the management of intractable
tumors such as MM.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW

1.1 Reactive oxygen species (ROS) production and metabolism

ROS are intracellular signaling molecules
Reactive oxygen species (ROS) are a group of molecules derived from
molecular oxygen that include radical (superoxide, hydroxyl radical), and non-radical
(hydrogen peroxide) forms (Finkel, 2003; Halliwell & Gutteridge, 1984). ROS, which
were first shown to have damaging effects on cellular macromolecules, have now been
shown to function as intracellular signaling molecules (Rhee, 2006). ROS regulate
cellular physiology, either through direct oxidation of cysteine residues in target proteins
or inactivation of resident scavenger/chaperone proteins, leading to increased local
oxidant levels in various subcellular compartments (Jones, 2010). Specific, structurally
distinct and solvent accessible cysteine residues are targets for oxidation by hydrogen
peroxide (H2O2), modifications that result in structural and functional changes in target
proteins (Reddie & Carroll, 2008). Newly developed technical approaches have allowed
for the identification of hundreds of proteins whose activity could be regulated through
cysteine redox modifications (Fomenko, Xing, Adair, Thomas, & Gladyshev, 2007;
Weerapana et al., 2010). Physiochemical characteristics of cysteine residues in target
proteins underlie the specificity and hierarchy of responses in redox signaling. The
production and metabolism of ROS by intracellular sources also is spatially and
temporally controlled in the cell, increasing specificity of ROS mediated signaling events
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(Go & Jones, 2008). Therefore cellular signals are transmitted through local and temporal
changes in ROS levels dictated by production and metabolism of specific ROS species.
Cellular sources of ROS
The numerous intra- and extracellular sources of ROS that contribute to cellular
physiology and pathophysiology have been reviewed extensively elsewhere (Halliwell,
1991). In the context of cancer, NADPH oxidases (Lambeth, 2004) and the mitochondrial
electron transport chain (ETC) (Figueira et al., 2013; Y. Liu, Fiskum, & Schubert, 2002)
are important ROS sources that contribute to the pathogenesis of cancer as well as many
other diseases (Weinberg & Chandel, 2009). The production of ROS from these sources
is tightly regulated by a myriad of cellular processes that include protein expression, posttranslation regulation, metabolic programming, and cell signaling pathways (Ray, Huang,
& Tsuji, 2012). In cancer, altered production and/or metabolism of ROS support the
genesis and progression of the disease, as well as resistance to many chemotherapeutic
drugs. However, increased oxidative stress may prove to be the Achilles heel of tumor
cells, for in many contexts promoting super physiological levels of oxidative stress has
shown to selectively kill tumor cells without damaging their normal counterparts
(Wondrak, 2009).
NADPH Oxidases
NADPH oxidases (NOXs) are a seven-member family (Nox 1-5 and Duox 1/2)
of six pass transmembrane enzymes that transfer electrons from NADH or NADPH to
molecular oxygen leading to the formation of superoxide (NOX 1-3 and 5) or hydrogen
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peroxide (NOX4, DUOX 1/2). Regulation of NOX activity is multifaceted, requiring
assembly of complexes that include regulatory proteins (as for NOX 1, 2 and 3, DUOX
1/2), changes in expression levels (primarily NOX4), and activation by calcium (NOX5,
DUOX 1/2) to activate each specific NOX enzyme (Lambeth, 2004) (Figure 1.1). The
expression levels of NOXs vary in tissues as well as in certain disease states. NOX2,
localized in the plasma membrane and enriched in phagocytic membrane structures, is
lost in patients with chronic granulomas disease leaving them unable to clear microbial
infections (Segal, 1996). NOX 1 and 4 have been implicated in lung (Hecker et al., 2009)
and cardiac disease (Brandes, Weissmann, & Schroder, 2010), and cancer (Lambeth,
2004). The production of ROS from NOXs has been shown to increase cell proliferation
(Brar et al., 2002), induce epithelial to mesenchymal transition (F. Liu, Gomez Garcia, &
Meyskens, 2012), and support angiogenesis (Arbiser et al., 2002), prominent signatures
of tumor progression. Interestingly, NOX4 has been identified in the mitochondria of
numerous cells types (Kuroda et al., 2010) contributing to numerous disease states. NOX
activity can be indirectly regulated by mitochondrial oxidants, through small GTPases,
implicating a cross talk mechanism of regulation that links mitochondrial function to
NOX activity (Lee et al., 2006).
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Figure 1.1 NADPH oxidase enzymes in mammalian cells. NADPH oxidases
(NOX) enzymes are a seven-member family of transmembrane proteins that
produce superoxide (O 2 -) and H2O2 by passing electrons of NADPH or NADH
to molecular oxygen. Figure taken from Bedard and Krause et al. (2007) with
permission from the American Physiological Society.

Mitochondria
Mitochondria are cellular organelles responsible for producing the majority of
cellular adenosine triphosphate (ATP), the primary molecule used for chemical energy in
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the cell. Mitochondria also function as retrograde signaling hubs that regulate nuclear
gene expression, buffer intracellular calcium stores, and produce reactive oxygen species
(ROS). ROS produced by mitochondria, as a byproduct of aerobic respiration, recently
have been shown to regulate cellular signaling pathways important in numerous aspects
of cell biology (Figure 1.2)(Yun & Finkel, 2014). The electron transport chain (ETC),
located in the inner mitochondrial membrane, is comprised of 4 membrane bound protein
complexes (complexes 1-4) that transfer electrons from NADH to the final electron donor
oxygen, while subsequently pumping hydrogen ions from the matrix across the inner
membrane to the inter-membrane space to produce a electrochemical gradient that drives
ATP production by ATP synthase (Complex 5). The ETC complexes are arranged
spatially in order of their redox potentials. The transfer of electrons between complexes
is not confined to a closed system, as thermodynamically all ETC complexes could
effectively reduce molecular oxygen (Y. Liu et al., 2002). Electrons derived from ETC
complexes I and III, react readily with molecular oxygen to form superoxide in the
mitochondrial matrix and the inner membrane space, respectively (Hamanaka & Chandel,
2010). The two primary sites for producing superoxide in the ETC are the flavin
mononucleotide (FMN) group of complex I and the ubiquinone of complex III (Y. Liu et
al., 2002). Although considerable debate concerning the most relevant site for ROS
production exists in the literature, both sites likely are biologically relevant ROS
producing entities (Jones, 2010; Y. Liu et al., 2002; Sena & Chandel, 2012). Metabolic
alterations in glycolysis, the pentose phosphate pathway and B-oxidation of fatty acids
dictate substrate availability to the mitochondrial ETC, and contribute to fluctuations in
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ROS production. Post-translational modifications that include phosphorylation,
nitrosation and glutathionylation of ETC complexes further dictates electron flow and
subsequent ROS production (Figure 1.2) (Nickel, Kohlhaas, & Maack, 2014).
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Figure 1.2. Mitochondrial ETC and ROS dictate cellular outcomes. Electrons are
passed from NADH through the electron transport chain (ETC) complexes I-IV, where
molecular oxygen is reduced to water. Hydrogen ions are successively pumped from the
matrix to the inner membrane space (IMS) creating an electrochemical gradient that
drives ATP production at ATP synthase (complex V). Electrons from FADH 2 can enter
the ETC at complex II and are transferred to co-enzyme Q (Q) and either passed to
complex III or moved backwards by reverse electron transport (RET). Electron leakage
leads to incomplete reduction of molecular oxygen and formation of superoxide (O 2 -)
which is spontaneously or enzymatically (SOD2) dismutated to hydrogen peroxide
(H2O2). Hydrogen peroxide that is not metabolized by peroxiredoxin 3 (PRX3) can
participate in redox dependent signaling events that dictate cellular outcomes through the
regulation of transcription factors (TF), kinases (KN), and retrograde signaling events
regulating gene expression in the nucleus (Nuc). Mitochondrial membranes associate
with the endoplasmic reticulum (ER) where signals and metabolites are exchanged to
regulate cellular function. OMM: outer mitochondrial membrane; IMM: inner
mitochondrial membrane; IMS: inner membrane space.
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The production of ROS by mitochondria has long been characterized as an
unwanted byproduct of aerobic respiration. This “necessary evil” accounts for 1 -2% of
total oxygen consumed by mitochondria (Balaban, Nemoto, & Finkel, 2005), and this
ROS is metabolized efficiently under normal conditions. Only when mitochondria
become metabolically inefficient do ROS levels increase and lead to cellular damage.
Recent advancements have put the concept of “necessary evil” largely to rest and begun
to shed light on the defined roles of mitochondrial oxidants in normal cell physiology.
Mitochondrial oxidant production is now considered as a cellular signaling hub that
participates in regulation of cytosolic kinases (Kamata et al., 2005), T cell activation
(Sena et al., 2013), mitohormesis (Schulz et al., 2007), adipocyte maturation (Huh et al.,
2012), inflammasome activation (Bauernfeind et al., 2011; Zhou, Yazdi, Menu, &
Tschopp, 2011), and disease onset through altered signaling pathways (Figueira et al.,
2013).
Mitochondrial ROS metabolism
Given the damaging effects of ROS on cellular macromolecules, numerous
cellular systems are in place to detoxify ROS.

The mitochondrion is a

compartmentalized source of ROS production and as such has its own specialized set of
antioxidant constituents. Mitochondria contain their own pool of non-enzymatic
antioxidants including glutathione (GSH), ascorbate (Vitamin C), and tocopherols
(Vitamin E), as well as enzymatic antioxidants (Yin, Sancheti, & Cadenas, 2012).
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Manganese containing superoxide dismutase (Mn-SOD2), glutathione peroxidase 1 and 4
(Gpx1 and Gpx4) and the thioredoxin reductase 2 (TR2)-thioredoxin 2 (TRX2)peroxiredoxin 3 (PRX3) antioxidant network all reside in the mitochondria and contribute
to maintaining the redox balance (Yin et al., 2012). Given that the TR2-TRX2-PRX3
pathway is responsible for metabolizing up to 90% of mitochondrial H 2O2 (Cox,
Winterbourn, & Hampton, 2010) it will be focused on in more detail below (Figure 1.3).
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Figure 1.3. Peroxiredoxin 3 catalytic cycle and regeneration by
thioredoxin. A) PRX3 is localized to the mitochondrial matrix by an Nterminal leader sequence that is removed upon entry into the matrix. The
peroxidatic cysteine 108 and the resolving cysteine 229 participate in the
metabolism of hydrogen peroxide (H 2O2 ). Cysteine 127 does not
participate in catalysis. B) Schematic of the PRX3 reaction cycle
involving oxidation of Cys 108 to sulfenic acid (-SOH) by H2O2,
spontaneous disulfide bond formation between Cys 108 and Cys 229 on
adjacent homodimers, and reduction by thioredoxin 2 (TRX2). Under
high levels of oxidative stress the SOH of PRX3 is further oxidized to
sulfenic acid, a process termed hyperoxidation, which inactivates the
enzyme until retro-reduction by sulfiredoxin using ATP.

Thioredoxin Reductase
Mammalian thioredoxin reductases (TR1-3) are a family of homodimeric
oxidoreductases that contain the rare amino acid selenocysteine (Sec, U) in the Cterminal catalytic center (Bock et al., 1991; Gladyshev, Jeang, & Stadtman, 1996). The
presence of selenocysteine instead of cysteine in the C-terminal redox center renders
mammalian TR insensitive to inactivation from oxidants (Snider et al., 2013). Each
subunit of the dimer contains a FAD prosthetic group that uses NADPH as the source of
hydride in the reduction mechanism (Mustacich & Powis, 2000). TRs function as the
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only known reductant of thioredoxin (TRX), which has numerous downstream substrates
including ribonucleotide reductase, methionine sulfoxide reductase, protein disulfide
isomerase, various transcription factors, and peroxiredoxins (Holmgren & Lu, 2010).
TR1 is found primarily in the cytoplasm while splice variants have also been detected in
the nuclear compartment (Damdimopoulos et al.,2007). TR2 is highly similar to TR1,
with the addition of a 33 amino acid sequence to the N-terminus that is responsible for
localized targeting of TR2 to the mitochondria (Miranda-Vizuete et al., 1999) . TR 1 and
2 have been implicated in redox dependent signaling and may play a role in contributing
to redox dependent disease progression (Sun & Gladyshev, 2002; Sun et al., 1999). Of
note, TR 1 and 2 have been found overexpressed in many cancers, including malignant
mesothelioma cells (Newick et al., 2012), and may play a prominent role in protecting
cancer cells from oxidant induced senescence and apoptosis (Lu, Chew, & Holmgren,
2007). Inhibitors of TR including selenite and the gold compound Auranofin reduce
cancer cell growth and induce apoptosis (Marzano et al., 2007), indicating TRs and
cellular redox status are potential targets for cancer therapy.

Thioredoxins
Thioredoxins (TRX) are a class of approximately 12 kD oxidoreductases that
function to maintain a wide variety of substrates in a reduced state under basal cellular
conditions and contain redox dependent chaperone properties (Holmgren & Lu, 2010).
The active site of TRX (Cys-Gly-Pro-Cys) is conserved throughout all kingdoms of life
and is crucial for its antioxidant defense (Eklund, Gleason, & Holmgren, 1991).
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Cytosolic/nuclear TRX1 and mitochondrial TRX2 regulate numerous metabolic
pathways, protect cells from oxidant induced damage and apoptosis, and contribute to the
progression and survival of cancer (Holmgren & Lu, 2010).
The mechanism of disulfide reduction by TRX consists of 3 steps: 1) noncovalent binding of TRX to the target protein, catalyzed by a hydrophobic surface near
the active site. 2) nucleophilic attack of the target disulfide by the N-terminal thiolate of
TRX forming a mixed disulfide intermediate, and 3) reduction of the disulfide
intermediate by the C-terminal active site thiolate of TRX leaving a reduced target
protein and disulfide bonded TRX active site. TR reduces the active site disulfide of TRX
by using reducing equivalents from NADPH. Structural cysteine residues outside of the
active site have been implicated in regulating the activity of TRXs as well as promoting
conformational changes in the protein; these properties are influenced by hydrogen
bonding during reduction, and alter binding interactions that may disrupt downstream
physiology (Holmgren, 1995).
Peroxiredoxins
Peroxiredoxins (PRXs) are a family of thiol peroxidases whose cellular function
is to metabolize hydrogen peroxide, peroxynitrite, and lipid peroxides (Hall et al., 2009;
Hall et al., 2011). PRXs play a central role in redox signaling, as they are exquisite
sensors of ROS, with a rate constant of 1 x 105 to 1 x 107 M-1 s-1 for metabolizing H 2O2
(Manta et al., 2009; Ogusucu et al., 2007; Parsonage et al., 2005). PRXs act as sensors of
the cellular redox balance and can transmit redox-dependent signals to downstream
substrates, often through direct protein-protein interactions (Kang et al., 2005). There are
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6 PRXs that exist in the cell and these isoforms differ from one another through their
structure, catalysis and subcellular localization. All PRXs share a common first step in
catalysis in which the peroxidatic cysteine attacks a molecule of peroxide (Poole et al.,
2011). The remaining steps of catalysis are what differentiate between the classes of
PRXs.
PRXs 1-4 are classified as “typical 2-Cys” PRXs that exist as obligate head to
tail homodimers. These enzymes utilize a peroxidatic cysteine and a resolving cysteine
(on an opposing monomer) for catalysis (Chae et al., 1994). PRX 1 and 2 are localized to
the cytoplasm, PRX 4 is localized in the endoplasmic reticulum, while PRX3 resides
specifically in the mitochondrial matrix by virtue of a N-terminal mitochondrial
localization sequence (Figure 1.3) (Watabe et al., 1997). During catalysis of H2O2 to
water, the structurally distinct low pKa peroxidatic cysteine attacks one molecule of H2O2
forming a sulfenic acid intermediate; this intermediate spontaneously collapses to form a
disulfide bond with the resolving cysteine on the opposing monomer. Disulfide bond
formation induces local unfolding of the protein complex and changes to the quaternary
structure (Perkins et al., 2013). Thioredoxin 1 (cytoplasm) and thioredoxin 2
(mitochondria) further reduce the PRX disulfide bond back to reduced dimers (Flohe et
al., 2011; Poole et al., 2011). Due to structural motifs that slow disulfide formation with
the resolving cysteine, under high levels of oxidative stress, a second molecule of H 2O2
can react with the sulfenic acid intermediates of PRX 1-4 to form a hyperoxidized
sulfinic acid group (Baker & Poole, 2003; Rabilloud et al., 2002; Yang et al., 2002). The
hyperoxidized form of PRXs, which is typically an irreversible modification in other
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proteins, is regenerated back to reduced dimers through the action of sulfiredoxin (SRX)
in an ATP dependent manner (Biteau et al., 2003). Hyperoxidation results in the
enzymatic inactivation of PRXs, which could result in increased H2 O2 levels that drive
signaling events, the formation of higher molecular weight protein aggregates, or changes
in interactions with regulatory proteins (Barranco-Medina et al., 2009).
PRX 5 is classified as an “atypical 2-Cys” PRX, and functions as a monomer, due
to the peroxidatic and resolving cysteine existing on the same polypeptide. The
peroxidatic and resolving cysteines of PRX5 function in a manner entirely alike to typical
2-Cys PRXs, and the resulting intra-moleuclar disulfide bond is also reduced by
thioredoxin. PRX5 is localized to the mitochondria as well as peroxisomes and the
cytosol (Nelson et al., 2011). PRX 6 is classified as a “1-Cys” PRX because it only
contains the peroxidatic cysteine. After oxidation of the peroxidatic cysteine to sulfenic
acid, glutathione and GST pi form a transient disulfide with PRX 6, leading to the
reduction of the peroxidatic cysteine (Flohe et al., 2011).

PRX 5 and 6 are less

susceptible to hyperoxidation than PRX 1-4 and are not reduced by SRX (Poole et al.,
2011).
H2O2 metabolism by PRXs is controlled through their relative expression levels,
subcellular location, oligomeric state, and posttranslational modifications. The
subcellular distribution of PRXs is important for maintaining a balanced redox state in
the cell, and favors compartmentalized redox signaling as the downstream pathways
affected through PRX oxidation/reduction reactions varies. PRXs form higher molecular
weight (HMW) oligomers that are regulated at least in part by the oxidation states of the
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protein (Barranco-Medina et al., 2009). Reduced decamers are reported as having
increased peroxidase activity, while disassembly to dimers facilitates reduction by the
electron donor (Chang et al., 2002).

HMW oligomers stabilize PRX2 membrane

association in erythrocytes and control the switch from peroxidase to chaperone function
in human cells (Moon et al., 2005). PRX1 can be glutathionylated at 3 different cysteines,
a modification which is increased under oxidative stress (Fratelli et al., 2002; Park et al.,
2009) that disrupts decamer assembly and inactivates chaperone activity (Park et al.,
2011). The phosphorylation of PRX 1 and 2 by the cyclin dependent kinase Cdc2 reduces
the peroxidase activity, and for at least PRX1 plays an important role in cell cycle
progression at mitosis (Chang et al., 2002). Excess PRX3 phosphorylation in neurons
reduces peroxidase activity and increases mitochondrial oxidative stress and dysfunction
(Angeles et al., 2011)

1.2. ROS production and phenotypic response in cancer

ROS in Cell Proliferation

Cell proliferation is a complex coordinated event that consists of intricate
spatially and temporally controlled signaling events required for cell growth, division,
and segregation of intracellular constituents, including mitochondria.

ROS are now

known as vital signaling molecules required from proper cell cycle entry and progression
(Figure 1.4) (Burch & Heintz, 2005; Menon & Goswami, 2007). The spatial regulation of
ROS leads to transient, reversible and compartmentalized signals that alter protein
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structure and function that modulate cell-signaling cascades (Jones, 2010). The dynamic
balance between ROS production and metabolism further adds to the complexity of cell
cycle signaling events as too much ROS leads to cell cycle arrest while lower levels
activate pro-proliferative pathways that support cell growth (Goswami et al., 2000). In
the absence of sufficient levels of ROS cells cannot proliferation (Burch & Heintz, 2005).
Treatment of H4IIEC hepatocytes with 25-50 µM H2O2 for 3 hrs leads to the activation of
Jun-N-terminal kinase (JNK) and phosphorylation of its downstream substrate C-Jun,
accompanied by down regulation of AKT phosphorylation, and reduced proliferation.
Lower concentrations of H2O2 (5-10 µM) increase phosphorylation of AKT, emphasizing
the biphasic nature of redox signaling. This is further evidenced by treatment of NIH3T3
cells with low concentrations of H 2O2 (0.02-0.13 µM), which enhanced cell proliferation,
while higher levels (0.25-2 µM) induced growth arrest and cell death (Laurent et al.,
2005).
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Figure 1.4. Cell cycle entry and progression are regulated by transient increases
in ROS. Growth Factor binding to target receptors activates signaling cascades
that require spatially and temporally controlled ROS from NADPH oxidases and
mitochondria. Inactivation of the lipid phosphatase PTEN leads to prolonged
AKT activation and subsequent Cyclin D1 nuclear entry. ROS levels rise at
G2/M and may support sustained FOXM1 expression regulating mitosis.
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Growth factor signaling leads to compartmentalized increases in H 2O 2 that
contribute to the activation of kinases and inactivation of phosphatases, tipping the
balance toward activation of phosphorylation dependent signaling pathways (Go & Jones,
2008; Jones, 2010). Due to its low pKa (4.5-6) a conserved cysteine in the active site of
protein tyrosine phosphatases (PTPs) is a target of oxidation, making it susceptible to
transient and reversible inactivation by H 2O2 (Lee et al., 1998; Lee et al., 2002; Salmeen
et al., 2003). H2O2 production by NOX1 following binding of growth factors to epidermal
growth factor receptor (EGFR) supports prolonged receptor activation and downstream
RAS/MAPK (Rao, 1996) and PI3K/Akt (Leslie, 2006) signaling events, while
concomitantly inactivating phosphatase and tensin homologue (PTEN) phosphatase
activity (Lee et al., 2002), further sustaining this pro-growth pathway. Protein tyrosine
phosphatase 1B (PTP1B), which negatively regulates EGFR activity, is primarily
localized in the endoplasmic reticulum with its phosphatase domain oriented towards the
cytoplasm (Frangioni et al. 1992). EGF mediated H2O2 production through NOX1 and 4
inactivates PTP1B through oxidation of Cys 215 and correlates with EGFR activation
(Salmeen et al., 2003). Therefore the combined inactivation of PTEN and PTP1B by
H2O2 exacerbates mitogen-activated cell signaling events that support cell proliferation
and survival.
Cellular oxidants increase as cells progress from G1 to M phase, as indicated by
changes in the GSH/GSSG ratio (Mauro et al., 1969), increased oxidant levels measured
at specific cell cycle phases (Cunniff et al., 2013; Goswami et al., 2000), and inhibition of
PRX1 oxidase activity by CDK1 during G2/M transition (Chang et al., 2002). Cell cycle
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entry requires a threshold of oxidants while transient increases in oxidant levels at G1 is
required for the G1 to S phase transition (Menon et al., 2003). Both in HeLa cells and
malignant mesothelioma cells, redox dependent florescent probes show maximal
fluorescence at the later stages of the cell cycle (i.e. S and G2/M) (Cunniff et al., 2013;
Goswami et al., 2000). These changes in oxidant production correlate with observed
decreases in MnSOD2 activity during S phase, which otherwise would disrupt the redox
balance during this cell cycle phase (Li & Oberley, 1998). Bioinformatics studies that
predicted redox-dependent cell cycle proteins identified 92 candidates that could
influence cell cycle progression, and 50% of these redox-motif containing proteins were
associated with the G2/M cell cycle phase (Conour et al., 2004). Of note, the G2/M
transcription factor Forkhead Box M1 (FOXM1) induces the expression of mitochondrial
antioxidant enzymes MnSOD2 and PRX3 (Park et al., 2009) that may counteract
increased G2 oxidant levels during mitotic exit.
Oncogene Induced Senescence
ROS are required for cell cycle entry and progression when levels and
localization are tightly regulated (Burhans & Heintz, 2009; Goswami et al., 2000). As
described above low levels of ROS stimulate growth through modulation of the RASRaf-MEK and AKT signaling pathways, which also are linked to tumor cell growth. In
contrast, high ROS levels induce p38 expression, activate cell cycle checkpoints, and
induce cell cycle arrest leading to senescence or apoptosis (Dolado et al., 2007).
Therefore it is not surprising that p38 is mutated or down regulated in numerous tumors
(Wagner & Nebreda, 2009). Oncogene activation, loss of tumor suppressor function, and
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metabolic reorganization are all import contributors to highly tumorigenic cells. Stepwise transformation is coupled to successive increases in cellular oxidants, proteotoxic
stress, and metabolic adaptation to promote growth and escape apoptotic and senescent
cell fates (Figure 1.5) [4].

Figure 1.5. Stepwise increases in cellular oxidants accompany transformation.
Oncogene activation and cellular transformation increase cellular oxidants in a
stepwise fashion providing a redox vulnerability. Tumor cells must adapt to the
increased levels of ROS to counteract ROS induced senescence and apoptotic
death. Figure taken from Gorrini et al. (2014) with permission from Nature
Publishing Group.
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In the following paragraphs I will address metabolic adaptations, specifically
oncogene induced ROS production and antioxidant detoxification strategies, in the
context of tumor progression.
The requirement for tightly regulated ROS levels is indicated in the ability of
sub-lethal concentrations of H2O2 to induce both proliferation and growth arrest (Laurent
et al., 2005). These endogenously produced signaling molecules are increased during
growth factor mediated signaling to support cell proliferation, albeit in a regulated and
compartmentalized manner (Oakley et al., 2009). Excessive levels and deregulated
temporal rises and falls in ROS slow growth and activate apoptotic pathways. Early
reports showed human fibroblasts expressing oncogenic V12Ras produce excessive
levels of mitochondrial oxidants that induced growth arrest (Lee et al., 1999).
Scavenging of H 2O2 (but not superoxide), and culturing of cells in low oxygen
environment (1%) rescued cells from the V12Ras-induced senescent phenotype (Lee et
al., 1999). Activated Ras leads to the increased expression of the cyclin dependent kinase
inhibitors (CDKIs) p21 and p16, critical negative regulators of cell proliferation (Serrano
et al., 1997). Both concomitant expression of either V12Rac or activated RhoA GTPase
can partially rescue V12Ras induced oncogenic senescence (Lee et al., 1999). This
counterintuitive transformative phenotype indicates there must be further adaptations,
both genetic and phenotypic, to support excessive cellular proliferation (Cairns et al.,
2011; Gorrini et al., 2013).
Mouse embryonic fibroblasts virally infected with oncogenic H-RasV12
produce increased levels of cellular oxidants and have increased expression levels of the
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oncogenic transcription factor Forkhead Box M1 (FOXM1) (Park et al., 2009). FOXM1
is only expressed in proliferating cells, has important functions in cell cycle progression,
and is expressed in a wide variety of human malignancies (Millour et al., 2011) (Myatt &
Lam, 2007; Wierstra, 2013). FOXM1 is a member of the Forkhead Box (FOX) family of
transcription factors that mediate cell growth, proliferation, development, and
differentiation (Table 1). FOX proteins share a conserved winged helix DNA binding
domain but have diverse transcriptional targets due to varying regulatory domains
(Wierstra, 2013). FOXO3a a member of the FOXO subfamily of FOX transcription
factors is considered a tumor suppressor and promotes tumorigenesis when its expression
is reduced. AKT phosphorylates FOXO3a to reduce its transcriptional activity, promoting
its nuclear exit (Myatt & Lam, 2007). FOXM1 and FOXO3a have been proposed to
compete for the same promoter binding sites and both have been shown to regulate
antioxidant gene expression in response to oxidative stress (Lam et al., 2013). FOXM1
therefore could retain the expression of necessary antioxidant proteins needed to combat
oncogene-induced senescence, in the absence of FOXO3a, while simultaneously
promoting un-restrained cell growth.
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Table 2. Targets and biological processes regulated by FOXM1. Table adapted from
Myatt et al., (2007) with permission from Nature Publishing Group.
FOXM1 has been shown to respond directly to changes in the cells redox status
as treatment with H2O2 increased expression whereas the antioxidant TEMPOL decreased
it (Park et al., 2009). Oncogenic induction of FOXM1 expression is required as adaptive
response to combat ROS levels, as siRNA to FOXM1 in H-Ras V12 MEFs reduced cell
proliferation and viability (Park et al., 2009). One important mechanism is that FOXM1
controls the transcript levels for mitochondrial peroxiredoxin 3 and MnSOD2; thereby
counteracting cytostatic mitochondrial ROS levels. Furthermore cells expressing
activated AKT require FOXM1 expression for full tumorigenesis and are addicted to
FOXM1 expression (Park et al., 2009).
The transcription factor, signal transducer and activator of transcription 3 (Stat3)
typically elicits it’s activity on the regulation of transcription in the nucleus (Levy &
Inghirami, 2006). Recent reports have identified a portion of STAT3 that resides in the
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mitochondria (mitoStat3) and functions to regulate electron transport chain activity,
specifically at complex I (Wegrzyn et al., 2009). Transformation of mouse embryonic
fibroblasts (Mefs) requires mitoStat3 and the presence of serine 727 (Gough et al., 2009),
while specific inhibition of mitoStat3 reduces pancreatic cell growth in mice (Mackenzie
et al., 2013). Thus the “moonlighting” activity of STAT3 in the mitochondria plays an
important role in tumor cell survival by regulating ROS levels from the mitochondria to
generate optimal levels of pro-proliferative redox signaling (Zhang et al., 2013).
Antioxidant Adaptations in Cancer
Oncogene

activation,

mitochondrial

DNA

mutations,

and

metabolic

reprogramming during tumorigenesis induce ROS levels above the threshold that
supports growth, and without adaptive compensation, leads to senescence and apoptosis
(Figure 6). Therefore along with increases in oxidant production, changes in antioxidant
gene expression often accompany oncogenic transformation, a cellular adaption to
combat the increased levels of ROS and maintain a pro-proliferative redox state.
(Burhans & Heintz, 2009; Newick et al., 2012; Phalen et al., 2006). Still an understudied
aspect of tumorigenesis, due to the inherent variability of tumor types, tumor
microenvironments, and experimental approaches, a universal antioxidant response has
not been observed in cancer. Below a subset of antioxidant networks that support tumor
cell growth will be addressed in detail.
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Figure 1.6 ROS adaptation in cancer. Oncogene activation and changes in metabolic
profiles in cancer cells leads to excessive ROS levels incompatible with growth.
Metabolic reprogramming and changes in antioxidant gene expression counterbalance
these otherwise toxic molecules to support proliferation and survival. Figure taken from
Cairns et al., (2011) and used with permission from Nature Publishing Group.

Nuclear factor erythroid 2-related factor 2 (NRF2) is considered to be one of the
most important intracellular sensors of oxidative stress and electrophilic compounds
(Sporn & Liby, 2012). NRF2 regulates the transcription of genes involved in the
production, regeneration, and utilization of glutathione (GSH) (Taguchi et al., 2011),
thioredoxin (Chorley et al., 2012), and NADPH (Mitsuishi et al., 2012), as well as
numerous other genes involved in antioxidant and non-antioxidant pathways (Gozzelino
et al., 2010; Kim et al., 2007). NRF2 is normally sequestered in the cytoplasm through
the binding to Kelch-like ECH-associated protein 1 (KEAP1) and is released upon
oxidation of critical cysteines in KEAP 1, allowing NRF2 nuclear entry and binding to
antioxidant response elements/electrophile response elements (ARE/EpRE) in gene
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promoters (Taguchi et al., 2011). Mutations in NRF2 and KEAP1 that support NRF2
stabilization have been found in human tumor samples (Hayes & McMahon, 2009;
Shibata et al., 2008). Oncogenes such as KRAS and MYC have also been implicated in
NRF2 stabilization and NRF2-dependent antioxidant response (DeNicola et al., 2011).
Thioredoxin (TRX) is up-regulated in numerous cancers, including malignant
mesothelioma (MM) where it promotes growth and reduces the incidence of apoptosis
(Kahlos et al., 2001; Mahmood et al., 2013). Increased TRX expression in cancer cells is
a phenotypic adaptation supporting tumor survival rather than an oncogenic driver as
transgenic mice overexpressing TRX1 do not develop cancer at a higher incidence
compared to WT mice (Mitsui et al., 2002). The metabolic adaptation to increase TRX
expression in highly proliferative cells under increased oxidative stress makes it an ideal
candidate for cancer therapy. MM cells treated with micromolar concentrations of the
TRX2 inhibitor gentian violet (Zhang et al.) had an IC50 as much as 5X lower than
primary and immortalized mesothelial cells. Mice harboring xenoplant MM tumors
treated with GV showed marked reduction in tumor weight and volume (See Chapter 4).
Overexpression of TRX1 increased resistance to chemotherapy while reduction in TRX1
expression sensitized human blader cancer cells to a variety of anti-cancer therapeutics
(mitomycin C, etoposide, UV irradiation, and doxorubicin) (Yokomizo et al., 1995).
Peroxiredoxin (PRX) expression and activity is found to be important for the
tumorigenesis of numerous cancers including breast, lung, prostate, skin, hematologic,
and mesotheliomas. Peroxiredoxins are primary scavengers of cellular H 2O2 and
therefore play a critical role in the detoxification and maintenance of physiological ROS
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levels (Poole et al., 2011). PRX1 is overexpressed in A549 adenocarcinoma cells and
fibroblasts deficient in PRX1 undergo p38 dependent senescence (Chang et al., 2001).
Expression of PRX1 in numerous cancers correlates with poor prognosis, while mice
deficient in PRX1 are more prone to develop malignancies and have reduced lifespan
(Neumann et al., 2003). This seemingly paradoxical observation indicates dual functions
of PRXs in cancer, one role as tumor suppressors through reduction in DNA damaging
oxidants, and a second as necessary for metabolic adaptations during tumorigenesis.
Given the role of mitochondrial ROS in tumorigenesis (Weinberg et al., 2010), it
is not unexpected that mitochondrial antioxidant enzymes such as manganese superoxide
dismutase (MnSOD, or SOD2) and PRX3 are linked to cancer. While PRXs appear to
play a central role in the adaptation to oxidative stress in cancer, as members of this
enzyme family are over-expressed in a wide variety of malignancies (Neumann & Fang,
2007), PRX3 may play a crucial role in adaptive responses in tumor cells. PRX3 is a
mitochondrial peroxidase responsible for metabolizing ~90% of mitochondrial oxidants
and protects cells from apoptosis (Cox et al., 2010).

PRX3 has been found to be

overexpressed in a variety of cancers including cervical (Kim et al., 2009), hepatocellular
(Qiao et al., 2012) and prostate tumors (Basu et al., 2011). PRX3 is a direct
transcriptional target of numerous oncogenes including FOXM1 (Park et al., 2009) and
MYC (Wonsey et al., 2002) and reduction in its expression and/or activity sensitizes cells
to oxidant-induced apoptosis (Chang et al., 2004). Over expression of key proteins in the
mitochondrial antioxidant network (TR2/TRX2/PRX3) of malignant mesothelioma cells
supports expression of pro proliferative redox responsive proteins such as FOXM1
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(Newick et al., 2012). Yong et al. demonstrated a suppression in tumorigenicity by miR17* through the inhibition of mitochondrial antioxidant enzymes (MnSOD, TR2, GPX2)
(Xu et al., 2010).
Manganese superoxide dismutase (MnSOD, SOD2) is a manganese containing
mitochondrial-targeted isoform of SOD that enzymatically dismutates O 2- to H2O2
(Weisiger & Fridovich, 1973). MnSOD has been predicted to be a tumor suppressor and
identified as reduced in numerous cancers (Kim et al., 2010), but the role of MnSOD in
cancer seems to be more complicated with tumor heterogeneity and metastatic
progression influencing variations in MnSOD expression and activity (Hempel et al.,
2011). In the case of esophageal and gastric cancers, as they progress MnSOD expression
increases as does the metastatic potential, correlating with poor patient prognosis (Malafa
et al., 2000). MnSOD overexpression in fibrosarcoma cells increased migration that
directly correlated with expression levels of MnSOD (Connor et al., 2007). MnSOD
exerts significant control over cell cycle progression and dose-dependent reduction in
expression disrupts cell cycle entry and progression (Sarsour et al., 2014). It is important
to consider the relative species of ROS that are either increasing or decreasing with
modulation of MnSOD activity and how O 2 - and H2O2 have different chemical properties
and distinctive functional targets (Burdon, 1995; Winterbourn & Metodiewa, 1999).
Overexpression of MnSOD in NIH 3T3 fibroblasts increased peroxide levels in quiescent
and cycling cells and subsequent G2/M arrest (Li & Oberley, 1998). This early
observation would indicate production of H 2O2 through the action of SODs would
overwhelm cellular peroxidases and induce cell cycle arrest. Together these findings
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support cellular adaptation to oxidative stress as a key characteristic of cancer survival
and growth (Figure 6).
ROS Driven Tumor
ROS driven cancers are characterized by excessive ROS production and
phenotypic adaptation that support a pro-oxidant, pro-proliferative phenotype. In
malignant melanoma, numerous phenotypic characteristics have been described that
underscore a designation as an ROS driven tumor (Fried & Arbiser, 2008). These
designations include loss of p16Ink4a activity, retention of p53, activation of NF-kB, and
constitutive activation of protein kinase B (PKB, AKT) and extracellular regulated kinase
1 and 2 (ERK 1/2). Malignant mesothelioma retains the characteristics of a ROS driven
tumor as well as other identified signatures that may support and promote the ROS driven
phenotype (Figure 1.7).

Further characterization of ROS driven tumors is necessary to establish a
complete tumor signature that may be amenable to treatment through modulation of ROS.
As mentioned previously ROS from NADPH oxidases and mitochondria are major
contributors to cellular transformation and tumor progression. The Nox isoforms Nox1, 2,
4, and 5 have been found upregulated in a number of cancer cell lines (Lambeth, 2004).
Overexpression of the HRas V12 oncogene leads to increased NOX4 derived ROS that
promoted mitochondrial DNA lesions (Weyemi et al., 2012). Nox 2 and 4 are
transcriptional targets of HIF1a and support tumor angiogeneisis (Diebold et al., 2010;
Diebold et al., 2012). Nox 1, 2, and 4 also support metastasis through redox regulated cell
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migration, invasion and epithelial to mesenchymal transition (EMT) (Hecker et al.,
2012). Therefore based on this and other evidence, expression levels of Nox enzymes
could be determinants of ROS driven tumors. Furthermore, alterations in mitochondrial
metabolism support tumor cell growth and survival (Cairns et al., 2011). A common
feature of tumorigenesis is increased mitochondrial ROS, and that property also should
be taken into consideration as a marker of a ROS driven tumor type.

Figure 1.7 Features of the ROS driven tumor. Fried and Arbiser’s descriptors of the ROS
driven tumor type in malignant melanoma that reflects features of malignant
mesothelioma. Additional genetic and phenotypic features of malignant mesothelioma
that contribute to the ROS driven tumor phenotype.

1.3 Mitochondrial Structure and Function in Cancer

Mitochondrial ROS in cancer
Mitochondrial oxidants are potent mitogens that contribute to changes in cell
proliferation and dictate cell fate (Hamanaka & Chandel, 2010; Sena & Chandel, 2012).
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Numerous cancers show increased levels of mitochondrial oxidants and alterations in
mitochondrial antioxidant enzyme expression (Gorrini et al., 2013). Mitochondrial ROS
production (described above) can be influenced by numerous cellular stimuli including
excess

ETC

substrates,

aberrant

ETC

complex

expression,

posttranslational

modifications, and inhibition (Murphy, 2009): a phenotypic consequence of metabolic
reprogramming (Cairns et al., 2011). Numerous cells in culture with mutations to
mitochondrial DNA show increased mitochondrial ROS levels and enhanced
proliferation (Wallace, 2012). ATP synthase (complex V) inhibition has been identified
in cancers with increased expression of the inhibitor protein IF1 100 leading to reduced
OXPHOS and increased mitochondrial ROS production, similar to the phenotypic
response of cells treated with the mitochondrial un-coupler oligomycin (Sanchez-Cenizo
et al., 2010).
The BCR/ABL mutant oncogene found in several cancers was shown early on to
induce ROS production in a panel of hematopoetic cell lines harboring the mutation. The
increases in ROS led to reductions in phosphatase activity similar to that of adding
exogenous H2O2 (Sattler et al., 2000). Although these authors did not identify the exact
source of the ROS, inhibition of mitochondrial complex I reduced ROS levels in
BCR/ABL transformed cells (Sattler et al., 2000).
Oncogenic K-ras leads to increased levels of ROS that are essential for tumor
progression (Sundaresan et al., 1996; Weinberg et al., 2010). Antioxidants targeted to the
mitochondria via linkage to a triphenylphosphonium ion reduce colony formation in Kras
G12D mouse embryonic fibroblasts (MEFs). Furthermore, mutated Kras osteosarcoma
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cells devoid of their mitochondria (p0) fail grow in soft agar but regain their oncogenic
potential when reconstituted with mitochondria capable of producing ROS but not
competent for oxidative phosphorylation. These mitochondrial ROS competent cells were
less viable than cells harboring WT mitochondria, a phenotype attributed to the loss of
glutamine catabolism, but completely lost any growth advantage when complex III
activity was reduced and ROS levels abolished. This report by Weinberg et al. (Weinberg
et al., 2010) reinforced the importance of mitochondrial ROS and the pentose phosphate
pathway in tumor progression, and showed that these properties were independent of
energy demands. MtDNA instability and subsequent ROS production supports intestinal
tumorigenesis in the colon (Woo et al., 2012). The finding that expression of
mitochondrial targeted catalase into mice harboring activated

oncogenes (T

oncoprotein154, ApcMin/+, Tfam+/-) inhibited oncogene induced tumorigenesis (Goh et al.,
2011; Lee et al., 2010), further supports the role of mitochondrial ROS in tumorigenesis.
Mitochondrial ROS produced from complex III inhibit prolyl hydroxylases
(PHDs), thereby stabilizing HIF1a expression (Chandel et al., 2000). HIF1a induces
expression of pyruvate kinase isozyme M2 (PKM2), the pyruvate kinase isoform
expressed in the majority of human cancers (Luo et al., 2011). Dimeric PKM2 (Tumor
PKM2), mainly expressed in tumor cells, weakly interacts with its substrate
phosphoenolpyruvate (PEP) which normally interacts with tetrameric PKM2 to drive PEP
to pyruvate in untransformed cells.

Tumor PKM2 potentiates the channeling of

glycolytic intermediates upstream of pyruvate kinase into biosynthetic pathways that
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increase nucleic acid, phospholipid and amino acid synthesis necessary for highly
proliferative cells (Cairns et al., 2011).
Mitochondrial structural rearrangements
Mitochondria are dynamic organelles that undergo structural rearrangements
that influence their function. Mitochondria split and join through the process of fission
and fusion respectively, facilitating organelle performance and recycling. Furthermore,
mitochondria must be transported and sequestered into sites where mitochondrial
metabolites are required (Martin-Cofreces et al., 2014; Saxton & Hollenbeck, 2012), a
field of study still in its infancy (Jayashankar & Rafelski, 2014). The structure of
mitochondria has been linked to their metabolic capacity, in which tubular mitochondria
are more efficient at ATP production compared to fragmented ones (Picard et al., 2013;
Rossignol et al., 2004). The changes in structure that modulate ATP production have also
been linked to alterations in ROS production, calcium buffering and cell cycle
progression that contribute to numerous pathologies (Benard et al., 2007; Mitra et al.,
2009).
The list of proteins that facilitate fission and fusion is ever expanding but is
primarily mediated by a few major constituents (Figure 8). Mitochondrial fission is
mediated by the cytosolic guanosine triphosphatase (GTPase) Dynamin Related Protein 1
(DRP1), which assembles on mitochondria and associates with adapter proteins to drive
scission of mitochondrial membranes (Elgass et al., 2013; Otsuga et al., 1998; Smirnova
et al., 2001). Drp1 is recruited to mitochondrial membranes by accessory proteins Mid49,
Mid51, and Mff in mammals, and posttranslational modifications to DRP1, including
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phosphorylation of 2 defined serine residues, SUMOylation (Zunino et al., 2009), and
ubiquitinylation (Nagashima et al., 2014; Sugiura et al., 2011; H. Wang et al., 2011)
regulate mitochondrial recruitment and GTPase activity. Fission supports trafficking of
mitochondria in the cell and the equal distribution of mitochondria to daughter cells
during cell division (Taguchi et al., 2007).
Mitochondrial fusion is the process of joining two mitochondria into one and is
mediated primarily by two mitochondrial-membrane embedded GTPases, Mitofusin 1
and 2 (MFN 1 and 2). Fusion of mitochondria ensures organelle integrity and promotes
the exchange of mitochondrial DNA (Chen et al., 2010; Ranieri et al., 2013).
Mitochondrial fusion occurs under stressful conditions such as starvation (Tondera et al.,
2009) and can maximize oxidative capacity when cells are deprived of glucose
(Rossignol et al., 2004). In normal cells elongated mitochondria and a hyperfused
mitochondrial network are essential at S-phase for ATP production, and this network
must undergo fission prior to cytokinesis to ensure equal mitochondrial distribution to
daughter cells (Arakaki et al., 2006; Mitra et al., 2009).
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Figure 1.8. Fission and fusion dictate mitochondrial structure. Mitochondrial undergo
structural rearrangements that regulate their function. DRP1 assembles on mitochondria
and severs the membrane to drive fission. Mitofusions 1 and 2 tether two mitochondria
into one driving fusion. Figure taken from Blackstone et al. (2011), with permission from
Nature Publishing Group.

Aberrant mitochondrial fission and fusion influences mitochondrial function, and
is associated with numerous diseases including cancer (Ranieri et al., 2013; Youle & van
der Bliek, 2012). Inhibition of mitochondrial fission through reduction in DRP1
expression or activity leads to a hyper-fused mitochondrial network that has increased
levels of ROS and DNA damage, and elicits G2/M cell cycle arrest (Qian et al., 2012).
Interestingly, forced fission or fusion elicits a bidirectional phenotype as both have been
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shown to alter mitochondrial function similarly (Benard et al., 2007). These findings can
be partially reconciled due to the dynamic nature of mitochondrial reorganization;
chronic disruption would be expected to damage mitochondrial constituents required for
proper function. Recently mitochondria from various lung cancer cell lines were found to
have a highly fragmented mitochondrial population compared to controls (Rehman et al.,
2012). These tumor cells along with tumor sections from human patients with lung
adenocarcinoma, showed increased expression levels of DRP1 and reduced expression of
MFN2. Overexpression of MFN2 or inhibition of DRP1 with the pharmacological
inhibitor mdivi-1 slowed A549 cell growth in vitro and reduced tumor size in a xenograft
mouse model (Rehman et al., 2012). Increased expression of DRP1 also has been
reported in breast and lung cancers, and this was important for maintaining fractionated
mitochondrial networks that supported cell migration and tumor growth in vivo (Zhao et
al., 2013). Mitochondria are actively recruited to the leading edge of migrating cells in an
AMP-dependent protein kinase (AMPK) fashion to support localized energy demands
and actin reorganization, and therefore could provide metabolic support to metastatic
growth (unpublished data). The observations that structural alterations in mitochondria
support tumor phenotypes presents new molecular targets for the intervention of tumor
progression and metastasis (Jose & Rossignol, 2013; Qian et al., 2013)
Targeting Mitochondrial Function in Cancer
The earliest report of altered cellular metabolism came from seminal studies by
Otto Warburg who first described excess production of lactate from tumor tissue, even in
the presence of oxygen (Warburg, 1956). The Warburg effect (which was promulgated
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independent of Warburg’s support) drove the belief that mitochondria were damaged in
tumor cells, forcing them to be highly glycolytic to support growth. Although there was
still much to be explained after Warburg’s findings, these studies stimulated the targeting
of metabolic pathways in the treatment of cancer. Not until the mid 1950s was it realized
that normal and neoplastic tissues exhibit similar mitochondrial bioenergetic phenotypes
(oxygen consumption), but tumor cells had subtle alterations in energy transfer, that
could modify the mitochondrial functional phenotype (Weinhouse, 1955). These findings,
almost 7 decades ago, are now being further supported by numerous studies indicating
prominent roles for changes in mitochondrial function in tumor cell growth and survival
(Ralph et al., 2010). With the advent of new technology to analyze mitochondrial
function, we can now confirm that metabolic abnormalities identified 70 years ago in
tumor mitochondria are indeed plausible therapeutic targets.
Targeting Cellular Redox Status
As described in previous sections, reactive oxygen species (ROS) from
mitochondrial and non-mitochondrial sources support tumor cell growth through redox
dependent signaling pathways that drive proliferation. A phenotypic adaptation of tumor
cells is increased expression of antioxidant enzyme pathways to counteract excessive
levels of ROS that would otherwise induce senescence and subsequent cell death (Pan et
al., 2009). This phenotypic adaptation has stimulated research into modulating ROS in
tumor cells as a therapeutic target. Below I will briefly summarize two schools of
thought; 1) targeted reduction of ROS and 2) pro-oxidant therapies as cancer
therapeutics.
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The findings that NADPH oxidases contribute to the tumor phenotype has
stimulated research into specific inhibitors that would reduce NOX activity and
subsequent ROS levels. The often-utilized, yet non-specific, inhibitor of Nox’s,
diphenyleneiodonium (DPI) has stimulated research into structurally similar compounds
to be used as Nox inhibitors in cancer. Gentian violet (GV), brilliant green (BG), and
eosin are triphenylmethanes that share structurally similarities to DPI and have been
shown to reduce NOX4 and NOX2 derived ROS (Perry et al., 2006). Although GV and
BG have been described as Nox inhibitors, it seems they may have other cellular targets
that are more relevant then Nox inhibition (Newick et al., 2012; Zhang et al., 2011). The
Nox inhibitor VAS2870 effectively reduced superoxide levels and cell growth in rat
hepatoma cells that only express Nox1 (Sancho & Fabregat, 2011). Fulvene-5 is an
inhibitor of Nox2 and 4 in vitro and in vivo and blocks endothelial tumor growth in mice
(Bhandarkar et al., 2009). The novel dual Nox1/4 inhibitor GKT13690 reduced
endothelial cell migration tube formation in a mouse model of tumor angiogenesis
(Garrido-Urbani et al., 2011). The Nox 1 isoform specific inhibitor ML171 was identified
using the human colon cancer line HT29 that only expresses Nox1. ML171 had no affect
on mitochondrial ROS production but blocked ROS dependent invadopodia formation in
HT29 cells (Gianni et al., 2010).
The usage of antioxidants in the treatment of cancer has come with successes
and failures. Numerous cell culture and animal models have indicated the potential for
antioxidant supplementation in the prevention and treatment of cancer, but these findings
have failed to translate to humans. A meta-analysis of randomized controlled clinical
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trials found that antioxidant supplementation had no effect on cancer incidence and in
some cases statistically increased risk for bladder cancer in a subgroup of trials (Myung
et al., 2010). This and the ineffectiveness of translating findings with antioxidant
treatments from cell culture systems into animal models has led to a re-thinking of
antioxidant treatments in cancer. One such approach has been the targeting of specific
subcellular sources of oxidants, specifically the mitochondria (Smith et al., 2011). The
rationale behind this approach is that general antioxidants have been ineffective due to
the lack of accumulation at specific important sites of ROS production, i.e. the
mitochondria. Born out of this concept was the development of mitochondrial-targeted
antioxidants that would specifically accumulate within mitochondria at very high
concentrations and thus reduce local ROS levels before off target reactions can occur
(Smith et al., 2011).
Mitochondrial targeted compounds are a class of molecules that utilize a
targeting moiety to drive accumulation into mitochondrial membranes and the matrix
(Smith et al., 2011). The most utilized targeting moiety is the triphenylphosphonium
(TTP) moiety that is composed of three large phenyl rings that carries a delocalized
positive charge across the hydrophobic molecule. The large delocalized positive charge
of TPP facilitates its transport across mitochondrial membranes due to the high negative
membrane potential of energized mitochondria, leading to a 500-fold increase in the
concentration of the compound inside the organelle (Murphy, 2008). TPP can be
conjugated to a wide variety of compounds to be used as therapies or as probes to study
functional aspects of mitochondria such as ROS, ATP, calcium, and membrane potential
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changes. Recently, novel probes have been developed to study mitochondrial integrity in
old versus young mitochondria (MitoTimer)(Hernandez et al., 2013), mitochondrial ROS
levels (Mito-B)(Cocheme et al., 2012), and to selectively induce ROS production in a
subset of mitochondria (Mito-Killer-Red) through photosentization using a point source
laser (Bulina et al., 2006). All these have aided in our understanding of mitochondrial
function under varying physiological settings.
Tumor cells have an elevated mitochondrial membrane potential and accumulate
TPP and TPP conjugated molecules to a larger extent than normal cells (Sun et al., 1994),
which increases the selectivity of drug delivery to tumor cells. MitoQ was one of the first
mitochondrial-targeted antioxidants developed that utilizes a TPP moiety conjugated to a
ubiquinone derivative. MitoQ accumulates in mitochondria in a membrane-potential
dependent manner and scavanges H2O2, protecting cells from apoptosis. Mito-Q has
shown promise in cardiovascular disease, diabetes, and aging (Kelso et al., 2001; Smith
et al., 2011).
Although numerous compounds have been developed as mitochondrial targeted
antioxidants, it seems their mechanism of action in cancer is not due to antioxidant
properties but more so their ability to disrupt mitochondrial function. Breast cancer cells
are 30 times more sensitive to MitoQ than normal mammary cells. MitoQ treatment
increased oxidant levels, activation of NRF2, and subsequent G1/S cell cycle arrest in
breast cancer cells (Rao et al., 2010). The mitochondrial-targeted nitroxides (Mito-CP
and Mito-TEMPOL) were originally developed as mitochondrial targeted antioxidants
(Dhanasekaran et al., 2005). Recent evidence has shown that these molecules disrupt
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mitochondrial function and elicit specific tumor cell death. Mito-CP depleted ATP levels
in human breast cancer cells and synergized with the glycolysis inhibitor 2 -deoxyglucose
(2-DG) inducing tumor cell death while having no effect on untransformed cells. This
work was further supported by in-vivo studies in which mice administrated Mito-CP or
the combination of Mito-CP and 2-DG had reduced tumor weight compared to control
mice (Cheng et al., 2012). Mitochondrial targeted derivatives of Vitamin E showed
comparable results to Mito-CP in the reduction of tumors in a xenograft model of breast
cancer (Cheng et al., 2013). In work from our lab, Mito-CP and Mito-TEMPOL were
shown to disrupt mitochondrial membranes, increase mitochondrial ROS, deplete ATP
levels and synergize with the anti-cancer compound thiostrepton to potentiate malignant
mesothelioma cell death (Cunniff et al., 2013).
Pro-oxidant Therapies
The constitutive increases in tumor cell ROS levels drive genotypic and
phenotypic features of tumorigenesis. This characteristic puts tumor cells into a hyperproliferative state that requires maximal energy levels and high metabolite
concentrations. Consequently the increased ROS levels in cancer cells provides a redox
vulnerability via intervention with pro-oxidant therapies (Wondrak, 2009). It was
reported almost 75 years ago that tumor cells had limited “reserve capacity” that reduces
their ability to tolerate changes in oxygen consumption and subsequent ROS production
(Weinhouse, 1955). This concept has gained increased momentum, as mitochondrial
metabolism is becoming an evermore-evident therapeutic target in cancer (Gorrini et al.,
2013; Ralph et al., 2010; Zhang et al., 2014). The most widely used chemotherapeutics
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target the highly proliferative rate of tumor cells through disruption of DNA synthesis,
but off-target effects of these compounds, as for example specifically increasing ROS
levels, contributes to their efficacy (Davis et al., 2001). It certain circumstances, such as
with the DNA crosslinking compound cisplatin, increased oxidant levels independent of
DNA damage induces tumor cell death (Berndtsson et al., 2007).
Literally dozens of therapeutic candidates and compounds have been identified
that act through redox-dependent mechanisms in cancer have been identified. These have
been extensively reviewed elsewhere (Wondrak, 2009), and here I will discuss two
compounds that target mitochondrial redox metabolism and are pertinent to the research
described within.
Gentian Violet
Gentian violet (GV) is a triphenylmethane dye (Figure 1.9), used extensively in
the basic research laboratory as a cell stain, and as of recent has shown great promise as a
cancer therapeutic (Newick et al., 2012; Zhang et al., 2011). GV has antifungal and
antibacterial properties and has been used as a topical antiseptic (Bhandarkar et al., 2008;
Czarlinsky et al., 1979). GV preferentially accumulates in mitochondria, most likely due
to its triphenyl structure (Docampo et al., 1983; Zhang et al., 2011). Although GV and
similar compounds have been used in medicine for over a century, the mechanism of
action is still unclear. The activity of GV has been shown to be dependent on the redox
potential of the cell leading to the formation of free radicals (De Groot & Sies, 1989;
Docampo et al., 1983). There are numerous reports indicating that GV functions as an
inhibitor of NADPH oxidases (Maley & Arbiser, 2013). However substantial new
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evidence indicates that GV, and it’s sister compound brilliant green, inhibits the
expression of the mitochondrial oxidoreductase thioredoxin 2 (TRX2) at low nanomolar
concentrations (Zhang et al., 2013; Zhang et al., 2011). Inhibition of TRX2 increases
mitochondrial oxidant levels and reduces cell viability in both Hela cells and malignant
mesothelioma cells (Newick et al., 2012; Zhang et al., 2011). Treatment of Hela cells
with GV for 3 hours increases transcript levels for the mitochondrial Lon protease, a
mitochondrial protease that degrades oxidized proteins that may contribute to the
reduction in TRX2 expression levels (Zhang et al., 2011).

Figure 1.9. Molecular structures of thiostrepton and gentian violet. Figure adapted from
Nicolaou et al. (2004) and Zhang et al. (2011) with permission from John Wiley and sons
and Elsevier, respectively.
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Thiostrepton
Thiostrepton (TS) is sulfur containing thiazole antibiotic produced by
Streptomyces azureus, a Gram-positive bacteria (Figure 1.9) (Anderson et al., 1970). TS
has also been successfully synthesized in the laboratory (Nicolaou et al., 2004). TS was
initially identified to bind to the 23S ribosomal RNA subunit of bacteria with high
affinity and thereby inhibit bacterial protein synthesis (Bausch et al., 2005). Numerous
groups have recently reported on the anti-cancer properties of TS, although with
discordant mechanisms (Gartel, 2013; Hegde, Sanders et al., 2011; Newick et al., 2012).
TS was identified by the Gartel lab in a screen for small molecules that inhibit the
expression of the oncogenic transcription factor FOXM1 (Gartel, 2013). In this context
TS has been described as a proteasome inhibitor, stabilizing p21 and p53 expression and
perhaps leading to the stabilization of an unknown entity responsible for inhibiting
FOXM1 expression (Pandit & Gartel, 2011a, 2011b). As discussed earlier, FOXM1
regulates cell cycle progression, and is thought to bind its own promoter in a positive
feedback loop in response to redox status. In certain circumstances TS elicits similar
effects on FOXM1 expression as other described proteasome inhibitors such as MG132
and bortezomid. This evidence is not supported by published work from our lab, for in
MM cells, MG132 stabilized the expression of FOXM1 in cells treated with TS (Newick
et al., 2012). When administrated alone or in combination with bortezomid, TS has been
shown to reduce tumor volume in mouse models (Wang & Gartel, 2012; Wang et al.,
2012). Others have also reported the direct binding of TS to FOXM1 protein, thereby
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blocking DNA binding and reducing the expression of FOXM1 and its target genes
(Hegde et al., 2011), although there is contention regarding this finding (Gartel, 2011).
Our group has identified the mitochondrial peroxidase peroxiredoxin 3 (PRX3)
as a molecular target of TS in malignant mesothelioma cells. Treatment of MM cells with
TS induces a non-denaturable, non-reducable modification in PRX3, doubling the
apparent molecular weight of PRX3 as visualized by SDS-PAGE. Pre-treatment or cotreatment with the TRX2 inhibitor GV potentiates modifications of PRX3 induced by TS.
TS also reduces FOXM1 expression in a redox dependent manner, as FOXM1 expression
is retained in response to TS after pre-treatment of cells with the antioxidant N-acetyl-Lcysteine (Schwarzenberger et al., 1998). Since PRX3 is responsible for metabolizing the
majority of mitochondrial derived H2O2 it is not surprising that TS leads to increased
mitochondrial oxidant levels, and that these increases are further potentiated by cotreatment with GV (Newick et al., 2012). The evidence that TS disrupts mitochondrial
function, potentially through PRX3 inactivation, is supported by evidence from Bowling
and colleagues that showed TS inhibits mitochondrial protein translation and sensitizes
melanoma cells to redox-dependent apoptosis (Bowling et al., 2008). In work from Georg
Wondrak’s laboratory, TS was shown to induce redox and proteotoxic stress, leading to
increased expression of chaperone proteins and cell death in melanoma cells, while
leaving primary melanocytes unscathed (Qiao et al., 2012). In their studies disruption of
mitochondrial redox status precluded proteasome inhibition which suggests a hierarchy of
early and late phenotypic responses to TS.
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As tumors and tumor microenvironments are notoriously heterogeneous it is of
great importance to target multiple pathways for efficient reduction in tumor burden. A
number of groups have described using thiostrepton to sensitize tumor cells to secondary
chemotherapeutics. As described above TS sensitized melanoma cells to arsenic trioxide,
and inhibition of FOXM1

by TS sensitizes medulloblastoma

cells to the

chemotherapeutic agent cisplatin (Lin et al., 2013). We have also identified combinatorial
effects of TS with the TRX2 inhibitor GV, as TS and GV target two essential antioxidant
proteins involved in mitochondria redox defense. Because PRX3 is over expressed in
numerous cancers, and its expression has been recently correlated with the marker of
proliferation Ki67 (Hu et al., 2013), combinatorial therapy using TS and other
mitochondrial agents, with or without conventional chemotherapy, may be a promising
approach in managing aggressive tumors.
1.4 Malignant Mesothelioma
Malignant mesothelioma (MM) is an intractable tumor linked to the
occupational exposure to asbestos (Tsao et al., 2009). MM tumors originate on the
mesothelial lining of the pleura, peritoneum and pericardium (Tsao et al., 2009).
Prolonged inflammation and frustrated phagocytosis of asbestos fibers leads to increased
cytokine levels and recruitment of pro-inflammatory cells to the mesothelial lining (Izzi
et al., 2012). Increased growth factor production by mesothelial cells to initiate tissue
repair, combined with increased inflammation initiate MM tumorigenesis (Izzi et al.,
2012).
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There is an intimate relationship between redox-dependent tumorigenesis and
mesothelioma. Certain asbestos fibers are redox active due to large amounts of associated
iron associated that redox cycles, inducing damage to cellular macromolecules. In cell
free systems asbestos fibers generate ROS, specifically the highly reactive and damaging
species hydroxyl radical (Liu et al., 2010). Molecular antioxidants and antioxidant
enzymes ameliorate the cytotoxic and tumorigenic properties of asbestos (Boutin et al.,
1994; Schwarzenberger et al., 1998).
The exposure to asbestos fibers induces expression of antioxidant proteins, most
likely as a protective mechanism against the pro-oxidant environment (Boutin et al.,
1994). Exposure of immortalized mesothelial and primary mesothelial cells to asbestos
induced the expression of MnSOD and heme oxygenase 1 (HO1) and depletion of GSH
(Robinson et al., 2003). Examination of the literature indicates MM falls into the
classification of a reactive oxygen species driven tumor (Fried & Arbiser, 2008). MM
tumors are characterized by loss of p16 INK4A (Wong et al., 2002), retention of p53
(Kafiri et al., 1992), and constitutive activation of NF-kB (Carbone & Yang, 2012). A
microarray gene expression study conducted by our laboratory showed that MM cells
have adapted to a pro-oxidant environment through up-regulation of numerous
antioxidant enzymes and DNA repair proteins (unpublished data). Mitochondrial
ultrastructural changes have also been observed in MM cells under increased oxidative
stress (Cunniff et al., 2013).
MM cells also exhibit phenotypic features of metabolic stress similar to other
tumor types that rely predominantly on aerobic glycolysis (Zhang et al., 2009). Poorly
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vascularized tumors are hypoxic and rely heavily of glycolysis and biosynthetic shunts
for reducing equivalents to protect cells from redox imbalance and cellular
macromolecules that support excessive growth (Cairns et al., 2011). Gene profiling of
MM tumor samples from human patients showed increased expression of genes involved
in glucose metabolism and hypoxia (Singhal et al., 2003). Additionally MM cells have
reduced mitochondrial reserve capacity, an indicator of mitochondrial energetic status
(See Chapter 4).
There is no effective chemotherapeutic option for MM, in spite of numerous
clinical trials (Moore et al., 2008). Common chemotherapeutics such as cisplatin and
doxorubicin elicit a response in MM patients but do not prolong survival (Moore et al.,
2008). Experimental approaches such as targeting tumor necrosis factor-alpha and
proteasome inhibition with bortezomid (Stahel et al., 2010) are currently in phase III and
II trials respectively for the treatment of MM.
1.5 Hypothesis and Specific Aims
Metabolic reorganization is a requirement for cancer initiation and a hallmark of
tumorigenesis (Hanahan & Weinberg, 2000, 2011). Metabolic reorganization often
includes increased production of cellular oxidants, and we have shown that mitochondria
are the primary cellular source for oxidant production in malignant mesothelioma (MM)
cells. The pro-oxidant phenotype of tumor cells provides hyper-proliferative signals
through redox-responsive signaling pathways that drive cell cycle progression (Gorrini et
al., 2013). Excessive levels of ROS lead to senescence and apoptotic cell death in
untransformed cells and therefore tumor cells have reprogrammed cellular antioxidant
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defense systems in order to survive and proliferate at an increased rate (Wallace, 2012).
This redox program is distinct from normal cells and provides for selective vulnerability,
and therefore a therapeutic window for treating cancer. Our group and others have
proposed and identified redox dependent targets in cancer that sensitize cells to death,
alone or in combination with other compounds, by increased oxidative stress.
Due to the metabolic reorganization of cancer cells that leads to increased
mitochondrial oxidant levels, I hypothesized that exacerbating mitochondrial oxidative
stress through targeting mitochondrial antioxidant networks would sensitize malignant
mesothelioma (MM) cells to cytotoxic levels of mitochondrial oxidants. The specific
aims of this thesis were to: 1) identify and characterize metabolic features of ROS
metabolism in MM cells that are distinct from normal and primary mesothelial cells, 2)
test the in-vitro efficacy of mitochondrial-targeted drugs as potential anti-cancer agents in
the treatment of MM, and 3) further elucidate the redox-dependent mechanism of action
of the anti-cancer compound thiostrepton. The three papers here reinforce the concept
that antioxidant reprogramming of tumor cells supports growth under increased oxidative
stress, and that targeting multiple aspects of this phenotype is a plausible therapy in
intractable tumors such as MM.
In the first study I show that several drugs targeted to mitochondria, presumably
antioxidants, enhance superoxide production in mitochondria, most likely as a
consequence of disrupting mitochondrial architecture.

These drugs enhance the

cytotoxicity of thiostrepton, a thiazole antibiotic that disables PRX3 through the covalent
adduction of cysteine residues. In the second paper we show over-expression of the
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mitochondrial antioxidant enzyme TR2 promotes cell survival under conditions of
chronic mitochondrial oxidative stress, providing an explanation for the elevated
expression of TR2 in MM and other tumor types. This survival benefit is only evident
when TR2 enzyme includes selenocysteine, which renders the enzyme resistant to
inactivation by oxidants. We also show that once oxidative stress is alleviated, disulfidebonded dimers of PRX3 are slowly reduced, indicating that this catalytic intermediate of
the PRX3 reaction cycle is present at significant levels in pro-oxidant states.
The third paper provides detailed evidence for the anti-cancer mechanism of TS.
Specific cysteine residues adducted in PRX3 by thiostrepton are identified by mass
spectrometry, and thiostrepton is shown to increase mitochondrial hydrogen peroxide
production, as is expected if thiostrepton disables PRX3.

Together this work indicates

that PRX3-S-S-PPRX3 dimers are the preferred target of TS. Studies with cells in which
PRX3 expression is stably reduced support the contention that PRX3 is a relevant
molecular target of TS, and studies with primary and immortalized mesothelial cells
indicate they are less sensitive to the drug, presumably because they have less
dependence on the TR2-TRX2-PRX3 pathway. We also show that our strategy for
disabling the TR2-TRX2-PRX3 pathway is effective at impeding tumor progression in a
mouse model of MM.
We hypothesize, based on functional assays of mitochondrial ROS production,
bioenergetic profiling, and mitochondrial structural alterations, that MM cells have
undergone metabolic reorganization that supports tumorigenesis. Interventions based on
these distinctive metabolic programs are largely independent of oncogene activation or
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tumor suppressor loss, and therefore provide broad applicability across other tumor types
that share common metabolic signatures. In summary, this thesis describes a therapeutic
approach that is effective in cell and animal models of MM that is based on disabling the
mitochondrial TR2-TRX2-PRX3 pathway.
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Abstract
Malignant mesothelioma (MM) is an intractable tumor of the peritoneal and
pleural cavities primarily linked to exposure to asbestos. Recently we described an
interplay between mitochondrial-derived oxidants and expression of FOXM1, a redoxresponsive transcription factor that has emerged as a promising therapeutic target in solid
malignancies. Here have investigated the effects of nitroxides targeted to mitochondria
via triphenylphosphonium (TPP) moieties on mitochondrial oxidant production,
expression of FOXM1 and peroxiredoxin 3 (PRX3), and cell viability in MM cells in
culture.

Both Mito-carboxy proxyl (MCP) and Mito-TEMPOL (MT) caused dose-

dependent increases in mitochondrial oxidant production that was accompanied by
inhibition of expression of FOXM1 and PRX3 and loss of cell viability. At equivalent
concentrations TPP, CP and TEMPOL had no effect on these endpoints. Live cell
ratiometric imaging with a redox-responsive green fluorescent protein targeted to
mitochondria (mito-roGFP) showed that MCP and MT, but not CP, TEMPOL, or TPP,
rapidly induced mitochondrial fragmentation and swelling, morphological transitions that
were associated with diminished ATP levels and increased production of mitochondrial
oxidants. Mdivi-1, an inhibitor of mitochondrial fission, did not rescue mitochondria
from fragmentation by MCP. Immunofluorescence microscopy experiments indicate a
fraction of FOXM1 coexists in the cytoplasm with mitochondrial PRX3. Our results
indicate that MCP and MT inhibit FOXM1 expression and MM tumor cell viability via
perturbations in redox homeostasis caused by marked disruption of mitochondrial
architecture, and suggest that both compounds, either alone or in combination with
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thiostrepton or other agents, may provide credible therapeutic options for the
management of MM.
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Introduction
Mitochondria are dynamic organelles, constantly adapting their structure and
function in response to environmental cues and intracellular signals [2-4]. Beyond their
role as the primary source of ATP in the cell, mitochondria have emerged as signaling
hubs that regulate normal and pathological cellular processes through redox-responsive
signaling cascades, as reviewed in [3, 5]. It has long been appreciated that cancer cells
harbor mitochondria with altered energy production and structural aberrations [6]. The
“Warburg effect” first described altered metabolism in malignant tissues that is
characterized by increases in aerobic glycolysis, lactic acid production, and loss of
oxidative phosphorylation [7]. Along with altered energy metabolism, the mitochondria
of tumor cells produce increased amounts of oxidants [8-10], mainly through electron
leakage to molecular oxygen in the electron transport chain (ETC) located in the inner
mitochondrial membrane. Leakage of electrons from the ETC to molecular oxygen leads
to the formation of superoxide radical which is spontaneously and enzymatically
dismutated to hydrogen peroxide, the primary oxidant capable of freely crossing
membranes [11-14]. Through oxidation of reactive cysteine residues in signaling factors,
hydrogen peroxide has been implicated in the modulation of regulatory pathways that
control proliferation, apoptosis, metabolism, migration and survival [15, 16].

It is

important to note that the balance between oxidant production and metabolism, as well as
the array of susceptible targets expressed in the cell, is critical in determining phenotypic
responses.

Moreover, redox-signaling by endogenous hydrogen peroxide involves
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significant spatial and temporal regulation, as either too little or too much hydrogen
peroxide impairs cell cycle progression and viability [8].
Activation of certain oncogenes, such as Ras, leads to increased production of
cellular oxidants, a metabolic response that in most normal cells induces senescence [17].
Tumor cells evade senescence and tolerate constitutive increases in the production of
cellular oxidants, either through loss of checkpoint function or adaptive responses,
including the up-regulation of anti-oxidant enzymes. Indeed, some tumor types appear to
rely on enhanced production of oxidants for viability and other properties of malignancy
[9, 18]. FOXM1, a redox-responsive transcription factor that regulates genes involved in
S phase and the G2/M transition, functions at the interface between oxidative stress,
aging, and cancer [19-21]. Because FOXM1 is up-regulated in all carcinomas examined
to date, and is expressed only in proliferating cells [19], FOXM1 has emerged as a
promising therapeutic target in cancer treatment [22]. FOXM1 has also been shown to
respond to changes in cellular redox status, with its expression increasing in response to
exposure to low levels of exogenous hydrogen peroxide and decreasing following
overnight treatment of cells with the free radical scavenger TEMPOL [21]. Through upregulation of anti-oxidant enzymes that include mitochondrial superoxide dismutase
(SOD2) and peroxiredoxin 3 (PRX3), FOXM1 permits cells to escape senescence
induced by activated Ras [21].
Previously we showed that MM cells in culture constitutively produce 2-3-fold
more mitochondrial superoxide than non-transformed mesothelial cells, and that
compounds that inactivate the major mitochondrial anti-oxidant network of thioredoxin
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reductase 2 (TR2) – thioredoxin 2 (TRX2) – PRX3 increase mitochondrial oxidative
stress and block FOXM1 expression [23], albeit through an unknown pathway. Other
small molecules that perturb mitochondrial redox status may therefore prove useful for
inhibiting FOXM1 expression and the clinical management of MM.
Due to its high negative membrane potential, compounds can be selectively
targeted to mitochondria through the conjugation of a triphenylphosphonium (TPP)
moiety, which provides a large, dispersed positive charge to the test agent [24]. The
selective accumulation of TPP-containing compounds in mitochondria has allowed for
targeted delivery of a large number of test agents, with levels that can be 100-500-fold
higher than the bulk concentration [24, 25]. The higher negative membrane potential of
tumor mitochondria also facilitates increased accumulation in tumor cell mitochondria
versus normal cell mitochondria [26, 27]. In this study we evaluated the activity of two
TPP conjugated mitochondrial targeted nitroxides, Mito-carboxy proxyl (MCP) [25] and
Mito-TEMPOL (MT) [28] on malignant mesothelioma tumor cell proliferation and
survival (Fig. S1). Our results indicate that MCP and MT inhibit FOXM1 expression by
inducing marked mitochondrial fragmentation and increased production of mitochondrial
oxidants, a phenotypic response that appears distinct from mitochondrial fission. In
contrast, the parent compounds, carboxy proxyl (CP), TEMPOL and TPP alone had no
effect on FOXM1 expression, mitochondrial architecture, or cell viability at equivalent
concentrations. These observations demonstrate that altered mitochondrial energy and
oxidant metabolism in tumor cells is linked to FOXM1 expression, thereby providing a
rationale for exploiting this relationship for cancer therapy.
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Results
FOXM1 expression responds to mitochondrial oxidants:

Quantification of the

reduction of NBT showed HM cells produce more superoxide under standard culture
conditions than do LP9 cells (Fig. 2.1A), in agreement with other studies [23]. Flow
cytometry with the redox-responsive mitochondrial probe MitoSOX Red showed that
production of mitochondrial oxidants was increased at all phases of the cell cycle in two
MM cell lines as compared to hTERT-immortalized (but not tumorigenic) LP9 cells (Fig.
2.1B).

Using rotenone, an inhibitor of complex I of the ETC, we examined the

relationship between mitochondrial superoxide production and FOXM1 expression in
LP9 cells and malignant mesothelioma HM cells. Cells were treated with increasing
concentrations of rotenone, and superoxide production was measured by the reduction of
NBT. In both cell lines, rotenone increased the rate of NBT reduction, most likely by
blocking electron flow from complex I [29, 30]. However, in LP9 cells, which siRNA
experiments showed express a larger isoform of FOXM1 than HM cells [23], expression
of FOXM1 increased in response to rotenone, whereas in HM cells expression of
FOXM1 decreased (Fig. 2.1C). These results suggest that expression of FOXM1 is tuned
to the production of cellular oxidants that include mitochondrial superoxide and hydrogen
peroxide or oxidants formed there from, but that tumor cells function closer to a threshold
of oxidant production that inhibits FOXM1 expression.
MCP and MT induce a dose-dependent increase in mitochondrial oxidant levels in
MM cells. Although MCP and MT have been described to act as antioxidants in a
number of in vitro and cellular systems [25, 31, 32], changes in mechanism of action as a
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function of dose are still poorly understood. There is evidence that TPP compounds with
similar properties to MCP and MT can lead to increases in oxidant levels by interacting
with complex I at sites similar to those influenced by rotenone, which reduces reverse
electron transport while increasing superoxide production from forward electron transport
[33, 34] . To determine if MCP and MT influence oxidant production in MM cells, total
cellular superoxide or superoxide-derived oxidant production was examined using DHE
fluorescence, which also responds other oxidative events [35]. Cells were incubated with
test compounds for 6 hr, washed, and loaded with DHE, using co-staining with Hoechst
to control for the number of cell nuclei. When normalized to DNA content, MCP and
MT led to dose-dependent increases in DHE fluorescence (Fig 2.2A); with significant
increases occurring at doses as low as 400 nM. These findings have been confirmed by
quantifying the reduction of NBT in response to test compounds, and flow cytometry
with Peroxycrimson [36], a fluorescent probe that directly reacts with hydrogen peroxide,
albeit slowly, indicating that the majority of mitochondrial superoxide is converted to
hydrogen peroxide (data not shown).
To better identify the source of cellular oxidants after MCP or MT treatment,
cells were treated with test agents for 6 hr as before, loaded with the mitochondrial
oxidant probe MitoSOX Red for 30 min, and relative fluorescence was determined by
flow cytometry. Both MCP and MT led to dose-dependent increases in MitoSOX Red
fluorescence, while CP, TEMPOL and the targeting moiety TPP had no effect on
mitochondrial oxidant production at any concentration tested (Fig 2.2B).

While

MitoSOX Red responds to general mitochondrial oxidative stress, together the results
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with NBT staining and multiple redox-responsive fluorescent probes suggest that
nitroxides targeted to MM cell mitochondria with a TPP moiety cause marked increases
in mitochondrial superoxide and/or oxidants formed from hydrogen peroxide in
malignant mesothelioma cells.
To further confirm the increase in oxidative stress after treatment with MCP,
protein lysates from treated cells were probed with an antibody that reacts with overoxidized forms of peroxiredoxins (PRX). Incubation with MCP for 6 hours leads to a
dose dependent increase in hyperoxidized PRXs in HM cells (Fig 2.2C). PRXs function
as obligate homodimers that form disulfide-bonded dimers during the catalytic cycle [37,
38]. To test if the oxidation state of mitochondrial PRX3 was affected by MCP, nonreducing but denaturing gel electrophoresis conditions were used to examine the ratio of
disulphide-bonded PRX3 (.e.g. PRX-S-S-PRX3) dimers to PRX3 monomers, which
represent either reduced or hyper-oxidized monomers. After 6 hr of treatment with MCP,
the fraction of mitochondrial PRX3 dimers increased in both HM and H2373 cells (Fig
2.2D), indicating increased activity of the PRX3 catalytic cycle, likely due to increased
catabolism of hydrogen peroxide. Together the assays for cellular oxidant production
provide evidence that MCP and MT lead to increases in mitochondrial oxidative stress in
MM cells.
MCP and MT alter mitochondrial architecture.

Changes in mitochondrial

architecture have been linked to alterations in membrane potential, energy production and
superoxide production [4, 39-42]. Using expression of a green fluorescent protein (GFP)
targeted to the mitochondrial matrix that is responsive to redox status (mito-roGFP2) [43,
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44], and live cell ratiometric imaging to quantify changes in mitochondrial redox status,
we investigated the effects of MCP and MT on mitochondrial morphology. HM cells
were transfected with the mito-roGFP2 expression vector, and mitochondrial morphology
was examined in individual cells for 10 min prior to the addition of test compounds
directly to the cell culture on the microscope stage. Images were then collected every 30
seconds for 1 hr, and videos of individual cellular responses were generated as described
in Materials and Methods.

For each compound, at least 10 individual cells were

independently examined in the same dish to judge the uniformity of the response. Within
minutes of adding doses as low as 1 µM MCP or MT, mitochondrial architecture was
drastically altered in HM cells (Fig 2.3A, Supplementary Data Videos 1 and Video 2).
Long tubular mitochondria were observed forming circular ring-like structures and
vesicles of variable dimensions in a process reminiscent of mitochondrial fission (insets,
Fig 2.3A). Occasionally long filamentous mitochondria were observed to form lasso-like
structures that eventually collapsed into vesicular bodies of varying dimensions. Staining
of the nucleus with DAPI showed that in both treated and untreated cells the majority of
mitochondria were clustered in the perinuclear region (Fig. 2.3A and data not shown).
An identical morphological response was observed in LP9, H2373 and SKOV3 ovarian
cancer cells treated with MCP or MT (data not shown).
To quantify changes in mitochondrial architecture we utilized computer-assisted
methods described previously by Koopman and colleagues [30]. Both MT and MCP led
to marked decreases in form factor (Fig. 2.3B), a measure of mitochondrial length and
branching. In contrast, untargeted CP, TEMPOL and TPP had no effect on mitochondrial
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architecture (not shown) or form factor (Fig. 2.3B). To further investigate the mechanism
by which MCP alters mitochondrial architecture we used mdivi-1 to inhibit the activity of
dynamin-related protein 1 (DRP1), a major regulator of mitochondrial fission [45]. By
inhibiting fission, mdivi-1 promotes the formation of dense mitochondrial networks [46].
When HM cells were incubated with mdivi-1 for 3 hours and monitored by live cell
imaging, mitochondria remained located in the perinuclear region (Fig. 2.3C) and an
increase in form factor was observed (Fig. 2.3D). After 3 hr 1 µM MCP was added
directly to plates on the microscope stage and cells were observed for an additional 1 hr.
Inhibiting mitochondrial fission machinery with mdivi-1 did not attenuate the effect of
MCP on mitochondrial architecture (Fig. 2.3C) or the reduction in form factor (Fig.
2.3D), suggesting other components of the fission machinery or membrane dynamics
disrupted by MCP may be responsible for the architectural aberrations [47]. After 6 hr
with MCP the redox status of mito-roGFP2 was increased over control cells, while CP
did not change to redox status of the probe (Fig. 2.3E), confirming earlier results with
other oxidants probes (as in Fig. 2.2). We also examined if changes in mitochondrial
architecture led to changes in ATP levels and disruption of mitochondrial membrane
potential, as previously reported [48]. Incubation of MM cells with 1 µM MCP led to
moderate yet significant decreases in ATP levels after 6 hr, with no change in MM cells
treated with either TPP or CP at equivalent concentrations (Fig. 2.3F). MCP, but not CP,
also caused marked loss of mitochondrial membrane potential (Fig. 2.3G).
To gain further insight into structural aberrations caused my MCP we visualized
mitochondria of HM cells treated for 6 hrs with 1 µM MCP or control compounds by
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transmission electron microscopy.

The mitochondrial matrix of MCP treated cells

appeared swollen and devoid of electron density, with loss of mitochondrial cristae, and
frequently the inner membrane was closely associated with the outer membrane (Fig.
2.4).

Electron microscopy of MCP treated-cells also showed a preponderance of

vesicular mitochondria (Fig. 2.4, panels D and F), in agreement with the results of live
cell imaging.

Ultrastructural analysis also suggested that autophagasomes may be

increased in MCP treated cells, an observation that requires further investigation. Control
compounds TPP and CP had no visible effect on mitochondria architecture, and other
cellular structures (nuclear membrane, plasma membrane and rough ER) appeared largely
unaffected by treatment with MCP or control compounds. Together these data indicate
that in MM cells MCP and MT promote fragmentation of mitochondria that disrupts
multiple aspects of mitochondrial physiology, including ATP production, membrane
potential and oxidant metabolism.
Mdivi-1 inhibits expression of FOXM1. Transitions in mitochondrial morphology,
either through increased fission or fusion, can alter the metabolic function of the
organelle. It has been reported that mitochondrial oxidants are increased during fission
events [41] , and that fusion can also promote increased oxidant levels and alter ATP
production [4, 40]. Therefore we investigated the effects of incubation with midivi-1 on
ROS levels and FOXM1 expression in MM cells. Incubation of HM or H2373 cells with
mdivi-1 for 12 hrs led to a dose-dependent loss in FOXM1 protein expression (Fig.
2.5A), along with a dose-dependent increase in cellular oxidants as measured by DHE
fluorescence (Fig. 2.5B). The loss in FOXM1 protein expression correlated with the
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increase in oxidant levels in the two MM cell lines tested, further supporting the concept
that FOXM1 is responsive to mitochondrial oxidant production. Interestingly, FOXM1
enters the nucleus during G2 in an ERK-dependent manner [49], and is degraded during
mitosis [50, 51], two events that are associated with cell cycle-dependent transitions in
mitochondrial fission [52, 53] and an increase in the cellular oxidation state [54]
MCP causes a loss of PRX3 and FOXM1 protein in MM cells. Given that agents
which perturb mitochondrial oxidant production inhibit FOXM1 expression, we
examined the effect of manipulating mitochondrial oxidant production with MCP on
FOXM1 expression, as well as PRX3, an antioxidant gene product up-regulated by
FOXM1 [21]. MM cells were incubated for 12 hr with indicated concentrations of MCP
or control compounds, and western blotting was used to assess changes in protein
expression. As shown in Fig. 2.6A, both FOXM1 and PRX3 protein expression were
reduced in cells treated with MCP, while CP and TPP had no effect at the same
concentrations. The loss of mitochondrial PRX3 expression was specific, as expression
of cytosolic PRX1 was not affected by MCP (Fig. 2.6B). Moreover, the loss of FOXM1
and PRX3 expression did not appear to be due to a simple loss of mitochondrial mass, as
levels of mitochondrial TR2 were unaffected by MCP (Fig. 2.6C). Loss of FOXM1 or
PRX3 expression was not observed in cells treated with both MCP and MG132 (Fig.
2.6C), an inhibitor of the proteosome and Lon protease, a mitochondrial protease that
prefers oxidized proteins as substrates [55, 56]. MCP did not affect expression of PRX3
mRNA (not shown).
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FOXM1 coexists with mitochondrial PRX3. Given that at least five compounds that
perturb mitochondrial redox status or architecture (gentian violet, thiostrepton, MCP, MT
and mdivi-1) decrease the expression of FOXM1 isoforms that migrate at ~ 105-115 kDa,
we investigated the subcellular localization of FOXM1 using immunofluorescence
microscopy (IF). Previously we reported that siRNA specific to FOXM1, but not control
siRNA, eliminated the expression of immunoreactive species of FOXM1 that migrate at
~ 105-115 kD on western blots [23]. Using three different FOXM1 antibodies (see
Material and Methods), and an antibody to PRX3 to define mitochondria,
immunofluorescence microscopy of HM cells showed a significant fraction of FOXM1
coexists with PRX3 in HM cells (Fig. 2.7, column A), suggesting that cytoplasmic
FOXM1, which is observed in human mesothelioma tumor specimens [23], may be
associated with or located within mitochondria. To test this possibility further, cells were
treated with thiostrepton (TS), a thiazole antibiotic which inhibits expression of FOXM1
in a wide variety of cancer cell lines [57-59]. Immunofluorescence of HM cells treated
with thiostrepton showed marked decreases in cytoplasmic staining of FOXM1 without
diminishing the signal for PRX3 (Fig. 2.7, column B), whereas treatment of cells with
MCP reduced the immunofluorescence signal for both FOXM1 and PRX3 (Fig. 2.7,
column C), confirming the results observed by immunoblotting (Fig. 2.6).

The

subcellular trafficking of FOXM1 from the cytoplasm to the nucleus is regulated during
the cell cycle [49], and the immunofluorescence results indicate that a significant fraction
of cytoplasmic FOXM1 is associated with mitochondria in HM cells. The precursor-
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product relationship between cytoplasmic FOXM1 observed in tumor specimens or cell
lines and nuclear FOXM1 that mediates gene expression, if any, is not known.
MCP inhibits MM cell viability and potentiates the cytotoxic effects of TS. The
cationic triphenylmethane gentian violet inhibits expression of TRX2 [60], and TS
adducts PRX3 [23], indicating that both compounds target mitochondrial antioxidant
enzymes that influence the expression of FOXM1 and MM cell viability. To test the
effects of MCP on MM cell viability, HM and H2373 cells were treated with low doses
of MCP, with or without exposure to either 0.5 or 1 µM thiostrepton, concentrations of
TS that are well below the ID50 of ~ 2.3 µM in HM cells [23]. HM and H2373 cells were
plated in 96 well dishes, treated in triplicate for 3 days, washed, and then stained with
crystal violet. After washing, the crystal violet was solubilized in 100% methanol and
total cell mass was quantified by absorbance at 540 nM (Fig. 2.8). Additive effects of the
two drugs on inhibition of cell growth as reflected by total cell mass were observed in
both HM and H2373 cells (Fig. 2.8A and B). Like gentian violet, MCP increased the
adduction of PRX3 by TS in HM cells (Fig. 2.8C), suggesting that mitochondrial
oxidative stress induced by MCP promote the formation of catalytic intermediates of
PRX3 that preferentially react with TS, thereby enhancing the cytotoxic activity of TS.
These studies add MT and MCP to the growing list of agents that influence tumor cell
viability through perturbations in mitochondrial physiology.
Discussion
Altered metabolism, redox status, and mitochondrial structure have long been
hallmarks of malignant transformation, and in the past decade there has been increased
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interest in exploiting these perturbations for cancer therapy [61]. In general, in cancer
cells mitochondria do not appear defective in many aspects of energy metabolism, but
rather respond to deregulation of the cell cycle and other signaling pathways by
exploiting aerobic glycolysis for production of reducing equivalents required for
biosynthetic processes and cell cycle progression [6]. While gaining a better
understanding of the alterations in mitochondria and their relationship to malignant
phenotypes has been challenging, there remains enthusiasm for testing new avenues to
target the altered metabolic and redox status of tumor cells, as these may provide
therapeutic targets that are not present in normal cells.
As in other tumor types, we have described an increase in the oxidative state of
MM cell mitochondria that is accompanied by an adaptive response of up-regulation of a
primary mitochondrial antioxidant network composed of TR2-TRX2-PRX3 [23], which
is responsible for 90% of the metabolism of mitochondrial H 2O2 [62]. This adaptation
permits increased cell proliferation and evasion of apoptosis by shifting redox status in
favor of pro-growth oxidant signaling without activating redox dependent pro-apoptotic
pathways.

Our previous findings have also demonstrated that targeting of the

mitochondrial antioxidant network with the TRX2 inhibitor gentian violet or the thiazole
antibiotic thiostrepton leads to intolerable levels of mitochondrial oxidants, loss of
FOXM1 expression and MM cell death [23].
Rehman and colleagues have recently shown that expression of the mitochondrial
fission regulator DRP1 is elevated in lung cancer, with a loss of mitochondrial tubular
networks being a phenotypic signature of this tumor [40]. Promoting mitochondrial
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fusion reduced the growth of lung cancer cells in vitro, and impeded tumor growth in vivo
[40], indicating that increased mitochondrial fission has pro-tumorigenic effects. The
phenotypic properties of MM and LP9 cells are similar in that we also have observed that
the mitochondria in MM cells tend to be less tubular and are predominantly small and
vesicular, whereas LP9 and primary human mesothelial cells contain mitochondria with a
more trabecular organization (data not shown). Similar studies on expression and activity
of DRP1 in MM cells will be required to determine if enhanced mitochondrial fission is a
characteristic of MM.
Although MT and MCP have been shown to block increases in oxidant levels
both in vitro and cellular systems, their effects appear to be dose-dependent and vary
depending on cell type. At similar concentrations as used herein (1-5 µM) MCP has been
shown to inhibit H2O2 -induced oxidative damage in endothelial cells [25]. Weinberg et
al. have attributed the ability of MCP to inhibit tumor growth in a KRAS driven mouse
tumor model to inhibition of oxidant-dependent signaling [31], but their data also indicate
that MCP leads to hyper-phosphorylation of ERK1/2, a MAPK exquisitely responsive to
increased oxidative stress [63]. Others have shown that Mito-Q, a mitochondrial targeted
form of the antioxidant ubiquinone, is very effective at reducing mitochondria derived
oxidants and reducing lipid peroxidation [64-66]. In contrast Mukherjere and O’Malley
have shown that Mito-Q is capable of increasing oxidant production in cellular systems
and isolated mitochondria, and that the carbohydrate source for fueling the organelle had
varying effects on the production of oxidants [33, 34].
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Here live cell imaging with mito-roGFP2 showed that both MCP and MT
dramatically alter mitochondrial architecture at concentrations that result in increased
production of mitochondrial oxidants, suggesting that MCP and MT may perturb
enzymes present in the electron transport chain in MM cell mitochondria, as has been
reported for other compounds targeted to mitochondria by the TPP moiety [33]. The
evidence that TPP compounds can perturb mitochondrial membrane dynamics was shown
in the early 1990’s [47, 67] but susceptible protein targets were not described. MCP and
MT, but not CP, TEMPOL, or TPP, increased mitochondrial derived oxidants (Fig.
2.2B), inhibited ATP production (Fig. 2.3F) and decreased mitochondrial membrane
potential in MM cells (Fig. 2.3G). Disruption of mitochondrial architecture with MCP
also increased levels of hyper-oxidized 2-Cys peroxiredoxins (Fig. 2.2C), and over short
time periods increased the levels of disulfide-bonded dimers of PRX3 (Fig. 2.2D),
signatures of increased oxidative stress. These phenotypic effects do not appear to result
from induction of mitochondrial fission, for the lasso and ring-like mitochondrial
structures observed in response to these compounds are not characteristic of
mitochondrial fission [45], and pre-treatment of cells with mdivi-1 did not attenuate the
effects of MCP on mitochondrial fragmentation and the reduction in form factor (Fig.
2.3D). Electron microscopy suggests that swelling of the mitochondrial matrix leads to
protein degradation and disruption of electron chain dynamics.
Several of the compounds we have investigated to date that target mitochondria
affect expression of FOXM1, but only MCP and MT decreased expression of PRX3.
Over the short time intervals studied here, MCP did not affect PRX3 mRNA levels (data
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not shown), but clearly decreased PRX3 expression as detected by immunoblotting and
IF. MCP promotes oxidation of PRX protein (Fig. 2.2C), which may enhance PRX3
proteolytic destruction by Lon protease [55]. We have not investigated the levels or
activity of sulfiredoxin, which repairs hyper-oxidized PRX3, so presently it is unclear if
PRX3-SO2H is repaired over time in MM cells. While several compounds over time
increase the relative levels of mitochondrial oxidants (i.e. gentian violet, TS, MCP and
MT), the results with PRX3 indicate it is unlikely that a common mechanism is
responsible for inhibition of FOXM1 by each agent. Immunofluorescence experiments
indicate that a significant fraction of cellular FOXM1 is associated with mitochondria in
the MM cell cytoplasm, which may link mitochondrial oxidant production and
metabolism to FOXM1.

However, a much better understanding of the expression,

modification, subcellular trafficking and turnover of specific FOXM1 isoforms will be
required to deduce the mechanism of each agent. Nonetheless, certain combinations of
agents that influence mitochondrial function are more cytotoxic than either compound
alone. For example, like gentian violet, MCP promotes the adduction of PRX3 by TS
(Fig. 2.8C), and each has either a synergistic or additive effect with TS on MM cell
cytotoxicity. These findings indicate that combinations of compounds that act through
complementary mechanisms on mitochondrial physiology may prove effective at lower
doses, with fewer collateral effects on normal cells.
Materials and Methods
Cell lines and cell culture: Two human MM cell lines were used in these studies.
HMESO1 (HM) was obtained from J. Testa (Fox Chase Cancer Center, Philadelphia,
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PA); this cell line was originally isolated by Reale and colleagues [68]. H2373 was
established from human MMs after surgical resection [69], and was verified to be
mesothelial using a calretinin antibody. Morphologically, in culture HM appears
epithelioid, while H2373 has fibrosarcomatoid morphology. LP9, a human mesothelial
cell line immortalized with hTERT, was obtained from J. Rheinwald (Dana Farber
Cancer Institute, Boston, MA). Cell lines were validated by STR DNA fingerprinting
using the Promega CELL ID System (Promega, Madison, WI). The STR profiles are of
human origin, and did not match known DNA fingerprints in the Cell Line Integrated
Molecular Authentication database (http://bioinformatics.istge.it/clima/), but will serve as
a reference for further work. Cells were maintained in DMEM-F12 with hydrocortisone,
insulin, transferrin, and selenite with 10% fetal bovine serum (FBS, GIBCO) as
previously described [70].
Inhibitors: Mito-Carboxy Proxyl (MCP), Mito-TEMPOL (MT), Carboxy Proxyl (CP),
TEMPOL and Methyl Triphenylphosphonium Chloride (TPP) were synthesized as
previously described [25]. Mdivi-1 was purchased from Enzo Life Sciences (NY, USA).
Thiostrepton was purchased from EMD Biochemicals (MA, USA). Rotenone was
purchased from Sigma (MO, USA). All compounds were re-suspended in molecular
grade sterile DMSO.
Immunoblotting: Cell lysates were prepared as previously described [63].

Protein

concentrations were determined using Bradford assays (Bio-Rad, Hercules, CA). For
non-reducing gels, dithiothreitol (DTT) was omitted from loading buffer. Lysates (15-20
μg protein/well) were resolved by SDS-PAGE and prepared for immunoblotting as
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previously described [71].

Blots were incubated at 4 C overnight with rabbit anti-

FOXM1 K19 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at a
1:500 dilution in blocking buffer, anti-PRX3 monoclonal antibody at a 1:2000 dilution
(Ab Frontier, Seoul, Korea), anti-PRX-SO2/3 antibody at a 1:2000 dilution (Ab Frontier),
or anti-PRX1 polyclonal antibody at a 1:2000 dilution (Ab Frontier), and after washing
protein bands were visualized with the Western Lightning chemiluminescent detection
system (Perkin Elmer, Waltham, MA) using secondary antibodies coupled to horse radish
peroxidase.

Blots were stripped and re-probed with a mouse anti-actin antibody

(Millipore, Billerica, MA) to verify equal protein loading.

Measurement of PRX3

monomer/dimer ratios by immunoblotting was carried out as described above with
sample buffer free of reducing agents.
Detection of oxidant formation: Cells were plated in black-wall, clear-bottom 96-well
microplates (Corning, Lowell, MA) and treated the following day for 6 hrs with indicated
compounds in triplicate. Cells were then washed in PBS and loaded with 10
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Dihydroethidium (Invitrogen) prepared in complete media, and read at 525 ex/595em using
a BioTek Synergy H4 Hybrid microplate reader (BioTek Instruments, Winooski, VT).
Plates were then washed and loaded with 4 µg/mL Hoescht 33342 (Invitrogen) for 15
min, washed and read at 350 ex/450em to normalize for cell number. For staining with nitro
blue tetrazolium (NBT, Sigma), cells were plated in 24-well dishes and treated as
described in the text. After treatment, cells were washed and incubated with 1.5 mg/mL
of NBT in Hanks buffered salt solution (HBSS) at 37˚C for 40 minutes. Cells were
subsequently washed with HBSS and fixed in 100% methanol.
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NBT formazan

precipitates were dissolved by adding 280 µL KOH and 240 µL DMSO. The amount of
reduced NBT was quantified by reading absorbance at 630 nm. Cells were subsequently
stained with DAPI and cell nuclei were counted to control for cell number.
MitoSOX Red Flow Cytometry: After the indicated treatments cells were loaded with
5 µM MitoSOX Red (Invitrogen) in tissue culture medium for 30 minutes. Cells were
washed with HBSS, collected by brief trypsinization, centrifuged and washed twice in
HBSS, and re-suspended in 1% bovine serum albumin (BSA) in HBSS with calcium and
magnesium and analyzed by flow cytometry. To monitor oxidized MitoSOX Red, cells
were excited at 488 nm and emission was collected in the FL2 channel. Cells without
dye and/or treated with menadione were used as controls for each experiment (data not
shown). For cell cycle determination Hoescht 33342 (Invitrogen) was included in the
incubation with MitoSOX Red and analyzed on a BD LSRII analytical flow cytometer.
Hoechst 33342 and MitoSOX Red alone controls were used to confirm specificity of
emission (data not shown).
Cell viability assays: Cells were plated in 96-well plates at a density of 1500 cells per
well. The following day, cells were treated with test compounds in complete medium.
After 5 days cells were washed with PBS, fixed in 3.7% para-formaldehyde and stained
for 30 min with 0.1% crystal violet in water. To quantify crystal violet staining, the dye
was dissolved in 100% methanol and absorbance was read at 540 nm. Signals were
normalized by subtracting the background signal from wells treated in the same fashion,
but with no cells.

73

Measurement of mitochondrial redox status by Mito-roGFP2: Cells were plated in 35
mm glass bottom imaging dishes (MatTek, Ashland, MA) and transiently transfected
with pEGFP-R12 (mito-roGFP2) using Lipofectamine 2000 (Invitrogen) according to
manufacturer’s instructions. pEGFP-R12, which expresses a redox-responsive version of
GFP targeted to mitochondria, was a gift from J. A. Melendez (College of Nanoscale
Science and Engineering, University at Albany, NY). The following day media was
changed to CO2 - independent imaging media (Invitrogen) supplemented with all other
components of complete MM media and imaged on a Nikon Ti-E inverted microscope
with a 100X 1.49 NA objective in a heated environmental chamber. To determine the
oxidation state of the probe, fluorescence images were collected with an Andor iXon X3
EMCCD camera (Andor Technology, Belfast, UK) after excitation with the violet (~400
nm) or teal (~495 nm) outputs from a Spectra X light engine (Lumencor, Beaverton, OR);
emission was collected at 525 nm for both excitation wavelengths. Individual cells were
imaged every minute for 30 minutes and the ratio of emission from 400 (oxidized) and
495 (reduced) was measured to determine the relative redox status of the probe in each
cell line tested.

Quantification of signals was determined using the NIS-Elements

software (Nikon Instruments, Melville, NY) and is graphically depicted as the mean of
the 400/495 ratio +/- SEM.
Measurement of mitochondrial morphology: Cells were plated and transfected
pEGFP-R12 (mito-roGFP2) as described above. Cells were imaged every 30 seconds for
10 min prior to addition of indicated compound in CO 2 independent imaging media
directly to the dish mounted on the microscope. Cells were further imaged for 1 hr post-
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drug addition. Representative images of each cell before and after treatment were used to
analyze mitochondrial form factor. Methods for analyzing mitochondria were adapted
from Koopman et al.[30, 72].

Briefly, using ImageJ software (ImageJ, NIH) images

were uniformly adjusted for brightness/contrast and a “top-hat” filter was applied to
isolate bright mitochondria from background. A threshold was applied to each image
equally and individual particles (mitochondria) were analyzed for area and perimeter.
Form factor (F), a measure of mitochondrial length and branching was determined for
each image using the equation F= (perimeter2/4π*area).
Immunofluorescence microscopy: Cells were plated on 18mm glass coverslips (Fisher
Scientific) in 12 well dishes and treated with indicated compounds in complete media.
Cells were washed once with PBS and fixed in 3.7% paraformaldehyde in PBS for 10
min, permeabilized in .25% Triton X100 in PBS for 10 min, and blocked in 1.5% BSA in
PBS for 1 hr at room temperature (RT). Coverslips were incubated with rabbit antiFOXM1 c-20 (Santa Cruz, 1:200) and mouse anti-PRX3 (1:200) in 1.5% BSA for 1 hr at
RT, washed 5 x 5 minutes with PBS and incubated with secondary goat anti-rabbit 488
(Invitrogen, 1:400) and donkey anti-mouse 594 (Invitrogen, 1:400) antibodies.
Coverslips were then washed 5 x 5 min with PBS, with the final wash containing DAPI
(Invitrogen, 1:4000), and mounted on glass slides (Labcraft, TX, USA) with Aqua Poly/Mount (Polysciences, Inc, PA, USA). Images were collected on a Nikon Ti-E
inverted microscope with a 60X oil immersion objective as described above. Exposure
times were adjusted based on secondary antibody controls.
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Transmission Electron Microscopy: HM cells were grown on Thermanox plastic
coverslips (Nalge Nunc International, Rochester, NY), and fixed for 30 min at 4 oC in
2.5% glutaraldehyde/1.0 % paraformaldehyde in 0.1 M cacodylate buffer, pH 7.2. After
three rinses in 0.1 M cacodylate buffer, the cells were post-fixed in 1% OsO4 for 1 hr at
4oC, rinsed three times in 0.1 M cacodylate buffer, and stored overnight in buffer at 4 oC.
The following day, the samples were dehydrated in a graded series of ethanol, and
infiltrated with and embedded in EMBed-812 resin by placing a BEEM capsule
containing resin over areas of the coverslip containing cells. Following polymerization in
an oven, the BEEM capsules were pried off of the coverslip by applying gentle pressure.
Ultrathin sections (60-80 nm thick) were cut with a diamond knife and retrieved onto
nickel 200 mesh copper grids, and contrasted with 2% alcoholic uranyl acetate and lead
citrate. The sections were imaged with a JEOL 1400 transmission electron microscope
(JEOL USA, Inc., Peabody, MA) operating at 60 kV. Digital images were acquired with
an AMT-XR611 11 megapixel ccd camera (Advanced Microscopy Techniques, Danvers,
MA), and saved in tiff format (12.2 mB/image).
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Figure Legends
Figure 2.1.

Rotenone influences FOXM1 expression levels differently in LP9

mesothelial and HM malignant mesothelioma cells. A) Oxidant levels were measured by
NBT absorbance as a function of cell number in LP9 and HM cells after treatment for 6
hr with the indicated concentration of the complex I inhibitor rotenone. (n = 3, ** p <
0.01). B) Mitochondrial oxidant levels were measured in the indicated cell lines by flow
cytometry with MitoSox Red, using quantification of nuclear DNA content with Hoechst
stain to determine cell cycle phase. Shown are the relative levels of mitochondrial
oxidants at the G1/0, S, and G2/M phases of the cell cycle. Mitochondrial oxidant levels
increase during transition from G0/G1 to G2/M phase in all cell lines, but mitochondrial
oxidants are elevated in MM cells as compared to LP9 cells at all phases of the cell cycle.
C) Immunoblot analysis shows the effect on FOXM1 expression levels in LP9 and HM
cells after treatment with rotenone for 6 hr. Actin was used as a loading control. Note
the increase of FOXM1 expression in LP9 cells in response to rotenone, whereas the
same concentrations of rotenone inhibit FOXM1 expression in HM cells.
Figure 2.2. MCP and MT increase mitochondrial oxidant levels. A) Total cellular
oxidant levels were measured by DHE fluorescence after 6 hr treatment with MCP or MT
in HM and H2372 MM cells. Staining with Hoechst was used to normalize the signals to
total cell number. B) Mitochondrial oxdiant levels were measured by flow cytometry
with MitoSox Red after treatment with MCP, MT or control compounds for 6 hr in MM
cells.

Flow cytometry histograms for TEMPOL, CP and TTP (bottom two panels)

overlaid one another, and are presented in perspective. C) Immunoblot analysis showing

82

hyper-oxidation of peroxiredoxins after treatment with MCP. HM cells were treated with
the indicated concentration of MCP for 6 hrs and total cellular PRX-SO2 H/SO3 levels
were assessed by western blotting. Actin was used as a loading control. D) Oxidation of
mitochondrial localized PRX3 was measured by formation of PRX3-S-S-PRX3 disulfide
bonded dimers. HM and H2372 cells were treated with the indicated concentrations of
MCP for 6 hr, and cell lysates prepared in the absence of DTT but with SDS were
resolved by native gel electrophoresis as described in Materials and Methods. The
relative amount of PRX3-S-S-PRX3 dimers was estimated by western blotting with an
anti-PRX3 antibody.

The ratio of dimer to monomer as measured by densitometry is

provided.
Figure 2.3.

MCP and MT disrupt mitochondrial architecture.

A) HM cells were

transfected with mito-roGFP2 and still frame images were captured before (control) and
after treatment with 1µM MCP or MT for 1 hr (drug). Enlarged images (insets) represent
magnified portions of the same cells (scale bar = 10 µm). Note that MCP and MT induce
mitochondrial fragmentation, with vesicular and ring-like structures.

Temporal

responses in MCP and MT are shown on the supporting imaging videos.

B)

Quantification of mitochondrial form factor F (as described in Materials and Methods) in
HM cells treated with MCP or MT, as well as CP, TEMPOL and TPP controls (n = 10,
****p = 0.0001, ns = not significant). C) Still frame images of HM cells transfected
with mito-roGFP2 and pre-incubated with the DRP-1 inhibitor mdivi-1 for 3 hr (middle
panel) prior to addition of 1µM MCP for 1 hr (bottom panel). Mdivi did not rescue
mitochondria from fragmentation by MCP. Scale bar =10 µm. D) Quantification of
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mitochondrial form factor from cells presented in C (n=3). E) Ratiometric imaging of
HM cells transfected with mito-roGFP2 was used to quantify increased oxidation in
mitochondria as compared to control cells after treatment with 1 µM MCP for 6 hr (n = 5,
***p = 0.0005). F) Total cellular ATP levels were measured after treatment with 1 µM
of the indicated compounds for 6 hr (*p = 0.05). G) Mitochondrial membrane potential
was measured at the indicated concentrations of MCP, CP TPP or the positive control
compound CCCP.

As compared to CP or TTP, MCP depolarized mitochondrial

membranes within 6 hr in a dose-dependent fashion, while CP and TPP had no effect on
the same end point.
Figure 2.4. Mitochondrial architecture by TEM of MCP treated HM cells.

HM cells

were incubated for 6 hrs with 1 µM of indicated compounds and visualized by TEM.
Arrows denote the cell membrane, arrowheads denote the nuclear membrane, and
asterisks denote mitochondria. Scale bar = 500 nm for (A-E), 2 µm for (F)
Figure 2.5.

Mdivi-1 increases mitochondrial oxidant levels and decreases FOXM1

expression in MM cells. A) HM and H2373 cells were incubated with the indicated
concentration of the DRP-1 inhibitor mdivi-1 for 12 hr and FOXM1 protein expression
was evaluated by immunoblotting. B) HM and H2372 cells were treated as in panel A
and DHE fluorescence was used to measure total cellular oxidant levels.

Hoechst

staining for DNA content was used to normalize the signal to cell number (n = 3, p =
0.0001).
Figure 2.6. MCP leads to loss of FOXM1 and PRX3 protein expression in MM cells. A.
HM cells were treated with the indicated concentration of MCP, CP or TPP for 12 hr, and
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FOXM1, PRX3 and TR2 levels were evaluated by immunoblotting. B) HM cells were
treated with the indicated concentrations of MCP for 12 hr, and PRX3 expression levels
were compared to PRX1 by immunoblotting. MCP reduced expression of PRX3 while
PRX1 was unaffected. C) HM cells were treated with the indicated concentration of
MCP, or MCP plus 10 µM MG132, an inhibitor of the proteosome and Lon protease.
FOXM1, PRX3 and TR2 expression levels were evaluated by immunoblotting. Actin
was used as a loading control.
Figure 2.7. FOXM1 and PRX3 coexist in the cytoplasm of HM cells. A) HM cells were
processed for immunofluorescence microscopy using the indicated primary antibodies;
nuclear DNA was stained with DAPI. B) HM cells were treated for 18 hr with 1 uM TS
and stained for subcellular localization of FOXM1 and PRX3 as in column A. C) HM
cells were treated for 18 hr with 1 uM MCP and stained for subcellular localization of
FOXM1 as in column A. As detected in by immunoblotting, TS reduced the signal for
FOXM1 without affecting PRX3, whereas MCP reduced the signal for FOXM1 and
PRX3.
Figure 2.8. MCP inhibits cell viability and potentiates the cytotoxic effects of TS. HM
(A) and H2373 (B) cells were treated with the indicated concentrations of MCP, TS or
MCP and TS for 3 days and total cell mass was quantified by solulbilizing crystal violet
stain.

The data are presented as % cell survival as compared to untreated controls (0

drug dose). Overall changes in each group were statistically analyzed by 1-way ANOVA
(n = 3, ****p = 0.0001), while differences between treatment groups were statistically
analyzed by students t-test (n = 3, ***p = 0.001, **p = 0.003, *p = 0.01). C) HM cells
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were treated with 1 µM MCP, 1 µM TS or 1 µM MCP + 1 µM TS as indicated for 18 hr,
and cell lysates were examined for PRX3 expression by immunoblotting.

MCP

potentiates the ability of TS to modify PRX3, leading to a SDS and DTT-resistant species
that migrates at ~50kD [23].

Supplementary Figure S1: Structures of mitochondrial targeted nitroxides.
Supplementary Video 1: HM cells were transfected with an expression vector for MitoroGFP2 and visualized by live cell imaging as described in Materials and Methods.
Images were taken every minute for 30 minutes. MCP (1 µM) was added directly to the
imaging

dish

in

complete

imaging

media

at

frame

8.

Available

online

http://onlinelibrary.wiley.com/doi/10.1002/jcp.24232/full
Supplementary Video 2: HM cells were transfected with an expression vector for MitoroGFP2 and visualized by live cell imaging. Images were taken every minute for 30
minutes. MT (1 µM) was added directly to the imaging dish in complete imaging media
at frame 3.
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Abstract
Thioredoxin reductase (TR) catalyzes the reduction of thioredoxin (TRX), which
in turn reduces mammalian typical 2-Cys peroxiredoxins (PRXs 1-4), thiol peroxidases
implicated in redox homeostasis and cell signaling. Typical 2-Cys PRXs are inactivated
by hyperoxidation of the peroxidatic cysteine to cysteine-sulfinic acid, and regenerated in
a two-step process involving retro-reduction by sulfiredoxin (SRX) and reduction by
TRX. Here transient exposure to menadione and glucose oxidase was used to examine
the dynamics of oxidative inactivation and reactivation of PRXs in mouse C10 cells
expressing various isoforms of TR, including wild type cytoplasmic TR1 (Sec-TR1) and
mitochondrial TR2 (Sec-TR2) that encode selenocysteine, as well as mutants of TR1 and
TR2 in which the selenocysteine codon was changed to encode cysteine (Cys-TR1 or
Cys-TR2). In C10 cells endogenous TR activity was insensitive to levels of hydrogen
peroxide that hyperoxidize PRXs. Expression of Sec-TR1 increased TR activity, reduced
the basal cytoplasmic redox state, and increased the rate of reduction of a redoxresponsive cytoplasmic GFP probe (roGFP), but did not influence either the rate of
inactivation or the rate of retro-reduction of PRXs. In comparison to roGFP, which was
reduced within minutes once oxidants were removed reduction of 2-Cys PRXs occured
over many hours. Expression of wild type Sec-TR1 or Sec-TR2, but not Cys-TR1 or
TR2, increased the rate of reduction of PRXs and improved cell survival after menadione
exposure. These results indicate that expression levels of TR do not reduce the severity
of initial oxidative insults, but rather govern the rate of reduction of cellular factors
required for cell viability. Because Sec-TR is completely insensitive to cytotoxic levels
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of hydrogen peroxide, we suggest TR functions at the top of a redox pyramid that
governs the oxidation state of peroxiredoxins and other protein factors, thereby dictating
a hierarchy of phenotypic responses to oxidative insults.
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Introduction
Cellular oxidants modulate the strength and duration of signaling through redoxresponsive pathways that govern cell proliferation and survival [1, 2]. In many disease
states management of endogenous and/or exogenous oxidants may be compromised,
leading to oxidative stress, damage to macromolecules and loss of cell viability.
Phenotypic adaptation to chronic oxidative stress, such as occurs in many cancers, often
involves up-regulation of stress response proteins and antioxidant enzymes, leading to
improved cell survival [3]. Among the families of antioxidant enzymes that are often
over-expressed in cancer and other disease states are thioredoxin reductases (TRs) and
peroxiredoxins (PRXs), both which are involved in the metabolism of hydrogen peroxide
[4]. Mammalian TRs are a family of selenocysteine-containing oxidoreductases that act
as the primary reductases for thioredoxin (TRX) in a NADPH dependent reaction [4, 5].
Recent studies show that selenocysteine in the C-terminal redox center renders
mitochondrial TR insensitive to inactivation from oxidants [6], suggesting TR and other
selenoenzymes may mediate resistance to oxidative stress.
Malignant mesotheliomas express elevated levels of TR1 [7, 8] and mesothelioma
cells propagated in vitro have higher levels of TR activity than do untransformed
mesothelial cells [9]. Given that this phenotype has been observed in many other tumor
types, TR has emerged as an attractive therapeutic target in human malignancies [10, 11].
Because of the limited number of cellular proteins that contain selenocysteine, one
approach is to use compounds (such as aurothioglucose and auranofin) that selectively
target selenocysteine [12-14]. However, the effects of inhibition or over-expression of
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TR on cell growth and survival are not straightforward, as expression of TR in which the
activity of selenium is compromised may induce cell death due to pro-oxidant activity
[15]. TR and TRX have been shown to influence the activity of transcription factors,
kinases and other factors in cell signaling circuits, and in some contexts the proproliferative role of its primary substrate thioredoxin (TRX) has been ascribed to
regulation of the ERK pathway leading to expression of cyclin D1 [16].
Peroxiredoxins are a family of thiol peroxidases that are ubiquitously expressed
throughout eukaryotes. In mammals there are six family members, with peroxiredoxins
1-4 representing typical 2-Cys PRXs; these enzymes function as head-to-tail homodimers
with two reaction sites, each consisting of a peroxidatic cysteine in one monomer and a
resolving cysteine in the opposing subunit [17]. During the metabolism of hydrogen
peroxide the initial step in the peroxiredoxin reaction cycle is oxidation of the peroxidatic
cysteine to sulfenic acid (-SOH), which then spontaneously reacts with the resolving
cysteine in the opposing subunit to produce an intermolecular disulfide bond.

The

intermolecular disulfide bond then is reduced by thioredoxin, which in turn is reduced by
TR, using reducing equivalents from NADPH. The peroxidatic cysteines of 2-Cys PRXs
are among the most reactive cysteines in the cell [18], in part due to the stabilization of
the thiolate in the active site and structural interactions positioning peroxide for attack
[19-21]. Curiously, an evolutionarily conserved carboxy-terminal extension on PRXs 1-4
stabilizes the peroxidatic –SOH intermediate, making it susceptible to further attack by
hydrogen peroxide, thereby leading to formation of sulfinic acid (-SOOH). This process,
which has been termed “over-oxidation” or “hyperoxidation”, precludes disulfide bond
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formation and would be expected to permanently inactivate the enzyme, for sulfinic acid
residues in proteins generally are not repaired. PRXs are a notable exception, for with
the aid of ATP the reductase sulfiredoxin (SRX) is capable of “retro-reduction” of PRXSOOH and regeneration of enzyme activity [22, 23]. In addition to homodimers, the
oxidation state of PRXs influences their relative distribution in dimers, decamers and
higher order oligomers that have chaperone and other functions [24].

The unusual

features of PRX catalysis and oligomerization, as well as their interaction with many
cellular regulatory factors, have led to proposals that PRXs act as peroxide sensors in
which structural transitions and/or changes in protein-protein interactions with cellular
regulators modulate responses to oxidative stress [25, 26]. In yeast, the TR system is
devoted to metabolism of hydrogen peroxide [27], and regulation of hierarchical
responses to oxidative insults by the thiol peroxidase Tsa1 has been elegantly dissected
[28, 29]. However, detailed descriptions of similar hierarchical pathways in mammalian
cells have yet to be reported.
Both TR and PRXs may be over-expressed in cancer, and studies in which TR has
been down-regulated by RNA interference strongly support the hypothesis that elevated
expression of TR promotes tumor cell proliferation in culture and tumor progression in
animal models [30, 31]. To mimic the situation often encountered in malignancies, we
have expressed cytoplasmic TR1 and mitochondrial TR2 in mouse lung epithelial C10
cells that are immortalized but not tumorigenic. Previously we described the relationship
between the oxidation state of PRX2 and C10 cell cycle progression in response to fluxes
of hydrogen peroxide, and showed that expression of cyclin D1 and cell cycle
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progression was not recovered after oxidative insult until PRX2 was completely reduced
[32]. However, in contrast to PRXs, mammalian TRs with selenocysteine in the Cterminal catalytic site are remarkably resistant to inactivation by hydrogen peroxide and
other oxidants in vitro [6], raising the possibility that TR sits at the top of a redox
pyramid that includes peroxiredoxins as exquisitely sensitive detectors of cellular
peroxide.
To test this possibility, we compared the ability of TRs encoding selenocysteine
in the C-terminal redox center to TRs in which the codon for selenocysteine had been
changed to that for cysteine to mediate recovery from oxidative insults. Our data suggest
that TR levels do not directly influence the extent of the initial insult, but rather dictate
the rate of recovery and cell viability, restoring proliferative capacity over time.
Moreover, only wild type TRs had the capacity to improve cell survival, indicating that
the insensitivity of selenocysteine to inactivation by hydrogen peroxide is an important
feature of mammalian TRs.
Results
Previously we characterized the responses of mouse lung epithelial C10 cells to
oxidative insults in regard to cell cycle arrest and recovery [1, 36, 37] and demonstrated
that after arrest expression of cyclin D1 and cell proliferation does not resume until
hyper-oxidized PRXs are reduced and high-molecular oligomers of PRX2 are resolved to
decamers and dimers [32]. C10 cells were chosen as model for these experiments since
airway epithelial cells are exposed to ambient levels of oxygen in vivo, and while C10
cells are immortalized, they do not form tumors in syngeneic mice. Given that TR and
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TRX play important roles in the reduction of PRXs, and that over-expression of TR is
often associated with resistance to oxidative stress and cell survival in tumor cells, we
examined the effects of expression of TR1 and TR2, with or without expression of the
cognate TRX, on recovery of C10 cells from oxidative insults and cell survival. To
examine the role of selenocysteine in TR-mediated cell survival, expression of wild type
TR mRNAs were compared to TR mRNAs in which the codon for the catalytic
selenocysteine was replaced with the codon for cysteine. To control for effects of noncoding sequences, plasmid cDNA vectors expressing full-length mRNAs with native 5
and 3 untranslated regions, including the cognate selenocysteine insertion element
(SECIS element), were used.
Cellular TR activity is insensitive to oxidative insults. After exposure of C10 cells to
concentrations of glucose oxidase (GOx) greater than 2.5 mU/mL for three hours,
expression of cyclin D1 ceases and cells arrest in the cell cycle [32]. Exposure of C10
cells to increasing concentration of GOx showed that concentrations of 1.25 mU/mL or
greater induced hyperoxidation of PRXs (Fig. 3.1B, lanes 1-6), whereas under the same
exposure conditions GOx caused no significant reduction of total cellular TR activity
(Fig. 3.1A). In contrast, exposure of C10 cells to the reactive aldehyde acrolein, which
attacks the selenocysteine moiety and thereby inhibits TR activity [38], completely
abolished cellular TR activity (Fig. 3.1A). These data indicate that cellular TR activity,
identical to purified TR enzyme [6], is highly resistant to inactivation by hydrogen
peroxide, and that the vast majority of TR activity detected in C10 cell lysates is sensitive
to acrolein.
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Under similar culture conditions exposure of C10 cells to highly cytotoxic
concentrations of menadione (MD), a quinone that produces oxidative stress in both the
cytoplasmic and mitochondrial compartments [39, 40], resulted in increased levels of
hyperoxidized PRX and modest reductions in TR activity, even at the highest
concentrations (Fig. 3.1C, D).

At lower but cytostatic doses of MD, increased

hyperoxidation of PRXs was still evident (Fig. 3.1E), but TR activity was completely
unaffected (Fig. 3.1F). These initial studies showed that under conditions in which PRXs
are inactivated by hyperoxidation, cellular TR activity is largely unaffected, supporting
the supposition that selenocysteine contributes to the resistance of TR to inactivation by
reactive oxygen species [41].
Expression of Sec-TR and Cys-TR on total cellular TR activity. To mimic overexpression of TR that occurs in malignant mesothelioma and other tumor cell types,
plasmid expression vectors were constructed for wild type human cytoplasmic TR (SecTR1) and mitochondrial TR2 (Sec-TR2), as well as mutants in which the codon for
selenocysteine was replaced by site-directed mutagenesis with a codon for cysteine (here
referred to as Cys-TRs, or TR1-U498C and TR2-U523C) (Fig. 3.2A). In transfection
experiments ectopic expression of immunoreactive TR1 polypeptides was dependent on
the concentration of plasmid DNA (Fig. 3.2B and data not shown), and in C10 cells
transfected with the WT TR1 expression vector (1 ug DNA/ 60 mm dish) total TR
activity increased 2-fold (Fig. 3.2C). In C10 cells transfected with the expression vector
for TR1-U498C levels of TR activity were not significantly greater than in C10 cells
transfected with the pCDNA3.1 vector alone (Fig. 3.2B and C). The increased TR1
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protein and activity levels after transfection of C10 cells with WT TR1 reflect those in
malignant mesothelioma and other tumor cell types [9]. Transfection of siRNAs targeted
to TR1 reduced expression of TR1 by 90% (data not shown) and reduced TR activity to
10% of endogenous levels (Fig. 3.2C). Expression of WT-TR2 and TR2-U523C at
relatively high levels did not result in increased total cellular TR activity (Fig. 3.2D), a
finding in agreement with previous studies that showed mitochondrial TR activity
represents less than 10% of the total cellular TR activity [42], as suggested here by the
residual TR activity after silencing TR1 (Fig. 3.2C). Approximately 50% of the TR
activity in control cells transfected with WT-TR1 or TR1-U498C was sensitive to the TR
inhibitor auranofin (Fig. 3.2E).

We recognize that the amount of WT-TR1 protein

expressed after 24 hr was significantly higher compared to endogenous levels, and while
the total TR activity also increased, it did not increase more than 2 to 3-fold. The reason
for this apparent discrepancy is not known.
These transfection studies established that the plasmid vectors for WT-TR1 and
Cys-TR1

mutants

produced

polypeptides

with

apparent

molecular

weights

indistinguishable from endogenous TR, and that expression of Sec-TR1 increased cellular
TR activity. Expression of TR1-U498C, in contrast, failed to significantly increase
cellular TR activity. Similarly expression of Sec-TR2 and Cys-TR2 resulted in increased
expression of immunoreactive TR2 polypeptides with apparent molecular weights
identical to endogenous TR2, but neither Sec-TR2 nor TR2-U523C resulted in
statistically significant increases to total cellular TR activity.

However, when

mitochondrial fractions were prepared that contained the ectopically expressed Sec-TR2,
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increased TR activity was observed (data not shown). Co-transfection of TRX1 or TRX2
with or without the cognate TR did not increase total TR activity above that observed
with transfection of TR alone (data not shown).
Effects of TR expression of reduction of roGFP.

Using genetically-encoded GFP

probes that are sensitive to oxidation-reduction (roGFP) [33], the effects of expression of
Sec and Cys-TRs on the basal redox state of the cytoplasm and mitochondria were
investigated with ratiometric live cell imaging (Fig. 3.3A). For examining the redox state
of the cytoplasm, C10 cells were co-transfected with vectors for roGFP targeted to the
cytoplasm (cyto-roGFP) and either Sec-TR1 or Cys-TR1, with or without an expression
vector for TRX1. For mitochondria, C10 cells were transfected with vectors for roGFP
targeted to the mitochondria (mito-roGFP) and either Sec-TR2 or Cys-TR2, with or
without an expression vector for TRX2. On the day following transfection, the ratio of
oxidized to reduced roGFP was evaluated by live cell fluorescence microscopy (Fig.
3.3A). Expression of Sec-TR1 but not Cys-TR1 reduced the basal redox state of the cell
cytoplasm (Fig. 3.3B), and in a similar fashion expression of Sec-TR2 but not Cys-TR2
caused a significant reduction in the basal redox state of mitochondria (Fig. 3.3C and D).
These results correlated well with the effects of expression of Sec and Cys-TRs on
cellular TR activity (Fig. 3.2).
Cells co-transfected with vectors for roGFP and WT-TR1 or Cys-TR1 (with or
without expression of TRX1) were then exposed to high concentrations of menadione for
30 min, followed by a recovery period after the menadione was removed by 5 successive
changes of imaging medium, and ratiometric imaging was used to assess changes in the
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roGFP oxidation state over time. As shown in a representative experiment in Fig. 3.3E,
roGFP was rapidly oxidized in response to menadione, and the probe remained oxidized
for at least 25 min. Once the menadione was removed, the reduction of the roGFP probe
was rapid, with a return to basal state within 10-15 min. In cells transfected with SecTR1 the change in the oxidation (ΔOx) of the roGFP probe from oxidized to reduced was
increased over cells transfected with vector control or Cys-TR1 (Fig. 3.3F). In a similar
fashion, expression of Sec-TR2 increased the ΔOx of mito-roGFP after washout of
menadione over cells transfected with pcDNA (Fig. 3.3G). Expression of Cys-TR2
tended to increase the ΔOx of mito-roGFP, but the increases were not statistically
significant across several experiments (Fig. 3.3G).

The ratiometric imaging data

confirmed that acute menadione exposure induces both cytoplasmic and mitochondrial
oxidative stress, as reported previously [40], and that expression of Sec-TR1 or Sec-TR2
reduces the basal redox state of C10 cells and improves reduction of the roGFP probes
targeted to the cytoplasm or mitochondria, respectively.
TR and hyper-oxidation and reduction of PRXs. The peroxidatic cysteines of PRXs
are among the most reactive thiols in the cell [18].

To compare the oxidative

modifications of PRXs to oxidation of roGFP in response to menadione, cells were
treated with 40 µM menadione for 1 hr, then the menadione was washed out, and cells
were allowed to recover for 4 hr. Cell extracts were prepared at various time points and
assessed for the presence of hyperoxidized PRXs by blotting with an antibody specific to
PRX-SO2/SO3H. A strip-reprobe blotting method was used to estimate the relative
amount of a specific PRX that was inactivated by hyperoxidation [32]. To assess the

106

levels of PRX-S-S-PRX dimers, which can only be generated during the PRX catalytic
cycle, extracts were resolved under denaturing conditions in the absence of reducing
agent (i.e. with SDS but no DTT) [32]. Under no exposure condition was a significant
reduction in the total levels of PRX1-3 observed (Fig. 3.4, Supplementary Fig. 1, data not
shown).
The response of PRX3 to oxidative inactivation and reduction during exposure
and recovery is shown in Fig. 3.4, and this response was representative of that for PRX1
and PRX2 (not shown). Within 1 hr of menadione treatment, markedly increased levels
of hyper-oxidized PRXs were observed and expression of WT-TR2 or TR2-U523C had
no effect on oxidative inactivation of PRXs, and reprobing the blot with antibody to
PRX3 indicated a significant fraction of PRX3 was inactivated under these conditions
(Fig. 3.4A, lanes 4-6). Hyper-oxidized 2-Cys PRXs are repaired by SRX, which is
recruited to mitochondria in response to inactivation of PRX3 [43].

Over time

hyperoxidized PRXs were repaired, and after 4 hrs the cellular pools of hyperoxidized
PRXs had returned to baseline, as did the signal for total PRX3 (Fig. 3.4A, lanes 7-17).
Although expression of WT-TR2 reduced the basal oxidation state of cellular
mitochondria (Fig. 3.3C), the change in basal redox state did not affect either the
inactivation of PRX3 by menadione or the apparent rate of retro-reduction of
hyperoxidized PRX3 by SRX. The redox status of roGFP probes as compared to cellular
proteins is not well understood and may contribute to the interpretation of this result [33].
Examination of the relative levels of PRX3 dimers by denaturing but not reducing
gel electrophoresis showed that increases in hyperoxidized PRX3 (which cannot form
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disulfide-bonded dimers) was accompanied by reduction in the abundance of PRX3
dimers, as expected (Fig. 3.4B, lanes 4-6). After 2 hrs of recovery, levels of PRXSO2/SO3H were reduced, and levels of dimeric PRX3 were increased as compared to
baseline levels (Fig. 3.4B, compare lanes 1-3 to lanes 10-12). Expression of WT or TR2U523C had no effect on the level of PRX3 dimers or monomers by this time, but after 4
hr of recovery expression of WT-TR2 increased the levels of both dimers and monomers
as compared to vector control or TR2-U523C (Fig. 3.4B lanes 16-18). Together these
expression experiments showed that both mito-roGFP and PRX3 were rapidly oxidized in
response to menadione, but mito-roGFP was reduced in the order of minutes whereas
repair of hyperoxidized PRX3 occurred over several hours. Only Sec containing WTTR2 had any perceptible effect on recovery from acute oxidative insult. Our results
confirm the relative sensitivity of PRXs to inactivation by oxidants and reinforce the
concept that oxidative modification of cellular proteins depends in part on the reactivity
of specific cysteine residues, thereby providing a mechanistic basis for a hierarchy of
modifications in regulatory factors that mediate phenotypic outcomes.
Sec-TRs but not Cys-TRs improve cell survival. Acute oxidative insults invoke stress
responses that differ from chronic oxidative stress, and to model these conditions cells
were exposed to lower doses (60 nM – 7.5 µM) of menadione for 24 hr. To evaluate the
level of cellular oxidants after chronic exposure to a range of menadione concentrations,
we incubated cells with the general oxidant probe DCF 24 hr after addition of menadione
to cells. DCF fluorescence showed that increasing concentrations of menadione caused a
corresponding continuous increase in cellular oxidants for at least 24 hr, and expression
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of either Sec-TR1 or TR1-U498C did not reduce the levels of DCF fluorescence (Fig.
3.5A). In contrast, viability assays showed that expression of Sec-TR1 promoted cell
survival and most likely cell proliferation above control values for menadione
concentrations up to 3.75 uM, above which concentration cell viability was markedly
reduced (Fig. 3.5B). Note that low concentrations of menadione apparently stimulated
cell growth as suggested by increases in total cellular mass, and that this effect was
increased by expression of Sec-TR1, strengthening the possibility that enhanced
production of oxidants and elevated expression of TR1 in tumor cells cooperate to
promote cell proliferation.
Under similar conditions the expression of Sec-TR2 and TR2-U523C
unexpectedly tended to increase DCF fluorescence (but not significantly) after 24 hr (Fig.
3.5C), but only Sec-TR2 improved viability at menadione concentrations between 0.5 and
3.75 uM (Fig. 3.5D). Expression of TR2-U523C tended to increase viability, especially
at higher concentrations of menadione, but this effect was not statistically significant
from experiment to experiment (Fig. 3.5D). Co-expression of TRX1 with Sec-TR1 or
TR1-U498C did not improve viability above that observed with expression of WT -TR1
alone (Fig. 3.5E), nor did co-expression of TRX2 with WT-TR2 or TR2-U523C improve
viability above that observed by expression of WT-TR2 alone (Fig. 3.5F).
Discussion
The thioredoxin system comprised of TR, TRX and NADPH, plays a complex
role in cancer [12, 44].

In normal cells TR is thought to impede neoplastic

transformation because it counteracts oxidative stress, but once cells are transformed,
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over-expression of TR promotes tumor progression by protecting tumor cells from
elevated levels of endogenous oxidants [45]. We sought to mimic these conditions by
expressing TR1 and TR2 in non-transformed but immortal mouse lung epithelial cells.
To evaluate the contribution of selenocysteine in TR to cell survival, we compared the
effects of expression of wild type cDNAs for TR1 and TR2 to cDNAs in which the
codons for selenocysteine had been changed to codons for cysteine. Gladyshev and
colleagues have previously demonstrated that even with normal levels of dietary
selenium, cysteine is inserted at the Sec codon in approximately 10% of cellular TR1
[46]. How often Cys is incorporated instead of Sec in TR1 in human malignancies is not
known, and although here the culture medium contained selenium, we did not investigate
the ratio between Sec-TR and Cys-TR in untransfected C10 cells, or in cell transfected
with various TR1 and TR2 expression vectors.

Rather we evaluated the relative

expression levels of various TR1 and TR2 polypeptides, their relationship to total TR
activity with and without oxidative insult, and their relative ability to support cell
viability under oxidative stress.
TR with selenocysteine in the active site is resistant to inactivation by a wide
range of cellular oxidants in vitro [6]. In response to extracellular fluxes of hydrogen
peroxide generated by glucose oxidase, total cellular TR activity was unaffected (Fig.
3.1A), whereas hyperoxidation of PRXs was readily evident (Fig 3.1B). Treatment of
cells with menadione results in the production of intracellular oxidants (Fig. 3.5A), but
TR activity was diminished only after acute exposure to very high, cytotoxic
concentrations over short periods of time (Fig. 3.1C). Overnight exposure to lower
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concentrations of menadione that affected cell viability (e.g 3.75 µM) did not affect total
cellular TR activity while hyperoxidation of PRXs was readily evident (Fig. 3.1E and F).
These data show that cellular TR is insensitive to levels of intracellular and extracellular
oxidants that influence redox responsive signaling pathways and PRX oxidation state and
function. While in yeast inactivation of thiol peroxidase by hyper-oxidation is required to
conserve pools of reduced thioredoxin for the repair of other oxidized proteins [47],
hyper-oxidation of PRXs may have more complex functions in mammalian cells. For
example, the oxidation state of PRXs is known to govern interactions with regulatory
factors [17]. In our previous studies we observed that expression of cyclin D1 and
recovery from cell cycle arrest did not occur until hyperoxidized PRXs were reduced
[32]. Because inactivation of PRXs in response to oxidative insult is rapid and recovery
is slow, whereas TR activity is unaffected, we suggest that TR sits at the top of a protein
redox pyramid that controls a hierarchy of responses to oxidative stress (Fig. 3.6).
The C-terminal extension of 2-Cys PRXs is a structural feature in eukaryotes
that stabilizes the sulfenic acid intermediate and promotes hyperoxidation.

In stark

contrast, we have proposed that the chemistry of selenocysteine in the C-terminal redox
center is the structural feature of mammalian TR that renders the enzyme resistant to
inactivation by oxidative insult [48], thereby providing an evolutionary advantage that
permits TR to regulate a hierarchy of responses to oxidative stress. While cellular TR
contains a pool of TR1 with cysteine in the C-terminal redox center, in viability assays
only Sec-TR1 or SecTR2 provided a survival advantage (Fig. 5). The Cys mutant of TR1
has lower enzymatic activity than WT TR1 containing selenocysteine [49], and may or
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may not be more sensitive to oxidative inactivation. It is interesting to note that overexpression of Cys-TR2 tended to enhance viability under low menadione concentrations,
yet this effect was not statistically significant. Two factors may contribute to the ability
of Cys-TR2 to support viability: 1) mitochondrial and cytosolic redox potentials differ
[50], and 2) the substrate specificity for TR1 and TR2 varies [51].

Moreover, co-

expression of TRX1 or TRX2 with its cognate reductase did not enhance survival,
suggesting the expression levels of TRX1 and TRX2 were not rate limiting survival
factors under these experimental conditions.
TR functions as a homodimer, and in the absence of stress we observed no
adverse effects from expressing Cys-TR1 or Cys-TR2 on cell viability, indicating these
polypeptides do not exert a dominant-negative phenotype or induce cell death via a
SecTRAP mechanism [15]. Together these studies support the hypothesis that tumor
cells maintain a pro-proliferative state under increased oxidative stress through upregulation of antioxidant networks, and that over-expression of TR potentiates cell
growth under increased endogenous and exogenous oxidant levels [3].

Further,

selenocysteine in TR1 and TR2 may play an important role in cell viability in response to
oxidative insult by rendering both enzymes insensitive to inactivation by oxidation [6].
Materials and Methods
Cell culture. C10 mouse lung epithelial cells were maintained in CMRL cell culture
media (Corning Cellgro, Manassas VA), supplemented with 10% fetal bovine serum
(FBS), 200 mM glutamine, and 0.5% penicillin streptomycin and propagated in a
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humidified incubator at 37°C and 5% CO 2. Cells were trypsinized and re-plated to obtain
75% confluence on the following day for all subsequent experiments.
Molecular cloning. Full length human TR1 was amplified from pCMV6-XL4 vector by
PCR using specific forward (TR1: 5 -GAAAGTCGAGGAGACAGTTAAGCATG-3 )
and reverse (TR1: 5 -CACAAGGAAAGGTCATGCTAAAACTG-3 ) primers and
subsequently cloned into pcDNA 3.1 mammalian expression vector (Promega, Madison
WI). Full length cDNA for human TR2 was recovered from pCMV6-XL4 by digestion
with XbaI and EcoRI, purified by gel electrophoresis, and ligated into linear pcDNA 3.1
using T4 DNA Ligase. Insertion of wild type Sec-TR1 and Sec-TR2 full-length cDNAs,
including the 3 SECIS elements, into pcDNA 3.1 was confirmed by sequencing using the
appropriate forward and reverse primer sets (T7 Forward: BGH Reverse). PCR-based
mutagenesis was performed by Mutagenex (Piscataway, NJ) to replace the Sec codon
with Cys and was confirmed by sequencing. Expression vectors for human TRX1 and
TRX 2 were purchased from Open Biosystems (Thermo Scientific, Waltham MA).
Expression vectors for cytosolic and mitochondrial targeted roGFPs were a kind gift from
J. A. Melendez (College of Nanoscale Science and Engineering, Albany, NY).
Plasmid transfection and siRNA silencing.

Plasmid expression vectors were

introduced into C10 cells by transfection or co-transfection using Lipofectamine 2000™
following the manufacturer’s guidelines (Invitrogen, Grand Island NY). Pilot
experiments with GFP and RFP expression vectors showed co-transfection efficiency
with Lipofectamine 2000™ in C10 cells was 90% or better (data not shown). Specific
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siRNA to TR1 (si-TR1, 5 -CCAUAGAGGGCGAAUUUAAUU-3 ) was introduced into
C10 cells using Dharmafect™ following the manufacturer’s guidelines (Dharmacon,
Thermo Scientific).
Live cell imaging with roGFP. Cells were transfected with indicated expression vectors
in combination with either cytosolic (Cyto-roGFP) or mitochondrial targeted (MitoroGFP) dynamic oxidant sensors [33]. Eighteen hours after transfection cells were replated into 35-mm glass bottom imaging dishes (MatTek™, Ashland MA).

The

following day media was changed to imaging media (20 mM HEPES, 134 mM NaCL,
5.4 mM KCL, 1 mM MgSO4 , 1.8 mM CaCl2, 5 mM glucose pH 7.4) and dishes were
mounted on a Nikon Ti-E inverted microscope. Images were collected and oxidation state
was determined as previously described [34]. Briefly, fluorescence emission was
collected at 525 nm after sequential excitation at ~405 nm and ~488 nm. The ratio of
oxidized (emission after excitation at ~405) to reduced (emission after excitation at ~488
nm) roGFP probe, after subtraction of background for each channel, is presented as a
measure of relative redox status of the cytosol (Cyto-roGFP) or the mitochondria (MitoroGFP). The change in oxidation (ΔOx) of roGFP was determined by calculating the
change in the ratio 10 minutes after removal of menadione.
Detection of oxidant levels by DCF.

Post-transfection, cells were plated into flat-

bottom 96 well tissue culture plates, allowed to adhere and treated as indicated in the text
in complete media. The following day cells were washed 2x with pre-warmed HBSS
plus calcium and magnesium and incubated with HBSS containing 20 uM 2',7'-
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dichlorodihydrofluorescein diacetate (DCF).

After a 30 min incubation, DCF was

removed and the cells were washed 2x with HBSS and fluorescence intensity was
determined using a Synergy HT Microplate Reader™ with excitation at 495 nm and
emission at 525 nm.
Thioredoxin reductase activity assay. Thioredoxin reductase activity was determined
in whole cell lysates using the SC-TR assay as previously described [35]. Briefly, cells
were grown to ~75% confluence, treated as indicated in the text, and lysed on ice in NP40 lysis buffer (150 mM NaCl, 50 mM Tris pH 8.0, 1% NP-40, 1 mg/mL leupeptin, 1
mg/mL aprotinin, 1 mM NaF, 1 mM NaVO 3, 1 mM PMSF). Lysates were cleared by
centrifugation at 14,000 rpm and total protein amount was determined by reading the
absorbance of Bradford reagent at 595 nm. Equal protein amounts (25 µg) were added to
individual wells of a clear round bottom 96 well microplate. Master mix contacting 1 mM
NADPH, and 2 mM selenocystine in ddH2O were added to each well, yielding a final
concentration of yielding a final concentration of 400 µM and 800 µM, respectively. The
conversion of NADPH to NADP+ was monitored in 30 sec intervals over a 20 min time
period at 340 nm on a synergy HT Microplate Reade™ (BioTek). TR activity was
determine by comparing the initial slopes of NADPH oxidation for each experimental
condition and expressed as nmoles NADPH x min-1 x mg-1 of protein lysate using an
extinction coefficient of 6220 M-1 cm-1.
Immunoblotting. Equal amounts of protein sample (15-35 ug/lane) were separated on
12% gels by SDS-PAGE and transferred to PVDF membrane. Membranes were blocked
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in 5% milk (Tris-buffered saline with 0.2% Tween-20, TBST) for 1 hr at room
temperature. Primary antibodies were diluted in 5% milk/TBST and incubated for 1 hr at
room temperature.

Anti-TR1 (1:2000), anti-Trx1 (1:2000), anti-Trx2 (1:2000) were

purchased from Santa Cruz Biotechnology (Dallas, TX). Anti-TR2 (1:2000) and antiPRX-SO2/SO3H (1:2000) were purchased from ABFrontier (Seoul, Korea). Anti-actin
antibody (1:5000) was from Millipore (Billerica, MA). The membranes were washed for
5 min with fresh TBST and washed in this manner 5x, after which the membranes were
incubated with appropriate species of horseradish peroxidase conjugated secondary
antibody (Millipore) diluted in 5% milk/TBST for 1 hr at room temperature.

The

membranes were again washed 5x (5 min each) with TBST and protein bands were
visualized with Enhanced Chemiluminescent™ detection system (Millipore).
Cell viability assays. Post transfection, cells were plated into flat bottom 96-well tissue
culture plates, allowed to adhere, and treated as indicated in the text in complete media.
The following day wells were rinsed 2x with phosphate buffered saline (PBS) and fixed
in 3.4% paraformaldehyde for 10 min and washed 1x in PBS. Viable cells were stained
with 0.1% crystal violet dissolved in ddH 2O for 30 min and then rinsed sufficiently with
water and allowed to dry. Crystal violet was solubilized by addition of 100% methanol
and absorbance was read at 540 nm on a Synergy HT Microplate Reader™.
Statistics. Statistical significance was determined using the Students t-test (two-tailed,
unpaired). The data within is presented as the mean +/- S.D. of 3 replicates unless
otherwise stated and the level of significance is described in the figure legends.
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Figure Legends
Figure 3.1. Cellular TR activity is insensitive to oxidative insults. A) TR activity in C10
cell lysates after treatment with 30 µM acrolein (Acr) for 1 hr or the indicated
concentrations of glucose oxidase (GOx) for 3 hrs (n = 3, ***p < 0.001, ns = not
significant). B) Immunoblot analysis of hyper-oxidized PRXs in C10 cell lysates after
treatment of cells with indicated concentrations of GOx for 3 hr. C) TR activity was
quantified in C10 cell lysates after acute treatment with the indicated concentrations of
menadione (MD) for 45 min (n = 3, **p < 0.01). D) Immunoblot analysis of TR1
expression levels and hyper-oxidized PRXs in cell lysates from (C). E) TR activity was
quantified in cell lysates treated with low levels of MD overnight (n = 3). F) Immunoblot
analysis of TR1 expression levels and hyper-oxidized PRXs in cell lysates from (E). In
panels B, D and F actin was used as a loading control.
Figure 3.2. Effects of expression of Sec and Cys containing TR1 and TR2 on total
cellular TR activity. A) Schematic depiction of Sec-TR (WT-TR1, WT-TR2) and Cys-TR
(TR1-U498C and TR2-U523C) expression vectors used in subsequent studies.

U

indicates selenocysteine and C cysteine. B) Immunoblot analysis of cell lysates from
C10 cells transfected with the indicated expression vectors and blotted for TR1 (upper
panel) or TR2 (lower panel). C) Rate of NADPH consumption (A340, see Materials and
Methods) in lysates from C10 cells transfected with the indicated TR1 expression vectors
or with TR1-siRNA (left panel). TR activity from 3 replicate samples is summarized in
the right panel (**p < 0.01). D) Rate of NADPH consumption measured at A340 of lysates
from C10 cells transfected with the TR2 expression vectors (left panel); TR activity from
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3 replicate samples is summarized in the right panel. E) TR activity in the indicated cell
lysates with or without Auranofin (Aur) (n =3).
Figure 3.3. Sec-TRs but not Cys-TRs accelerate roGFP reduction after oxidative insult.
A) Schematic of the dynamic response of the roGFP probe to changes in intracellular
thiol status. In the presence of oxidants a disulfide bond is formed in roGFP that
increases fluorescence intensity after excitation of the probe at 405 nm (Ox). Under
reduced conditions, fluorescence intensity is increased after excitation at 488 nm (Red).
The ratio of oxidized to reduced roGFP reflects cellular redox status. B) Basal cytosolic
redox state in cells co-transfected with Cyto-roGFP, TRX1, and the indicated TR1
expression vectors (n = 20 cells). C and D) Basal mitochondrial oxidation state in cells
transfected with Mito-roGFP, TRX2, and the indicated amount of TR2 expression vectors
(n = 20, p value determined by students t-test). E) The basal cellular redox state in C10
cells expressing Cyto-roGFP was assessed by ratiometric imaging prior to adding 40 uM
menadione (MD) for 20 min. After washing out MD by 5 exchanges with fresh imaging
media the same cells were re-examined over time to quantify change in oxidation (ΔOx)
of the cyto-roGFP probe.

F) The experiment in panel E was repeated in cells co-

expressing the indicated TR1 expression vector and Cyto-roGFP, and the ΔOx was
calculated post menadione washout after 10 min (n =10, *p < 0.05). G) The experiment
in E was repeated using cells co-transfected with Mito-roGFP and the indicated TR2
expression vectors and the and the ΔOx was calculated post menadione washout after 10
min (n=10, *p <0.05).
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Figure 3.4. Hyper-oxidation and reduction of PRXs in response to ectopic expression of
TR1 or TR2. A) C10 cells were transfected with indicated TR2 expression vectors (WT
= TR2, U/C = TR2-U523C) and the following day were treated with menadione (MD) for
1 hr before exchange with fresh culture media. Cell lysates were prepared from control
cells (Ctrl), cells treated with MD for 1 hr (MD), and cells allowed to recover for 1, 2, 3
or 4 hr after removal of menadione. Cell lysates were prepared and separated by SDSPAGE under reducing conditions for immunoblot analysis to evaluate the levels of hyperoxidized PRXs (PRX-SO2/SO3H).

The blot was then stripped and reprobed with

antibody to PRX3 to specifically reveal the amount of hyper-oxidized PRX3 (see
reference [32]). Note expression of TR2 did not influence retro-reduction of PRX3SO2/SO3H by SRX. B) The extracts in (A) were resolved under denaturing but nonreducing conditions to evaluate PRX3-S-S-PRX3 dimers (D) and PRX3 monomers (M).
All hyper-oxidized PRX3 migrates as a monomer under both electrophoretic conditions
because PRX3-SO2/SO3H cannot form disulfide bonds.
Figure 3.5. Overexpression of Sec-TRs but not Cys-TRs supports increased cell viability
in response to low levels of oxidative stress. A and C) C10 cells were transfected with
the indicated constructs, treated overnight with subcytotoxic concentrations of MD, and
oxidant production was evaluated by monitoring DCF fluorescence. Expression of any
isoform of TR1 or TR2 had no statistically significant effect on the relative intensity of
DCF fluorescence by 24 hr. B and D) C10 cells were transfected with the indicated
expression vectors and cell viability after 24 hrs treatment with MD was quantified (* p <
0.05, WT-TR1 compared to pcDNA). E and F) C10 cells were transfected with the
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indicated TR expression vectors as in B and D, but in this instance with or without
expression vectors for the cognate TRX.

Cells were treated with the indicated

concentrations of MD and after 24 hr cell viability was quantified. Note that expression
of TRX1 or TRX2 alone, or with the cognate TR, did not improve viability over that
observed with expression of Sec-TR1 or Sec-TR2 alone.
Figure 3.6. TR sits at the top of a protein redox pyramid. We suggest selenocysteine
renders thioredoxin reductase insensitive to inactivation by oxidative insult and permits it
to regulate a hierarchy of responses via regulation of the oxidation state of peroxiredoxins
and other regulatory protein factors.

In contrast, typical 2-Cys mammalian

peroxiredoxins have acquired evolutionary adaptations that render them highly sensitive
to inactivation by oxidation, and therefore are well suited to function as intracellular
redox sensors. The levels of TR affect the rate of reduction of PRXs, but not the rate of
inactivation, thereby contributing to survival in response to chronic oxidative insults.
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Abstract
Dysregulation of energy metabolism in cancer enhances production of
mitochondrial oxidants that support tumorigenesis. To counteract adverse effects of
mitochondrial oxidants tumors up-regulate the mitochondrial peroxiredoxin 3 (PRX3)
antioxidant network. Using mesothelioma as a model, we show that thiostrepton disables
PRX3 via covalent adduction of cysteine residues, and that gentian violet potentiates
adduction by increasing levels of disulfide-bonded PRX3 dimers. Because activity of the
PRX3 catalytic cycle dictates the rate of adduction by TS, untransformed mesothelial
cells are less sensitive to both compounds. In a xenoplant model of human mesothelioma,
administration of TS and GV together reduced tumor progression more effectively than
either agent alone. These studies show targeting mitochondrial peroxide metabolism is a
feasible strategy for managing human cancers.
Significance
Malignant mesothelioma is a rare mesenchymal tumor highly refractive to
conventional and targeted therapies. As for many other tumor types human
mesotheliomas express elevated levels of peroxiredoxin 3 (PRX3), an adaptive response
for managing increased levels of mitochondrial hydrogen peroxide that arise from
changes in energy metabolism. Here we show disabling the PRX3 antioxidant network
with two redox-active antibiotics, thiostrepton and gentian violet, selectively kills
mesothelioma cells in vitro and markedly impairs tumor progression in vivo. Because
increased production of mitochondrial peroxide is a common malignant phenotype
independent of any specific oncogene or tumor suppressor gene, and TS and GV are well
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tolerated in humans, we propose targeting PRX3 is a feasible redox-dependent strategy
for managing a variety of malignancies.
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Introduction
Altered redox balance in tumor cells, characterized by an increase in the
production of reactive oxygen species (ROS) and changes in antioxidant gene expression,
supports a pro-proliferative state and evasion from apoptosis (Fried and Arbiser, 2008).
Increased oxidant production originates from multiple sources, including but not limited
to up-regulation of NADPH oxidase expression and activity (Kamata, 2009) and altered
mitochondrial structure and function leading to electron leakage to molecular oxygen
(Cheng et al., 2013; Gupta et al., 2012). The primary mitochondrial oxidant implicated in
redox signaling is hydrogen peroxide (H2 O2), which reacts with structurally distinct and
solvent accessible low pKa cysteine residues on target proteins. Reversible oxidation of
specific cysteine residues has been shown to modify the structure, function, and
subcellular distribution of numerous proteins (Jones, 2010).
Many factors that are regulated via cysteine oxidation-reduction cycles, such as
kinases, phosphatases and transcription factors, function in redox-responsive signaling
circuits that control cell proliferation and survival (Finkel, 2011). Moderate levels of
H2O2 support proliferation (Burhans and Heintz, 2009), while higher levels create a prooxidant environment leading to activation of stress response pathways, damage of cellular
macromolecules and cell death (Sena and Chandel, 2012). Due to oncogene activation
and changes in cellular metabolism, neoplastic transformation results in a pro-oxidative
state that may induce cell cycle arrest, cellular senescence or apoptosis (Lee et al., 1999).
Tumor cells escape from redox-dependent cytotoxic responses via loss of tumor
suppressor genes and/or up-regulation of antioxidant enzymes and stress response factors,
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allowing tumor cells to prosper in a pro-oxidative state (Cairns et al., 2011). Because this
phenotypic adaptation is not limited to a specific subset of oncogenes and tumor
suppressor genes, exploiting perturbations in the metabolism of mitochondrial and
cytosolic-derived oxidants has been proposed to be a valuable therapeutic target in human
cancers (Weinberg et al., 2010; Wondrak, 2009).
Altered oxygen metabolism in cancer cells has been evident since the seminal
studies of Otto Warburg (Warburg, 1956). The preference for glycolysis, even under
aerobic conditions, fostered the belief that mitochondria were damaged in tumor cells.
Mutations in mitochondrial DNA do indeed promote tumorigenesis (Wallace, 2012), but
mitochondria from tumor cells generally have only subtle alterations in energy transfer
(Weinhouse, 1956; Weinhouse and Wenner, 1956). Rather, cancer cells reorganize their
metabolic phenotype in response to an imbalanced redox status that originates from rapid
growth, oxygen changes, and low nutrient availability (Gorrini et al., 2013).
Mitochondrial reserve capacity, which is the difference between basal and maximal
respiration, has been shown to play an important role in tolerance to changes in ROS
levels (Dranka et al., 2011; Dranka et al., 2010)). Mitochondria from tumor cells have
been found to have reduced reserve capacity and therefore cannot tolerate excessive ROS
production as efficiently as normal cell mitochondria (Diers et al., 2010). There is
considerable interest in exploiting these changes in metabolic vulnerability for
therapeutic intervention.
The antioxidant network composed of NADPH, thioredoxin reductase 2 (TR2),
thioredoxin 2 (TRX2), and peroxiredoxin 3 (PRX3) is the primary system responsible for

136

metabolism of mitochondrial H2O2 (Cox et al., 2010). PRX3, which is found exclusively
in the mitochondrial matrix (Watabe et al., 1997), is a member of the typical 2-Cys
peroxiredoxin family (PRX 1-4). PRXs metabolize hydroperoxides in a multistep process
that involves oxidation of a peroxidatic cysteine to sulfenic acid (–SOH), spontaneous
disulfide bond formation with a resolving cysteine located on the adjacent PRX subunit
(i.e. forming PRX-S-S-PRX), and subsequent reduction by the oxidoreductase TRX to
regenerate active enzyme (Wood et al., 2003). Due to highly conserved changes in the
carboxy-terminus of eukaryotic PRXs that stabilize the sulfenic acid intermediate and
slow the rate of disulfide bond formation, moderate levels of H 2O2 may hyper-oxidize the
sulfenic acid intermediate of the peroxidatic cysteine to sulfinic acid (-SOOH), thereby
inactivating the enzyme (Koo et al., 2002; Wood et al., 2002; Yang et al., 2002). 2-Cys
PRXs 1-4 are biologically unique in that the sulfinic acid form of the peroxidatic cysteine
can be repaired in an ATP-dependent fashion via retro-reduction by sulfiredoxin (Biteau
et al., 2003; Woo et al., 2003). Because PRXs in specific oxidation states associate with
and govern the activity of a number of cellular factors, PRXs have been proposed to serve
as exquisitely sensitive peroxide sensors that modulate redox-responsive signaling
pathways (Choi et al., 2005; Fourquet et al., 2008; Kang et al., 2005).
Elevated expression of PRX3 is linked to resistance to apoptosis and increased
cell proliferation (Chang et al., 2004; Chua et al., 2010). PRX3 is over expressed in
multiple cancers (Song et al., 2011), and increased expression may be related to adaptive
responses required to maintain mitochondrial function. Recently it was shown that
mitochondrial oxidants were essential for tumorigenicity mediated by activated K-RAS
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(Weinberg et al., 2010), which induces ROS-dependent cell senescence in normal cells
(Lee et al., 1999). Interestingly, the pro-oxidant state induced in mitochondria by
activated K-RAS is counterbalanced through increased expression of Forkhead Box M1
(FOXM1), which in turn promotes expression of the mitochondrial antioxidant enzymes
manganese superoxide dismutase (MnSOD) and PRX3, permitting cells to escape from
ROS-induced induced senescence (Park et al., 2009). Other studies show expression of
PRX3 in MCF-7 and MDA-MB-231 breast cancer cells promotes cell cycle progression,
while silencing PRX3 impairs cell proliferation (Chua et al., 2010). Prostate cancer cells
over-expressing PRX3 also grow faster than their control counterparts (Ummanni et al.,
2012).
Thiostrepton (TS) is a thiazole antibiotic that has shown promise as a cancer
therapeutic, specifically through targeting the oncogenic transcription factor FOXM1
(Bhat et al., 2009; Kwok et al., 2008) and induction of oxidative and proteotoxic stress
(Qiao et al., 2012). Fragments of TS have been reported to directly bind FOXM1 in
human breast MCF-7 cells, blocking the recruitment of FOXM1 to target promoter sites
(Hegde et al., 2011). Others have proposed TS acts as a proteasome inhibitor (Gartel,
2010), though this effect may be secondary to the induction of oxidative stress (Qiao et
al., 2012). TS has also been shown to sensitize melanoma cells to growth inhibition by
arsenic trioxide through an ROS-dependent mechanism (Bowling et al., 2008).
We recently identified PRX3 as a redox-dependent target of TS in malignant
mesothelioma (MM) cells (Newick et al., 2012). Treatment of MM cells with TS leads to
stable, non-reducible and irreversible modifications to PRX3, and co-treatment of MM
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cells with the triphenylmethane gentian violet, which selectively accumulates in
mitochondria and inhibits expression of the oxidoreducatse TRX2 (Zhang et al., 2011),
markedly potentiates modification of PRX3 by TS. Treatment of MM cells with TS
inhibits expression of FOXM1, and increases the production of mitochondrial oxidants,
activation of ERK1/2, and cell death, in a redox-dependent manner (Newick et al., 2012).
Here we describe studies that support a model for the molecular mechanism of
TS. We propose adduction of specific cysteine residues in PRX3 by TS inactivates its
activity, thereby compromising adaptive responses that permit tumor cells to tolerate a
pro-oxidant state. By inducing the accumulation of PRX3-S-S-PRX3 dimers, we propose
GV increases adduction of neighboring peroxidatic catalytic sites that are locally
unfolded (Perkins et al., 2013). Evaluation of the effects of TS and GV, alone or together,
in a mouse xenoplant model of human MM indicates combinatorial targeting of PRX3 is
a feasible strategy for managing intractable tumors characterized by dysregulation of
mitochondrial metabolism that results in high oxidant production.
Results
Thiostrepton irreversibly modifies PRX3 and increases mitochondrial H 2 O2 levels.
Previously our group showed the thiazole antibiotic thiostrepton (TS) irreversibly
modifies PRX3 in MM cells in a redox-dependent manner, and that adduction correlates
with the ability of TS to inhibit expression of FOXM1, suggesting PRX3 is a molecular
target of TS (Newick et al., 2012). As before, treatment of recombinant PRX3 (rPRX3)
with TS resulted in the dose-dependent formation of PRX3 species with retarded
electrophoretic mobility on reducing SDS-PAGE (Figure 4.1A, lanes 2-3). Modification

139

of rPRX3 was greatly diminished when rPRX3 was not fully reduced prior to reaction
with TS (data not shown). The modified rPRX3 species were resistant to reduction by
DTT and TCEP, and at 5 uM TS migrated with an apparent molecular weight of ~35-40
kDa (Figure 4.1A). Under reducing and denaturing conditions cellular PRX3 migrates as
~23 kDa monomers (Cox et al., 2010), but in extracts from cells treated with TS PRX3
migrates at ~35-40 kDa, the apparent molecular weight of PRX3 homodimers (Cox et al.,
2010). Since higher concentrations of TS resulted in the formation of additional species
of higher molecular weight (Figure 4.1A), other non-reducible forms of PRX3 are also
possible.
To test the effect of TS on the oxidation state of cellular mitochondria, HM cells
were transfected with an expression vector for mito-roGFP and ratiometric imaging was
used to measure mitochondrial redox status. Treatment of cells with 5 uM TS for 6 hr
resulted in a pronounced shift to a more oxidized mitochondrial environment (Fig. 4.1B).
In support of this observation, purified mitochondria treated with TS produced
significantly more hydrogen peroxide. Isolated rat heart mitochondria were incubated
with succinate to induce reverse electron transport (RET), which leads to H2O2
production from electron transport chain complex I (Hurd et al., 2007). Addition of TS to
mitochondria respiring on succinate led to a significant increase in H2O2 production as
compared to DMSO controls, and this increase was completely blocked by the complex I
inhibitor rotenone (Figure 4.1C), which blocks RET and reduces H 2 O2 production
(Friedrich et al., 1994).
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Using extracellular flux analysis, the effects of TS on the oxygen consumption
rate (OCR) and media acidification were measured in HM and hTERT immortalized LP9
mesothelial cells (Figure 4.1D and Figure S4.1A-B). Basal OCRs were very similar
between the two cell types, but addition of the mitochondrial ATP synthase inhibitor
oligomycin reduced the OCR in LP9 cells to a much lesser extent than in HM cells
(Figure 4.1D-E), indicating LP9 mesothelial cells have a lower demand for ATP (Hill et
al., 2012). Addition of the proton ionophore CCCP was used to uncouple electron
transport from the proton gradient and quantify the maximal mitochondrial respiration
rate, as the difference between the basal respiration and maximal respiration rate
represents mitochondrial reserve capacity. As compared to LP9 cells, HM cells had
virtually no reserve capacity, and TS reduced this limited reserve capacity to a higher
extent in HM cells than LP9 cells (Figure 4.1D and 4.1F). TS reduced the basal OCR to
nearly the same extent in LP9 and HM cells (Figure 4.1E); TS had no significant effect
on the extracellular acidification rate (Figure S4.1C and D). Oxygen consumption was
blocked to a greater extent in HM cells than in LP9 cells by treatment with antimycin A
and rotenone (Figure 4.1D). Cumulatively these data show that TS covalently modifies
PRX3, inhibits basal oxygen consumption, increases the intra-organelle oxidation state of
mitochondria, and increases mitochondrial production of H 2O2.
TS adducts specific cysteine residues in PRX3. TS has been reported to bind to
prokaryotic ribosomes and inhibit protein synthesis (Bausch et al., 2005). Further, TS
covalently adducts cysteine residues in the bacterial transcription factor TipAS through
dehydroalanine moieties, and does not react with any other free amino acid other than
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cysteine (Chiu et al., 1996). Human mitochondrial PRX3 contains three cysteine residues:
the peroxidatic cysteine at position 108 (Cys108), the resolving cysteine at position 229
(Cys229), and a conserved but non-catalytic cysteine at position 127 (Cys127).
Preliminary studies confirmed that TS interacts with reduced thiols such as reduced
glutathione (GSH) and N-acetyl-L-cysteine (NAC) (Figure S4.2B), but not oxidized
glutathione (GSSG, data not shown). Comparison of tryptic peptides from rPRX3 to
rPRX3 treated with TS by MALDI/TOF TOF mass spectrometry showed that the
peptides containing Cys108 and Cys127 were not observed in the samples treated with
TS, whereas the peptide containing the resolving cysteine (Cys229) was unaffected
(Figure 4.2A). Critically, under these MS conditions peptides greater than 4000 Da were
not resolved, suggesting that these peptides were modified to masses greater than 4000
Da. In particular, the PRX3-TS species predicted by crosslinking the Cys108 and Cys127
peptides was too large to be resolved by the mass spectrometer. Immunoprecipitation of
PRX3 dimers and monomers and subsequent analysis of tryptic peptides confirmed that
the modified PRX3 species migrating at 35-40 kDa in extracts of HM cells treated with
TS indeed contained PRX3 (Figure S4.2C and S4.2D).
To examine adduction of PRX3 further, wild type and cysteine mutants of FLAGtagged human PRX3 were expressed in HM cells. In these expression constructs the
FLAG tag is located on the amino terminus of the mature protein downstream of the
mitochondrial targeting sequence (M. Hampton, personal communication), and
immunoblotting of cell extracts with PRX3 antibody revealed two bands that likely
represent the processed species located in mitochondria and the larger uncleaved
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cytoplasmic precursor (Figure 4.2D, lanes 1-12). Treatment of transfected cells with TS
resulted in the formation of non-reducible species of PRX3 with the expected mobility of
endogenous PRX3 and FLAG-PRX3 dimers (Figure 4.2D, lanes 2-4). FLAG-tagged
PRX3 lacking the peroxidatic cysteine (Cys108) was not modified by TS (lanes 5-8), nor
was FLAG-tagged PRX3 lacking the resolving cysteine (Cys229) (Figure 4.2D, lanes 912). Since Cys229 was not modified by TS in rPRX3, and in vitro only a very small
fraction of rPRX3 was modified by TS under multiple experimental conditions, we
considered the possibility that TS attacks a specific intermediate in the PRX 3 catalytic
cycle. This possibility is further supported by the observation that inhibition of
expression of TRX2 (the primary reluctant of disulfide-bonded PRX3 dimers) with GV
markedly potentiates formation of modified PRX3 (see below).
Catalytic turnover of PRX3 promotes adduction by TS. We first investigated if an
active catalytic cycle is required for modification of PRX3 by TS in HM cells. Treatment
of HM cells with TS for 18 hr resulted in formation of the ~35-40 kDa modified PRX3
species, and this modified species was markedly enhanced by pre-incubating cells with
GV for 6 hrs prior to exposure to TS (Figure 4.3A). As oxidation of the peroxidatic
cysteine to sulfenic acid (-SOH) is the first step in catalysis, HM cells were incubated for
6 hr with dimedone, which specifically reacts with sulfenic acids (Allison, 1976), and
then treated with TS. Dimedone blocked the formation of the modified species of PRX3
in a dose-dependent fashion (Figure 4.3B, lanes 2-6), indicating that an active catalytic
cycle promotes adduction of PRX3 by TS, or less likely, that PRX3-SOH is a direct
target of TS.
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PRX3 functions as head-to-tail homodimers than can assemble into dodecamers
(Cox et al., 2009a; Cox et al., 2009b), and is actively recycled after oxidation of the
peroxidatic cysteine in a multi-step process that requires reduction of the disulfide bond
between opposing monomers by TRX2, and TRX2 reduction by thioredoxin reductase 2
(TR2) using reducing equivalents from NADPH (Figure 4.3C). Reconstitution of the
PRX3 catalytic cycle with purified components in vitro supported the possibility that an
active catalytic cycle promotes adduction by TS. Human rPRX3, E. coli TRX2, and
E.coli TR were incubated with or without an NADPH regenerating system under
conditions refined for PRX1 and PRX2 (Nelson and Parsonage, 2011) (Figure 4.3C), and
the reactions were pulsed with H 2O2 in the presence or absence of TS (Figure 4.3D).
Pulsing the reconstituted system with H 2O2 was intended to induce rPRX3 oxidation and
regeneration (referred to as “PRX3 turnover”), but a priori did not reproduce the
physiological flux of H2O2 in cellular mitochondria.
Modification of reduced rPRX3 by TS was investigated using the in vitro catalytic
system, using reducing and denaturing electrophoresis to resolve rPRX3 monomers and
TS-induced dimers. Addition of the reductant TCEP, which reduces oxidized thiols and
disulfide bonded cysteines, to the rPRX3 catalytic system led to the formation of PRX3
dimers in TS treated samples (Figure 4.3D, lanes 1 and 2), in accordance with previous
results. TCEP is a non-thiol based reducing agent and does not react with TS as does
DTT (Chiu et al., 1996). Addition of rTRX2 to the rPRX3 catalytic system increased TSinduced rPRX3 dimers over that of TCEP only in treated samples (Figure 4.3D, compare
lanes 2 and 4). Lastly reactions done in the presence of the NAPDPH regenerating system
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led to the largest amount of TS induced PRX3 modification (Figure 4.3D, lane 7), but this
still represented a very small fraction of the PRX3 pool.
We next investigated TS induced modifications to rPRX3 mutants where specific
cysteine residues corresponding to the peroxidatic (Cys108), resolving (Cys229) and the
non-catalytic (Cys127) were replaced with serine. In the full rPRX3 catalytic system,
addition of TS induced modifications to wild type rPRX3 as expected (Figure 4.3E and F,
lanes 1-2). Incubation of the Cys108 and Cys127 serine mutants significantly reduced the
levels of modification to rPRX3 by TS (Figure 4.4E and F, lanes 3-6), whereas the
Cys229 mutant showed an unexpected pattern of modification along with reduced TS
induced PRX3 dimers (Figure 4.4E and F, lanes 9-10). These experiments support the
conclusion that Cys108 and Cys127 are targets of adduction by TS, and that catalytic
turnover may promote modification of PRX3, but under any experimental condition
investigated to date modification of rPRX3 by TS in vitro was very inefficient.
PRX3 modification by TS correlates with cell viability. PRX3 is over-expressed in
mesotheliomas, though it is not a prognostic factor (Kinnula et al., 2002). Surgical
specimens from the pleural wall of human patients showed low levels of expression of
PRX3, but once propagated in culture human primary mesothelial cells (HMCs) showed
little difference in expression of PRX3 as compared to immortalized LP9 mesothelial
cells and MM cell lines HM and H2373 (data not shown). To examine the sensitivity of
PRX3 to adduction by TS, passage 3 primary HMCs, LP9 cells, and HM and H2373 MM
cell lines were incubated with 5 µM TS and cell lysates were prepared over a 24 hr. The
degree of modification of PRX3 by TS was markedly higher in MM cells as compared to
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primary or immortalized mesothelial cells (Figure 4.4A). Quantification of total cell mass
with crystal violet staining showed significant dose-dependent differences in the
cytotoxicity of TS between normal and MM cells (Figure 4.4B, left panel). The EC50 of
TS was found to be as much as ~6.75 times lower in MM cells as compared to primary
mesothelial cells and ~25 times lower than that observed with immortalized LP9
mesothelial cells. Similarly primary human mesothelial cells were less sensitive to GV as
compared to human HM and H2373 MM cells (Figure 4.4B, right panel). Unlike TS, GV
does not irreversibly modify PRX3, as under denaturing and reducing conditions PRX3
from HM cells treated with GV migrates in SDS polyacrylamide gels as reduced and/or
hyper-oxidized monomers (Figure 4.4C, lanes 6-8). However, under non-reducing
conditions that preserve disulfide bonds, GV induces the marked accumulation of
disulfide-bonded PRX3 dimers (Figure 4.4D, lanes 6-8), and under these conditions GV
potentiates the adduction of PRX3 by TS (Figure 4.4D, lanes 9-12). In two independent
isolates of human primary mesothelial cells, TS induced much lower levels of
modification of PRX3, and these levels were not enhanced by GV (Figure 4.4E and F).
Based on observations that indicate MM tumor cells produce more mitochondrial
superoxide, have a more oxidized mitochondrial environment, and have no respiratory
reserve capacity (Figure 4.1A and F), all properties of human tumor cells, we conclude
that the toxicity of TS and GV are enhanced in MM tumor cells by constitutively higher
demand for detoxification of H2O2 by the TR-TRX2-PRX3 antioxidant network.
shPRX3 MM cell are less sensitive to TS than WT controls. To ascertain if PRX3 is
an important primary target of TS, we used RNA interference to knock-down expression
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of PRX3. In transient transfection experiments with HM cells siRNA targeted to PRX3
mRNA reduced PRX3 protein expression 3-5 fold, whereas the scrambled siRNA control
had no effect (Figure 4.5A). Transfection of HM cells with siRNA to PRX3 resulted in
lower cell density (Figure 4.5B), and stable expression of shRNA to PRX3 reduced HM
and H2373 MM cell proliferation as compared to controls (Figure 4.5E and S4.3B), as
has been reported for breast cancer cells (Chua et al., 2010). Interestingly, in addition to
inhibition of expression of PRX3 mRNA (Figure 4.5D and S4.4A) and protein (Figure
4.5F), shPRX3 cells also showed lower expression levels of FOXM1 mRNA (Figure
4.5C and S4.3C). Comparison of wild type or control HM cells (not shown) to shPRX3
knock-down cells by immunofluorescence microscopy showed that inhibition of PRX3
expression resulted in lower levels of both cytoplasmic and nuclear isoforms of FOXM1
(Figure S4.3E-F). Reduced FOXM1 expression in shPRX3 cells as compared to vector
controls also was evident by immunoblotting (Figure 4.4F, lanes 1 and 2), and adduction
of PRX3 and inhibition of FOXM1 expression by TS was also reduced in shPRX3 cells
(Figure 4.5F, lanes 3-4).
To further investigate the sensitivity of cells with reduced PRX3 expression to
TS, vector control (HMshCtrtl) and shPRX3 (HMshPRX3) cells were treated with TS
and the levels of the 35-40 kDa modified species were evaluated by immunoblotting
(Figure 4.5G). In shPRX3 cells the modified form of PRX3 failed to accumulate over
time (Figure 4.5G, lanes 6-10), although this may be primarily due to reduced levels of
PRX3. That is, reduced abundance of disulfide-bonded intermediates in the PRX3
catalytic cycle may reduce modification by TS. Nonetheless, despite the fact that they
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proliferate more slowly than vector controls, shPRX3 cells were significantly less
sensitive to the cytotoxic effects of TS (Figure 4.5H), indicating that PRX3 is a relevant
target of TS in MM cells.
TS and GV impede tumor progression in a SCID mouse xenoplant model of MM.
The in vivo efficacy of TS and GV has been investigated in other tumor models with
promising results (Wang and Gartel, 2011; Wang et al., 2012). In a subcutaneous
xenoplant model in Fox Chase SCID mice, administration of 5 mg/kg TS every other day
impaired tumor growth and reduced FOXM1 expression (Figure S4.4A-C). However,
subcutaneous tumor burdens are irrelevant in MM as the primary lesions arise in the
pleural and peritoneal cavities. To test the effects of TS and GV in the peritoneal cavity,
Fox Chase SCID mice were injected intraperitoneally (IP) with 2 to 5 x 10 6 HM cells and
tumors were allowed to become established for two weeks. Six mice were randomly
assigned to each treatment group, and then TS at either 5 mg/kg, TS at 50 mg/kg, GV at 2
mg/kg or TS at 5 mg/kg plus GV at 2 mg/kg was administered every other day via IP
injection until control mice were moribund. The results for each treatment group were
compared to 6 mice receiving vehicle control (DMSO). In the IP model MM tumors grew
as both small free-floating spheroids and as large, multi-lobulated solid malignancies that
populated mesenteric surfaces and often invaded the pancreas, diaphragm and liver
(Figure 4.6A–D). Tumors were of biphasic MM morphology, with large areas of necrosis
than stained positively for eosin; tumors occasionally contained stromal tissue of mouse
origin (Figure 4.6B). In contrast to the results with subcutaneous MM tumor model,
administration of TS at 5 mg/kg every other day by IP injection had no significant effect
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on tumor volume in the IP model (Figure 4.6E). At 50 mg/kg, however, TS showed a
significant effect on tumor volume, reducing average tumor volume to 32% of that
observed for vehicle controls (Figure 4.6C, D and F). These results are consistent with
findings that administration of 40 mg/kg of TS led to significant decrease in tumor
growth in xenoplant models of breast and hepatocellular carcinoma (Wang and Gartel,
2011; Wang et al., 2012). Treatment with 2 mg/kg GV also resulted in a significant
reduction in tumor volume, reducing tumor volume in treated animals to an average of
62% of controls (Figure 4.6G). The most dramatic response was observed in mice treated
with 2 mg/kg GV plus 5 mg/TS, a regimen that reduced tumor volume after 21 days to
22% of vehicle control (Figure 4.6H). Immunoblotting of extracts of tumors from animals
treated with 50 mg/kg TS revealed the presence of the modified form of PRX3, which
was not present in extracts of control tumors (Figure 4.6I). The modified species was not
detected in extracts of tumors from mice treated with 5 mg/kg TS (not shown).
Immunohistochemical analysis of FOXM1 and PRX3 expression in IP tumors
from animals treated with TS or GV did not reveal profound differences in expression
(Figure S4.5B-E). The morphology and architecture of MM tumors from treated animals
were similar to those from control animals, albeit significantly smaller in total volume
(Figure S4.7A-F). Nonetheless, these results clearly indicate that administration of GV
and TS together was more effective than either agent alone.
Discussion
Controlled and localized production of cellular hydrogen peroxide is required
for growth factor signaling and cell cycle progression, and redox-responsive signaling
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pathways are known to be involved in cell differentiation, autophagy, migration and
survival, all processes relevant to carcinogenesis. A pro-oxidant state is detrimental to
normal cells, and therefore oxidant levels are managed by a broad array of small
molecules and a repertoire of antioxidant enzymes that include catalase, superoxide
dismutase, glutathione peroxidases and peroxiredoxins. Because tumor cells generally
produce high levels of oxidants, most often as a consequence of perturbations in energy
metabolism (Gorrini et al., 2013), they require adaptive responses to survive and benefit
from a pro-oxidative state. These responses are not always intuitive. For example,
catalase expression and activity is extinguished in lung cancer (Chung-man Ho et al.,
2001), whereas PRX1 is highly over-expressed (Chang et al., 2001). Given that it is a
common feature of many tumor types, oxidant metabolism has emerged as an important
therapeutic target, with accentuation of oxidant production that overwhelms antioxidant
reserve capacity showing the most promise (Wondrak, 2009).
The peroxiredoxin thiol peroxidases have gained considerable prominence in the
regulation of redox signaling and tumor cell biology. Peroxiredoxins interact with a wide
variety of kinases, growth factor receptors, phosphatases and other regulatory proteins
and thereby govern their redox state (Rhee and Woo, 2011). Given their role in regulating
redox signaling, and the pro-oxidative state of tumor cells, it is not unexpected that the
expression of PRXs is up-regulated as an adaptive response in many tumor types (Basu et
al., 2011; Karihtala et al., 2003). We have focused on this adaptive response due to its
almost universal existence in tumor cells (Gorrini et al., 2013).
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The mechanism of action of thiostrepton’s (TS) anticancer activity has been
attributed to inhibiting the expression of the oncogenic transcription factor FOXM1
(Kwok et al., 2008). TS has been proposed to inhibit the proteasome (Gartel, 2010),
perhaps as a consequence of proteotoxic and oxidative stress (Bowling et al., 2008; Qiao
et al., 2012). TS also has been proposed to bind FOXM1 directly and inhibit its
transcriptional activity (Hegde et al., 2011). We found that TS modifies the
electrophoretic mobility of the mitochondrial peroxidase PRX3 (Newick et al., 2012), and
that modification is enhanced by compounds targeted to mitochondria that promote
mitochondrial superoxide production (Cunniff et al., 2013) or inhibit the expression of
TRX2 (Newick et al. 2012), the primary reductant for PRX3. TS increases the production
of hydrogen peroxide in isolated mitochondria respiring on succinate (Figure 4.1), a
response consistent with inactivation of PRX3 peroxidase activity.
Our data suggest a model for the modification of PRX3 by TS that provides a
physiological basis for its selective effects on tumor cells (Figure 4.7). PRXs function as
head-to-tail homodimers, with two reaction sites in opposite orientations. Hence, the
peroxidatic cysteine in the N-terminus of one monomer forms a disulfide bond with the
resolving cysteine in the carboxy terminus of the opposing subunit, and vice versa. (Cao
et al., 2007). Our observations that dimedone reduces the formation of TS-induced
modification of PRX3, whereas GV increases modification, indicate that a specific
catalytic intermediate in the PRX3 reaction cycle is the preferred target of TS. Dimedone
reacts with sulfenic acid residues, an obligate step in the spontaneous formation of the
disulfide bond between the peroxidatic and resolving cysteine. In contrast, by inhibiting
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expression of TRX2, GV increases the level of disulfide-bonded dimers of PRX3 (Figure
4.3A). Structural studies by others show that formation of a disulfide bond between the
peroxidatic cysteine and resolving cysteine results in a change from a fully folded to a
locally unfolded conformation (Perkins et al., 2013). We propose that this conformational
change promotes access of TS to the neighboring catalytic center, thereby positioning the
dehydroalanine moieties in proximity to the peroxidatic Cys108 and Cys127, resulting in
an irreversibly crosslinked PRX3 homodimer. Under any condition investigated to date,
however, only a very small fraction of PRX3 is modified by TS to the 35-40 kD form in
vitro, even under conditions that promote PRX3 turnover (Figure 4.3). In contrast, in MM
cells treated with high concentrations of TS and GV virtually the entire cellular pool can
be modified by TS (Newick et al., 2012), suggesting the rate of hydrogen peroxide flux or
as yet other unknown factors influence the susceptibility of PRX3 to adduction by TS in
living cells.
In our model, agents that increase mitochondrial superoxide production promote
catalytic cycling of PRX3, and consequently increase the abundance of disulfide-bonded
dimers. As for GV, Mito-CP and Mito-TEMPOL, both of which increase mitochondrial
superoxide production, increase adduction by TS (Cunniff et al. 2013). Interestingly,
disulfide-bonded PRX3 dimers appear to be relatively long lived, most likely because the
sulfenic acid form of the peroxidatic cysteine is stabilized by the C-terminus of 2-Cys
PRXs. After cessation of acute oxidative stress, disulfide bonded dimers persist for
several hours in mouse lung epithelial cells, and their rate of reduction is dictated by the
activity of TR2 (Cunniff et al., 2014). Thus, the presumed target of TS is both present and
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persistent in MM tumor cells. Normal cells do not constitutively produce high levels of
mitochondrial oxidants and are less reliant on the TR2-TRX2-PRX3 network, and
therefore do not accumulate the PRX3 catalytic intermediate that is the preferred target of
TS.
Recent studies with increased temporal specificity support our model for the
activity of TS. Concentrations of TS that induce oxidative stress are lower than those
found to inhibit proteasome activity. TS has been shown to increase ROS levels and
deplete glutathione levels in malignant melanoma cells prior to the onset of proteasome
inhibition, a response also prevented by pre-incubation with NAC (Qiao et al., 2012).
Thiostrepton is known to target mitochondrial ribosomes (Zhang et al., 2005) and inhibit
mitochondrial protein translation (Bowling et al., 2008), showing TS accumulates in
mitochondria. An unresolved issue is how TS reaches mitochondria, both in cells in
culture and in tumor cells in vivo, without being inactivated by cellular thiols. Both GSH
and NAC interact with TS in vitro (Figure 4.2), and this may explain the protection
elicited by thiol-containing compounds. However, although GSH exists at mM
concentrations in the cell cytoplasm, micromolar concentrations of TS gain access to
PRX3. Tumor cells are under increased oxidative stress, tipping the ratio of GSH to
GSSG to a more oxidized state, but even under these conditions the cytoplasmic levels of
GSH would be expected to inactivate TS.
Finally, our data indicate PRX3 is an important and relevant molecular target of
TS. As for other cell types, knockdown of PRX3 impedes the proliferation of HM cells
(Figure 4.5). Even accounting for reduced rates of proliferation, shPRX3 HM cells were
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significantly less sensitive to TS (Figure 4.5), Knockdown of PRX3 expression also
inhibited the expression FOXM1 mRNA and protein (Figure 4.5), suggesting a
relationship between the regulation of PRX3 and expression of cytoplasmic FOXM1, a
possibility we will address elsewhere in detail. Given that FOXM1 regulates transcription
of the PRDX3 gene (Park et al., 2009), we favor a model where PRX3 participates in
retrograde signaling to the nucleus that controls a feedback loop in which FOXM1
promotes transcription of its own mRNA (Yun and Finkel, 2014).
Detection of the modified form of PRX3 in xenoplant MM tumors from animals
treated with 50 mg/kg TS provides evidence that the mechanism of action in vivo is
similar to that in vitro. If so, the modified form of PRX3 may prove to be a useful
biomarker for agents that promote mitochondrial oxidative stress and enhance the anticancer activity of TS. Moreover, determining the levels of mitochondrial oxidants that
dictate biological outcomes in response to TS may provide a useful bioassay for
understanding how cancer cells develop a dynamic balance between mitochondrial
oxidant production and metabolism to fuel growth.

Materials and Methods
Cell Culture and knockdown of PRX3. Human malignant mesothelioma cell lines
(HM, H2373) and immortalized but non-tumorigenic mesothelial cells (LP9) were
cultured as previously described (Newick et al. 2012). Human primary mesothelial cells
were isolated from ascites fluid from patients admitted to Interventional Radiology via
paracentesis and thoracentesis with no history of smoking or thoracic cancer. See
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supplementary experimental procedures for additional information. PRX3 and pLKO.1
lentiviral shRNAs (Sigma) were packaged following the manufacturers protocol (Sigma).
Cells were transduced with 150 µL of lentiviral particles and selected in media containing
2 µg/mL puromycin. On-Targetplus human PRDX3 siRNA and scramble control RNAs
(Thermo Scientific, Waltham, MA) transfection complexes were prepared in Optimem
and Lipofectamine 2000 (Life Technologies). 4-6 hr post transfection serum was added
back to each plate at a final concentration of 10%. Images of siPRX3 cells were acquired
using a light microscope equipped with a CCD camera 48 and 72 hr after transfection.
Cell growth assays. Cells were plated into 96 well plates at a density of 1000 cells/well.
The following day cells were stained with 4 µg/mL Hoechst 33342 (Life Technologies)
for 10 min, washed with PBS and incubated with fresh complete media. Hoechst 33342
fluorescence was quantified using a Synergy HT plate reader (BioTek, Winooski, VT)
340nm/460nm.
Immunoblotting. Tumor tissue lysates were prepared in modified RIPA (mRIPA) buffer.
Tissue was homogenized in Lysing Matrix A Tubes (MP Biomedicals Inc. Santa Ana,
CA) by shaking for 30 sec at 6.5 m/s on a FastPrep 24 benchtop homogenizer (MP
Biomedicals Inc.) and cleared by centrifugation. Supernatant was removed and combined
with 5X sample buffer (see below). Cell lysates were prepared by scraping on ice in NP40 lysis buffer (Phalen at al., 2006) and cleared by centrifugation. Protein concentrations
were determined using Bradford assays (Bio-Rad, Hercules, CA) and 10 µg of cell lysate
was resolved by SDS–PAGE and transferred to PVDF membranes. Membranes were
prepared for antibody addition following standard protocols and incubated at 4°C
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overnight with the indicated primary antibodies: PRX3 (1:2000, Ab Frontier, Seoul,
Korea), FOXM1 K-19 (1:500, Santa Cruz Biotechnology, Dallas, TX) and actin (1:5000,
Millipore, Billerica, MA). Blots were incubated with horseradish peroxidase conjugated
secondary antibodies (1:2500) for 30 min at RT and protein bands were visualized with
the Western Lightning chemiluminescent detection system (Perkin Elmer, Waltham,
MA).
Crystal violet assay for total cell mass. Cells were plated in 96-well plates at a density
of 1,500 cells per well. The next day, cells were treated as indicated in complete medium.
After 24 hr cells were washed with PBS, fixed in fresh 3.7% para-formaldehyde and
stained for 30 min with 0.1% crystal violet in water. To quantify crystal violet staining,
plates were washed with H2O, dried, and the dye was dissolved in 100% methanol,
absorbance was read at 540 nm. The Relative Potency (REP) of TS and/or GV was
determined using Gen5 software (BioTek Instruments, Winooski, VT) using primary
mesothelial cells as reference cell line. See supplemental experimental methods for more
details on REP.
Mass spectrometry of rPRX3. 2 µg of recombinant human PRX3 (rPRX3) (Prospec
Biochemicals, East Brunswisk, NJ) was reduced with sodium cyanoborohydride (0.5 µL
of 1 mM freshly made stock/20 µL reaction mix) for 5 min and excess sodium
cyanoborohydride was removed by addition of 1 µL acetone. Reduced rPRX3 was
reacted in the presence of DMSO (Ctrl) or 5 µM thiostrepton in reaction buffer (20 mM
Tris-HCL pH 8, 10% glycerol) at RT. Reactions were stopped by the addition of 5X
sample buffer (250 mM Tris-HCL pH 6.8, 2.5% sodium dodecyl sulfate (SDS), 45%
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glycerol, 0.2% bromophenol blue, and 200 mM dithiothreitol (DTT)) and protein bands
were detected after separation by SDS-PAGE and staining with coomassie blue. PRX3
dimers were cut from the gel, incubated in 100 mM N-ethyl maleimide for 30 min, and
digested by “in gel” cleavage (Wilm et al., 1996) at 37°C with 12.5 ng/mL sequence
grade trypsin in buffer consisting of 20 mM Tris-HCl, pH 8.0, and 5 mM CaCl2. Peptides
were extracted from the gel with a 4% ARISTAR-grade formic acid, 60% acetonitrile
solution and examined in a matrix-assisted laser-desorption ionization-time-of-flight
time-of-flight (MALDI-TOF-TOF) mass spectrometer (4800 Proteomics Analyzer,
Applied Biosystems), using α-cyano-hydroxy-trans-cinnamic acid as the matrix. The
instrument was calibrated with bovine trypsin autolysis products (m/z values 2163.057
and 2273.160) and a calcium-related matrix ion (m/z value 1060.048). Peptide masses
were identified by manual peptide fingerprinting, including the addition of 125.125 Da,
the molecular weight for NEM, for cysteine containing peptides.
In vitro TR-TRX-PRX3 system. The in vitro reaction contained recombinant human
PRX3, TRX, TR, and a NADPH regenerating system composed of glucose 6-phosphate,
glucose 6-phosphate dehydrogenase and NADPH. Assay components were pulsed with
successive additions of 100 µM H 2O2 to induce turnover of PRX3. Reactions were
stopped by the addition of 5X sample buffer and proteins were separated by SDS-PAGE
and visualized by coomassie blue staining.
Mitochondrial Isolations. Rat heart mitochondria were prepared by homogenization in
STE buffer (250 mM sucrose, 5 mM Tris-HCl, 1 mM EGTA, 0.1% fatty acid-free BSA,
pH 7.4) using an Ultraturrax blender followed by differential centrifugation as described
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(Chappell, 1972). Protein concentration was measured by the biuret assay with bovine
serum albumin (BSA) as a standard.
Amplex Red assay. H2O2 production from isolated mitochondria was measured by
horseradish peroxidase oxidation of Amplex Red to fluorescent resorufin (Zhou et al.,
1997). Mitochondria were incubated with stirring at 37 °C in standard assay medium
(250 mM sucrose, 5 mM HEPES, 1 mM EGTA, 0.01% BSA, pH 7.4 (NaOH)) containing
50 µM Amplex Red (Molecular Probes) and 4 units/ml horseradish peroxidase. Resorufin
was monitored continuously in a fluorimeter (Shimadzu Rf-5301PC) (ex = 560 nm, em =
590 nm). To generate endogenous mitochondrial H 2O2 by reverse electron transport
(RET), 10 mM succinate was included in the reaction (Hurd et al., 2007) .
Mitochondrial oxidation state as evaluated by mito-roGFP. MM cells transfected with
mito-roGFP as previously described (Cunniff et al., 2013) and imaged on a Nikon Ti-E
inverted microscope with a 100X 1.49 NA objective in a heated environmental chamber.
The following day media was replaced with CO2 -independent imaging media containing
134 mM NaCl, 5.4 mM KCl, 1.0 mM MgSO 4 , 1.8 mM CaCl 2, 20 mM HEPES and 5 mM
d-glucose (pH 7.4) and dishes were imaged on a To determine the oxidation state of the
probe, fluorescence images were collected with an Andor iXon X3 EMCCD camera
(Andor Technology, Belfast, UK) after excitation with the violet (~400 nm) or teal (~495
nm) outputs from a SpectraXlight engine (Lumencor, Beaverton, OR); emission was
collected at 525 nm for both excitation wavelengths. Individual cells were imaged and the
ratio of emission from 400 (oxidized) and 495 (reduced) roGFP was measured to
determine the relative redox status under indicated experimental conditions.
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Bioenergetic profiles: 40,000 cells were plated into individual wells of a XF24 cell
culture microplate in complete media excluding cells from 4 wells. The following day
cells were washed 1X with XF assay media and 560 µL of assay media was added back
to each well. Cells were allowed to equilibrate for 30 mins in a 37˚C CO2 free incubator
before loading into a XF24 extracellular flux analyzer temperature adjusted to 37˚C
(Seahorse Biosceince, Billerica, MA). Sensor cartridges were equilibrated with XF
celebrant for 24 hours before loading with inhibitors. Inhibitor concentrations were
titrated to determine optimal drug concentrations to establish bioenergetic profiles (data
not shown), final concentrations used were 1 µM oligomycin, 0.75 µM carbonyl cyanide
m-chlorophenyl hydrazone (CCCP), and 1 µM rotenone and antimycin A. Oxygen and
proton concentrations were measured every 8.5 min for 1 hr and 35 min, inhibitors
(oligomycin, CCCP, rotenone/antimycin A, respectively) to measure mitochondrial stress
were added to the plates through the microinjection ports every 17 min. Oxygen
consumption rates (OCR) and extracellular acidification rates (ECAR) , as well as reserve
capacity (difference between maximal and basal OCR), are shown for 5 replicates and 2
independent experiments. Cells were stained with 4 µg/mL Hoescht 33342 (Life
Technologies) following each run to ensure equal cell density (not shown).
RT-qPCR. Total RNA was extracted using the RNeasy Mini Kit following the
manufactures recommended protocol (Qiagen, Hilden, Germany). cDNA was prepared
from total RNA using the High Capacity cDNA Reverse Transcription kit following the
manufacturers protocol (Life Technologies) and gene expression levels were determined
using Assay on Demand TaqMan primers for PRX3 (Hs00428953_g1), FOXM1
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(Hs01073586_g1), and HPRT1 (Hs02800695_m1) as a housekeeping control. qPCR was
performed on an Applied Biosystems Prism 7900HT Sequence Detection System (Life
Technologies) using SDS software (version 2.4)
Xenoplant model of human malignant mesothelioma. Male Fox Chase (CB17/lcrPrkdcscid/lcrlcoCr background) severe combined immunodeficient (SCID) mice between
6-8 weeks old (Charles River Laboratories, Wilmington, MA) were injected with 2 to 5 x
106 HM cells intraperitoneal into the lower left quadrant. After 2 weeks animals were
treated with 5 gm/kg TS, 50 mg/kg TS, 2 mg/kg GV, 2 mg/kg GV plus 5 mg/kg TS, or
10% DMSO in PBS (Vehicle) every other day for 3-4 weeks (6 animals per group). After
3-4 weeks, mice were euthanized by IP administration of sodium pentobarbital. Freefloating spheroidal and mesenteric tumors were recovered by surgical resection, and
tumor volume was measured using the formula length x width x height x /6. Tumor
tissue samples were frozen for subsequent RNA extraction and fixed in 4%
paraformaldehyde in PBS for processing and immunohistochemical assays. All protocols
used in animal experiments were approved by the University of Vermont College of
Medicine Institutional Animal Care and Use Committee (IACUC).
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Figure Legends
Figure 4.1. Thiostrepton increases mitochondria H2 O2 and disrupts mitochondrial
bioenergetics in MM cells. (A) Recombinant PRX3 (rPRX3) was incubated with
indicated concentration of thiostrepton (TS) for 30 min and visualized by immunoblotting
with anti-PRX3 antibody after separation by reducing SDS-PAGE. (B) Mitochondrial
redox status was analyzed by ratiometric live cell imaging of mito-roGFP in HM cells
treated with 5 µM TS for 6 hrs (n = 10 cells). (C) Hydrogen peroxide production in
isolated mitochondria respiring on succinate (+ succinate) in the presence of indicated
compounds (TS = thiostrepton, ROT = rotenone). (D) Bioenergetic profiles (oxygen
consumption rate, OCR) for LP9 and HM cells (n=5). Dotted lines indicate time points of
drug injections (oligomycin, CCCP, rotenone/antimycin A, respectively) (E) Basal OCR
of LP9 and HM cells treated with 5 µM TS for 6 hrs (n=5, * p < 0.05, *** p < 0.001,
Error bars represent SD). (F) Reserve capacity of LP9 and HM cells untreated or treated
with 5 µM TS for 6 hrs (n=5, * p < 0.05, Error bars represent SEM). See also Fig. S1.
Figure 4.2. TS adducts specific cysteines of recombinant PRX3 in vitro. (A) MS
spectrums of rPRX3 incubated with or without 5 µM TS for 30 mins. Note the loss of
peptides containing Cys108 and Cys127 in TS treated samples. (B) Cells transfected with
Flag-Tagged PRX3 expression plasmids were treated with 5 µM TS, lysates were
collected at the indicated time points and TS induced modifications of PRX3 were
visualized by immunoblotting with anti-PRX3 antibody after separation by reducing
SDS-PAGE. See also Figure S2.
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Figure 4.3. PRX3 turnover promotes adduction of specific cysteine residues by
thiostrepton. (A) MM cells were treated with 5 µM TS for 18 hrs or pre-incubated with
1 µM GV for 6 hrs then treated with 5 µM TS (G/T) for 18 hrs and immunoblotted for
PRX3. (B) Pre-incubation of MM cells with dimedone for 6 hr blocked TS induced
modification of PRX3. (C) Reconstitution of the PRX3 catalytic cycle in vitro with
purified components. (D) rPRX3 was incubated with our without 50 µM TS under the
indicated reaction conditions (see text) and the formation of irreducible PRX3 dimers was
visualized by coomassie staining after reducing SDS-PAGE. Note the formation PRX3
dimers induced by TS was enhanced when rPRX3 was turned over by the addition of a
NADPH regenerating system (NADPH Reg. Sys.) (lanes 3-6). Band intensity was
determined by densitometric analysis of rPRX3 dimers compared to rPRX3 monomers
(n=2). (E) Recombinant WT PRX3 or the indicated PRX3 mutants were incubated with
or without TS as in lane 7 of (D) and formation of irreducible PRX3 dimers was
visualized by coomassie staining after reducing SDS-PAGE. (F) Densitometric analysis
of rPRX3 dimers as compared to rPRX3 monomers (n=2, Error bars represent SEM).
Figure 4.4. Adduction of PRX3 by TS correlates with cytotoxicity. (A) Human
primary mesothelial, immortalized LP9 mesothelial, and HM and H2373 mesothelioma
cell lines were incubated with 5 µM TS and lysates were collected at indicated time
points over 24 hr. Formation of TS induced PRX3 dimers was visualized by reducing
SDS-PAGE and immunoblotting with anti-PRX3 antibody. (B) Cell lines from (A) were
incubated with indicated concentrations of TS (left) or GV (right) for 24 hr and total cell
mass was determined by staining with crystal violet. The EC 50 of the indicated cell line to
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TS or GV and the relative potency (REP) of TS and GV as compared to primary
mesothelial cells is shown. (C) HM cells were treated with increasing concentrations of
TS, GV, or TS + GV for 18 hrs and extracts were resolved by reducing SDS-PAGE.
PRX3 modification was assessed by immunoblotting as before. Note that GV accentuates
modification of PRX3 by TS. (D) Extracts from cells treated as in (C) were resolved by
non-reducing SDS-PAGE and PRX3 monomers (~23 kD) and disulfide-bonded dimers
(~46 kD) were assessed by immunoblotting for PRX3. Note that GV markedly increased
the level of disulfide-bonded PRX3 dimers, an indication of severe mitochondrial
oxidative stress. (E) HMC2 and HMC3 (F) human primary mesothelial cell cultures were
incubated with increasing doses of TS, GV or TS + GV for 18 hours, and assessed for
PRX3 expression after reducing SDS-PAGE by immunoblotting. The formation of the
modified species of PRX3 in response to TS was less prominent in primary mesothelial
cells.
Figure 4.5. shPRX3 cells are less sensitive to TS than WT MM cells. (A) PRX3
expression in cells treated with scrambled control (Sc) or PRX3 siRNA for 48 and 72 hr.
(B) Cell morphology and density of cells as treated in panel A for 72 hr. (C and D)
Transcript levels for PRX3 and FOXM1 in WT HM, HMshCtrl cells and HMshPRX3
cell lines (** p < 0.01, * p < 0.05, n.s. = not significant). (E) Cell number in HMshPRX3
cells compared to controls over 4 days (n = 4, *** p < 0.001). (F) Cell lysates from
HMshCtrl and HMshPRX3 cell lines incubated with 5 µM TS for 18 hrs and were
examined for PRX3, FOXM1, and actin expression by immunoblotting after denaturing
SDS-PAGE. (G) HMshCTRL and HMshPRX3 cells treated with 5 µM TS, lysates were
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collected over time and examined for PRX3 by immunoblotting (ns=non-specific band).
(H) HMshCtrl and HMshPRX3 cells were incubated with increasing concentrations of TS
for 18 hr, total cell mass was determined by staining with crystal violet (n=4, p <0.0001).
Error bars represent SEM. See also Figure S3.

Figure 4.6. TS and gentian violet reduce tumor volume in a SCID mouse xenoplant
model of MM. (A) Hematoxylin and eosin (H&E) stained tumor tissue isolated from the
peritoneal cavity of a DMSO control Fox Chase SCID mouse 5 weeks after injection of
human HM cells. MM tumors were of biphasic morphology with necrotic areas that
stained with eosin (pink staining). Tumors often contained stromal tissue of mouse origin
and locally invaded the pancreas, liver and omentum. (B-D) H & E stained tumor from a
mouse treated with 50 mg/kg TS, 2 mg/kg GV, or 5 mg/kg TS plus 2 mg/kg GV,
respectively, every other day for 21-25 days. Tumor architecture and morphology was
similar between treated and untreated animals. Tumor volumes from animals treated with
5 mg/kg TS (E), 50 mg/kg TS (F), 2mg/kg GV (G), or 2 mg/kg GV plus 5 mg/kg TS (H)
are presented as percent of vehicle control (DMSO) (n = 4-6 animals per group, ** p <
0.01, *** p < 0.001). I) Immunoblot of PRX3 expression in tumor lysates after reducing
SDS-PAGE. Error bars represent SEM. See also Figure S5.
Figure 4.7. A catalytic intermediate of PRX3 is a molecular target of thiostrepton.
During the PRX3 reaction cycle the formation of a disulfide bond at one catalytic dyad
promotes local unfolding. This structural change induces a conformation that favors
adduction of cysteines 108 and 127 in the neighboring catalytic center by TS, leading to
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an irreducible, crosslinked PRX3 dimer and loss of peroxidase activity. Pro-oxidant
compounds (Gentain Violet, Mito-CP, Arsenic) and oxidative stress increase the level of
PRX3 disulfide-bonded dimers and promote adduction by TS. Dimedone attacks sulfenic
acid moieties and blocks disulfide formation, thereby blocking modification of PRX3.
Similarly, mutant forms of PRX3 lacking the peroxidatic or resolving cysteines are not
targets of TS.
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Supplemental Figures

Figure S4.1. Bioenergetic profiles for LP9 and HM cells treated with thiostrepton. (A)
Oxygen consumption rate (OCR) for LP9 cells and LP9 cells treated with 5 µM
thiostrepton (TS) for 6 hrs. (B) Bioenergetic profile for HM cells and HM cells treated
with 5 µM TS for 6 hrs. (C) Extracellular acidification rate (ECAR) for LP9 and HM
cells with or without TS for 6 hrs. (D) Basal ECAR for LP9 and HM cells with or without
TS. Error bars represent SEM.
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Figure S4.2. Immunoprecipitation of PRX3-TS complex from HM cells. (A) MS
spectrum of thiostrepton (TS, 1664.61 Da). (B) Thiostrepton was incubated with
glutathione (GSH, left) or N-acetyl-L-cysteine (NAC, right) in reaction buffer and
analyzed by LC–MS. (C) Whole cell lysate (WCL) from HM cells treated with 5 µM TS
and 1 µM gentian violet (T/G) were resolved by reducing and denaturing PAGE and
immunoblotted for PRX3 (Lanes 1 and 2). PRX3 was immunoprecipitated from 100 µg
of total protein from control cell lysates (O) and T/G lysates and resolved by reducing
and denaturing PAGE (lanes 3 and 4) (D) Bands corresponding to PRX3 monomers (~23
kD) and dimers (~40 kD) were recovered from the gel in C and trypsin digested. Peptides
corresponding to PRX3 were identified by LC-MS/MS.
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Figure S4.3. shPRX3 cells have reduced FOXM1 expression. (A) PRX3 transcript levels
in H2373 cells and shPRX3 H2373 (H2shPRX3) cells (n=3 * p < 0.05). (B) Nuclear
staining to determine cell number in H2373 cells and H2shPRX3 cells (n=4). (C)
FOXM1 transcript levels in H2373 cells and H2shPRX3 cells (n=3, * p < 0.05). (D)
Nuclear staining to determine cell number in HM cells transfected with scramble or
FOXM1 siRNA (n=4, ***p < 0.001). Error bars represent SEM. E) WT and HMshPRX3
cells were fixed and immunostained for FOXM1 and CoxIV (to visualize mitochondrial
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structures); nuclei were counterstained with DAPI (scale bar = 10 µm). F) Regions of
interest were drawn around the nucleus (Nuc, white circle) and mitochondrial
compartment (Cyto/Mito, blue half circle). Mean fluorescence intensity (MFI) is plotted
in G for representative mitochondrial and nuclear compartments of indicated cell lines (n
= 10 cells). Error bars represent SEM
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Figure S4.4. TS inhibits tumor progression in a subcutaneous SCID mouse xenograft
model of MM. A) Fox Chase SCID mice were injected subcutaneously with HM cells as
described in supplementary Materials and Methods.

After tumors became palpable

(about 2 weeks) mice were injected IP with 5 mg/kg TS dissolved in 10%
dimethylacetamide (10% DMA) or vehicle control every other day for 3-4 weeks. Just
prior to each injection tumor volume was estimated using calipers. At sacrifice, tumors
were dissected and tumor volumes were measured; tumor volume in TS treated animals
was significantly different from that of controls (n = 6 mice per group, results shown are
representative of 2 independent experiments, ***p < 0.001, *** p < 0.01, * p < 0.05).
Analysis of lung and liver specimens revealed no evidence of cytotoxicity due to TS
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treatment.

B)

Paraffin-embedded

tumor

sections

were

processed

for

immunohistochemical detection of FOXM1 by IHC (scale bar = 50 µm). C) Nuclear
FOXM1 expression was quantified by counting the number of cells with positive nuclear
staining in 5 quadrants per section (n=5, ** p < 0.01). Error bars represent SEM.
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Figure S4.5. Expression of FOXM1 in mouse intraperitoneal MM xenoplants. A) Freefloating tumor spheroids measured 3-5 mm in diameter and often contained necrotic areas
(scale bar = 0.5 mm). B) Tumor spheroids were typically encapsulated by layers of
FOXM1-positive cells of unknown origin. C and D) FOXM1-positive tumor cells often
displayed clear areas between cells, a histological feature of MM due to the presence of
microvilli.

FOXM1-positive tumor tissue was commonly interspersed with stroma

characterized by fibroblastic cells, presumably of mouse origin. E and F) Mesenteric
tumors often showed evidence of invasion into abdominal organs such as liver and
pancreas (scale bar = 50 µm). G) FOXM1 and PRX3 immunohistochemistry staining in
vehicle and 50 mg/kg TS tumor sections (scale bar top panels = 0.5 mm, bottom sections
= 100 µm)
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Supplemental Methods

Materials: Thiostrepton was purchased from EMB Biochemicals (Billerica, MA).
Gentian violet (Zhang et al.) was a kind gift from J. Arbiser (Emory University, Atlanta,
GA). Dimedone, glutathione, N-acetyl-L-cysteine, and N-ethyl maleimide were
purchased from Sigma (St. Louis, MO). Tris (2-carboxyethyl) phosphine (TCEP) was
purchased from Thermo Scientific (Rockford, IL).
Primary mesothelial cells. Acites fluid was processed for the isolation and cultivation of
mesothelial cells as previously described (Xiang et al., 2011). All protocols for the
collection of human specimens were approved by the University of Vermont Institutional
Review Board, and specimens were obtained with permission from patients as reflected
by signed informed consents.
Generation of shPRX3 stable cell lines and si-RNA to PRX3. To establish stable
shPRX3 and pLKO.1 (shCtrl) cell lines, 1.25 X 105 HM or H2373 cells were plated into
35 mm tissue culture dishes and allowed to adhere overnight. The following day 150 µL
of medium containing shPRX3 lentiviral particles or shCtrl particles was added to cells
for 18 hr. Virus particles were removed by washing and cells were incubated with
complete media.

After 2 days culture media was replaced with complete media

containing 2µg/mL puromycin and subsequently changed every 2 days until control nontransduced cells were completely non-viable
Mass spectrometry of rPRX3.PRX3 dimers were cut from the gel, incubated in 100
mM N-ethyl maleimide for 30 min, and digested by “in gel” cleavage (Wilm et al., 1996)
at 37°C with 12.5 ng/mL sequence grade trypsin in buffer consisting of 20 mM Tris-HCl,
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pH 8.0, and 5 mM CaCl 2. Peptides were extracted from the gel with a 4% ARISTARgrade formic acid, 60% acetonitrile solution and examined in a matrix-assisted laserdesorption

ionization-time-of-flight

time-of-flight

(MALDI-TOF-TOF)

mass

spectrometer (4800 Proteomics Analyzer, Applied Biosystems), using α-cyano-hydroxytrans-cinnamic acid as the matrix. The instrument was calibrated with bovine trypsin
autolysis products (m/z values 2163.057 and 2273.160) and a calcium-related matrix ion
(m/z value 1060.048). Peptide masses were identified by manual peptide fingerprinting,
including the addition of 125.125 Da, the molecular weight for NEM, for cysteine
containing peptides.
In vitro TR-TRX-PRX3 system. The human PRDX3 gene (residues 62-256) was codon
optimized for expression in Escherichia coli by GenScript and subcloned into the
pET15b vector. The resultant protein (residues 62-256) contained a non-cleavable, Nterminal His-tag. The Cys to Ser variants (C108S, C127S, and C229S) were generated
using the QuickChange protocol and the appropriate primers (Stratagene). The proteins
were expressed in C41(DE3) cells and purified using nickel-NTA (Qiagen), Q-Sepharose
FF and Superdex 200 columns (both GE Healthcare). The final storage buffer was 25
mM Hepes pH 7.5, 100 mM NaCl. Non-tagged wild-type PRX3 was purified using
established procedures (add 24003226). Comparable amounts of thiostrepton adducts
were observed in control reactions with either non-tagged or tagged wild-type Prx3. E.
coli thioredoxin reductase (TR) and E. coli thioredoxin 2 (Trx2, the trxC gene product)
were expressed and purified as previously described (10828978)
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Immunoprecipitation. Cell lysates from cells treated with DMSO or thiostrepton and
gentian violet were prepared in immunoprecipitation (IP) lysis buffer (500 mM Tris-Cl
pH 7.5, 150 mM NaCl, 1% NP-40, 0.2% SDS, 0.2% CHAPS, 20 mM N-ethyl maleimide
and protease inhibitor cocktail (Roche)) and 0.5 mgs of total protein was incubated with 1
µg anti-peroxiredoxin 3 antibody for 1 hr at 4°C on an orbital rocker.

50 µL of

equilibrated protein G magnetic Dynabeads (Life Technologies) were added to each tube
and rocked for 1 hour at 4°C. Protein/bead complexes were immobilized on a magnetic
support and washed 5X with IP buffer, mixing by vortexing between each wash. Proteins
were removed from Dynabeads with the addition of 5X sample buffer and heated at 95°C
for 10 minutes before separation by SDS-PAGE. 2 µL of a 25 µL total volume was used
for western blot to detect complex formation while the remaining volume was used for
Coomassie Blue staining and MS analysis. Gel bands were prepared for MS as described
in the main text LC-MS/MS experimental procedures.
Relative potency and EC50. REP measurements using Gen5 software are based on a
constrained model whereby the software “constrains” the reference and treatment curves
so that parameters for non-linear functions can be calculated together. The REP describes
the difference between the control and treatment curves to compare two (or more)
response curves. The EC50 for TS and GV was calculated for each cell line by calculating
the concentration of TS needed to reduce cell mass to 50% of untreated.
Transfection Protocol for mito-roGFP. 1 µg of mito-roGFP expression plasmid DNA
was mixed with 7.5 µL Lipofectamine 2000 (Life Sciences, Grand Island, NY) in 0.5 mL
Optimem (Corning cellgro, Manassas, VA). DNA/Lipofectamine 2000 complexes were
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incubated at RT for 30 min and then added drop-wise to cell cultures in Optimem. After
4 hrs cells were washed once with 1X PBS, trypsinized, and re-plated in 35 mm glass
bottom imaging dishes (MaTek, Ashland, MA) in complete media.
Bioenergetic profiles: 40,000 cells were plated into individual wells of a XF24 cell
culture microplate in complete media excluding cells from 4 wells. The following day
cells were washed 1X with XF assay media and 560 µL of assay media was added back
to each well. Cells were allowed to equilibrate for 30 mins in a 37˚C CO 2 free incubator
before loading into a XF24 extracellular flux analyzer temperature adjusted to 37˚C
(Seahorse Biosceince, Billerica, MA). Sensor cartridges were equilibrated with XF
celebrant for 24 hours before loading with inhibitors. Inhibitor concentrations were
titrated to determine optimal drug concentrations to establish bioenergetic profiles (data
not shown), final concentrations used were 1 µM oligomycin, 0.75 µM carbonyl cyanide
m-chlorophenyl hydrazone (CCCP), and 1 µM rotenone and antimycin A. Oxygen and
proton concentrations were measured every 8.5 min for 1 hr and 35 min, inhibitors
(oligomycin, CCCP, rotenone/antimycin A, respectively) to measure mitochondrial stress
were added to the plates through the microinjection ports every 17 min. Oxygen
consumption rates (OCR) and extracellular acidification rates (ECAR) , as well as reserve
capacity (difference between maximal and basal OCR), are shown for 5 replicates and 2
independent experiments. Cells were stained with 4 µg/mL Hoescht 33342 (Life
Technologies) following each run to ensure equal cell density (not shown).
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Immunofluorescence. HM and HM shPRX3 cells were plated on sterile 18-mm glass
coverslips (Fischer Scientific, Pittsburg, PA) and fixed the following day with fresh 3.4%
paraformaldehyde and permeabilized with 0.3% Triton X 100. Coverslips were blocked
with 1.5% bovine serum albumin (BSA) in PBS for 1 hr at room temperature (RT).
Coverslips were incubated with primary antibodies anti-FOXM1 K-19 and anti-CoxIV
(Abcam, Cambridge, UK) diluted 1:200 in 1.5% BSA for 1 hr at RT. Coverslips were
washed 5X5 min with PBS and incubated with secondary goat anti-rabbit 594
(Invitrogen, 1:400) and donkey anti-mouse 488 (Invitrogen, 1:400) antibodies for 1 hr at
RT. Coverslips were washed 5X5 min with PBS, with the final wash containing DAPI
(Invitrogen, 1:4000), and mounted on glass slides with Aqua-Poly/Mount (Polysciences,
Inc, Warrington, PA). Images were collected on a Nikon Ti-E inverted microscope with a
60x oil immersion objective. Exposure times were adjusted based on secondary antibody
controls.
LC-MS/MS. Samples were prepared as described above and analyzed by LC-MS/MS on
a linear ion trap LTQ-Orbitrap XL Mass Spectrometer (Thermo Fisher Scientific, MA).
6uL of the material was loaded onto a 100 um x 120 mm capillary column packed with
MAGIC C18 (5 um particle size, 20 nm pore size, Michrom Bioresources, CA) at a flow
rate of 500 nL/min. Peptides were separated by a gradient of 5-35% CH3 CN/ 0.1% formic
acid over 100 minutes, 40-100% CH3 CN/0.1% formic acid in 5 minutes, and 100%
CH3CN for 10 minutes. Product ion spectra were searched using the SEQUEST search
engine on Proteome Discoverer 1.4 (Thermo Fisher Scientific, MA) against a curated
Human database with sequences in forward and reverse orientations. The database was

191

indexed to allow for full trypsin enzymatic activity, two missed cleavages, and peptides
between the MW of 350-5000. Search parameters set the mass tolerance at 20 ppm for
precursor ions and 0.8 Da for fragment ions. Cross-correlation (Xcorr) significance filters
were applied to limit the false positive rates to less than 1% for each sample. Other filters
applied were a minimum peptide cutoff of 2 as well as DeltaCN >0.1.
Immunohistochemistry (IHC). Tumor and tissue sections were deparaffinized in xylene
(3 x 15 minutes) and subsequently rehydrated in a graded ethanol series (100% to 50%
ethanol). Slides were then subjected to antigen retrieval using a 1X DAKO solution
(Dako, Glostrup, Denmark) at 96 C according to the manufacturer’s specifications. IHC
was performed using antibodies to FOXM1 C-20 (Santa Cruz Biotechnology), and PRX3
(Ab Frontier) according to the manufacturers’ specifications; incubations with these
antibodies were performed for half an hour. 3’3-diaminobenzidine (DAB) was then
applied to each slide, rinsed off, and counterstained with hematoxylin prior to fixing with
Aqua-Poly/Mount (Polysciences Inc., Warrington, PA), and coverslipped.
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Chapter 5: Summary and Future Directions

The work presented here shows that targeting the thioredoxin reductase 2 (TR2)thioredoxin 2 (TRX2)-peroxiredoxin 3 (PRX3) pathway in malignant mesothelioma
(MM) is a feasible therapeutic strategy. Initial observations indicated that MM cells have
increased expression of the mitochondrial TR2-TRX2-PRX3 antioxidant network,
presumably to counteract the high levels of mitochondrial oxidants produced in these
cells (Newick et al., 2012). We further identified mitochondrial metabolic alterations that
may contribute to dysregulated redox status. MM cells were found to have an altered
mitochondrial bioenergetic profile compared to immortalized LP9 mesothelial cells,
which included reduced mitochondrial respiratory reserve capacity. The mitochondrial
reserve capacity (difference between maximal and basal respiration) is a qualitative
indicator of mitochondrial energy status (Hill et al., 2012). Alterations in reserve capacity
are complex and can be attributed to substrate supply, ATP demand, ETC complex
integrity/expression, allosteric regulation of metabolic enzymes, mitochondrial structure,
and oxidative stress (Hill et al., 2012). Reduced reserve capacity limits the ability for
mitochondria to buffer changes in oxidant levels (Hill et al., 2009), and we observed that
HM mitochondrial metabolism was more sensitive to the pro-oxidant thiostrepton (TS)
than LP9 cells.
Recent evidence has emphasized that distinct metabolic signatures dictate
responses to chemotherapeutics (Birsoy et al., 2014), and therefore characterizing
alterations in metabolism of tumor cells will support better drug development. Over the
past 5 years we have identified a number of compounds that interfere with mitochondrial
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redox balance that lead to MM cell death. We have attributed the sensitivity of tumor
cells as compared to normal cells is based on the altered redox status that puts MM cells
in a pro-oxidant state, reducing their capacity to tolerate increases in oxidant levels. We
have not investigated the potency of these compounds under variable metabolic
conditions, such as reduced oxygen and nutrient levels that are common to tumor
microenvironments (Hanahan and Weinberg, 2011). Using bioenergetic profiling under
varying environmental conditions, we could identify metabolic signatures that promote
the activity of compounds such as TS and gentian violet (GV). Certainly under hypoxic
conditions, common to human tumors, the activity of TS might be accentuated due to the
increased oxidant levels associated with low oxygen (Fruehauf et al., 2007). The
identification of common metabolic signatures that predict responsiveness to these
treatments would support clinical trials in the most relevant of tumor types.
Peroxiredoxin 3 is a relevant target of TS, as irreversible modification of PRX3
dimers induces mitochondrial oxidative stress (Newick et al., 2012). Using mass
spectrometry and site-directed mutagenesis, we identified two cysteine residues in PRX3
that are targets of adduction by TS, the peroxidatic cysteine 108 and the conserved noncatalytic cysteine 127. During catalysis of H 2O 2 PRX3 dimers undergo structural
rearrangements that facilitate disulfide bond formation between opposing monomers,
which is required for enzyme reactivation (Perkins et al., 2013). Increasing mitochondrial
oxidative stress with Mito-CP or by “stalling” PRX3 regeneration through inhibition of
its primary oxidoreductase TRX2 with gentian violet (GV), dramatically increases
modification by TS. These observations led us to hypothesize that a PRX3 catalytic
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intermediate formed during the metabolism of H 2O 2 is the preferred target for TS. The
initial step in the metabolism of peroxide by PRX3 is the formation of a sulfenic acid
intermediate on the peroxidatic Cys108 which precludes disulfide bond formation.
Trapping of this intermediate with the sulfenic acid probe dimedone effectively blocked
TS induced modifications of PRX3. Using in silico approaches, we are currently
investigating structural changes that occur during catalysis that might expose or position
Cys108 and/or Cys127 for attack by TS; this would further support catalysis as a
requirement for TS adduction. There is no crystal structure for PRX3 in the locally
unfolded state that occurs during disulfide formation (Perkins et al., 2013), but there is a
structure for the human 2-cys peroxiredoxin PRXIV (Cao et al., 2011) which is similar in
structure to PRX3.
Based on the above evidence, we have envisioned approaches to confirm an
intermediate in the PRX3 catalytic cycle is a target for adduction by TS. Preliminary
evidence from our lab indicates pre-treatment of cells with the mitochondrial targeted
antioxidant MitoQ prior to TS incubation reduces modifications to PRX3. MitoQ has
been shown to reduce the redox status of the mitochondria (Kelso et al., 2001), which
would reduce the need for PRX3 catalysis. These compounds can elicit side effects on
mitochondrial structure and increase ROS levels (Cunniff et al., 2013) therefore using
other tools such as genetically encoded mitochondrial catalase (mito-catalase) may be of
more relevance. Additionally, we could exchange the mitochondria of MM cells with that
of normal cells, and then monitor TS:PRX3 complex formation. These studies would
shed light on the underlying mitochondrial redox status and how it dictates the action of
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TS, as well as identify retrograde signaling events dictated by mitochondria in tumor cells
(Yun and Finkel, 2014).
Modifications to PRX3 in MM cells by TS accumulate at an increased rate and to
a greater extent than in normal mesothelial cells, indicating this antioxidant network is
most likely utilized to a greater degree in MM cells. To this date there is no accurate way
to measure peroxiredoxin activity in complex cell systems and our data indicates
reconstitution of this enzyme network in vitro does not recapitulate the adduction of
PRX3 by TS in cells. This is intriguing as we can effectively drive PRX3 catalysis in
vitro, but modifications by TS in this system are modest at best. These findings indicate
that the activity of TS is most likely increased by some unknown cellular constituents.
The oxidation state of TRX2, the primary electron supplier for the catalytic cycle of
PRX3, may also be compromised in MM cells under chronic oxidative stress,
contributing to the longevity of PRX3 intermediates. The most accurate yet difficult
approach to identify the species of TS that adducts PRX3 would be through mass
spectrometry of immunoprecipitated PRX3 complexes. We tirelessly attempted to
identify TS:PRX3 peptides without success and it may be necessary to develop a tagged
version of TS that does not affect the adduction mechanism.
It was hypothesized, prior to our publication identifying PRX3 as a target of TS
(Newick et al., 2012), that there must be a mitochondrial target of TS, as the earliest
effects of the compound are elicited on mitochondria (Qiao et al., 2012). We confirmed
that PRX3 was indeed a primary target of TS using HM cells harboring shRNAs to
PRX3. shPRX3 cells failed to accumulate TS induced PRX3 modifications as compared
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to wild type controls, and showed significantly reduced cytotoxic sensitivity to increasing
concentrations of TS. Furthermore, reduction of FOXM1 expression was not observed in
shPRX3 cells, indicating a possible role for PRX3 in the regulation of FOXM1
expression.
An interesting finding came out of characterizing MM cells transduced with
shRNAs to PRX3 and will be the primary focus of my future work. shPRX3 cells were
found to have reduced transcript and protein levels for the oncogenic transcription factor
FOXM1. These cells also failed to proliferate to the extent of wild type controls, which
has been observed in breast cancer cells with reduced PRX3 expression (Chua et al.,
2010). FOXM1 has been shown to respond to changes in oxidant levels (Cunniff et al.,
2013; Park et al., 2009) and we hypothesize that its expression is tuned to the levels of
cellular ROS. In normal mesothelial cells and NIH3T3 fibroblasts, increased oxidant
levels drive FOXM1 expression, while in MM tumor cells ROS leads to reduced FOXM1
expression (Appendix Figure 1) (Cunniff et al., 2013; Park et al., 2009). We hypothesize
that FOXM1 expression is dictated by a bell shaped curve of oxidant levels, where
moderate levels sustain FOXM1 expression while pro-oxidant environments reduce
expression (Figure 5.1). MM cells transduced with shPRX3 have increased levels of
mitochondrial oxidants (Appendix Figure 1) and reduced FOXM1 expression, a finding
in agreement with experiments in which increasing mitochondrial oxidants with rotenone
in MM cells led to reduction in FOXM1 expression (Cunniff et al., 2013). PRXs can
function as both peroxidases and chaperones (Rhee et al., 2011), so further investigation
is needed to decipher which functional aspect of PRX3 influences FOXM1 expression
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levels. Preliminary experiments with N-acetyl-L-cysteine (NAC) indicate that reducing
the redox status of shPRX3 cells does not rescue FOXM1 expression, and therefore
FOXM1 may be responding to other phenotypic features of shPRX3 cells (Appendix
Figure 1). These experiments need to be followed up with more specific technical
approaches, such as using mitochondrial targeted antioxidants such as MitoQ or the
genetically encoded mito-catalase to alter mitochondrial redox status (Chang et al., 2014).

Figure 5.1 Differential response of FOXM1 to cellular oxidant
levels. FOXM1 expression is dictated by a bell curve of oxidants.
Low to moderate levels stimulate expression while high levels
reduce expression.
Additionally, we have identified metabolic aberrations and mitochondrial
structural alterations in shPRX3 cells. shPRX3 cells have increased mitochondrial
membrane potential, ATP levels, oxygen consumption rates, and extracellular
acidification rates as compared to wild type controls (Appendix Figure 2). These
phenotypic changes indicate PRX3 expression levels are important for regulating
mitochondrial metabolism, either through simple buffering of H 2O2 levels or perhaps
through some other mechanism. Although these metabolic alterations increase energy
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levels in the form of ATP they do not support proliferation (See Chapter 3). This is not all
that surprising as metabolic reprogramming in tumor cells shunts glycolytic intermediates
towards biosynthetic and redox pathways, and levels of highly consumed nutrients like
glucose are typically reduced in tumor cells (Birsoy et al., 2014, Cairns et al., 2011).
PRX3 has already been shown to play a role in regulating metabolic programs,
specifically in adipogeneis (Huh et al., 2012), and therefore it is not unlikely that PRX3 is
supporting altered tumor cell metabolism.
Further characterization of shPRX3 cells indicates that the mitochondrial
networks of these cells are hyperfused as compared to the typical fragmented
mitochondrial reticulum that is found in MM cells (Appendix Figure 3). Because
mitochondrial structural rearrangements are required for proper cell cycle progression
(Mitra et al., 2009) we compared cell cycle profiles from wild type and shPRX3 cells.
Interestingly, shPRX3 cells exhibited an altered cell cycle profile with an increase in cells
in the G2/M phase of the cell cycle compared to wild types. We could mimic this result
by treating wild type cells with the mitochondrial fission inhibitor mdivi-1, which
induces hyperfusion of mitochondrial networks (Cassidy-Stone et al., 2008). Treatment
of wild type cells with mdivi-1 also recapitulated the G2/M cell cycle profile seen in
shPRX3 cells (Appendix Figure 3).

Interestingly, PRX3 overexpression leads to

disintegration of mitochondrial networks (data not shown), implicating a possible
structural role for PRX3 in mitochondria. More research will be required to connect the
metabolic, structural, and proliferative defects identified in MM cells with reduced PRX3
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expression, and these studies may further our understanding of other roles of PRX3 that
are independent of its peroxidase activity.
Mitochondrial oxidants have been shown to dictate cellular fates and participate
in retrograde signaling that regulates cellular processes distinct from mitochondrial
metabolism (Yun and Finkel, 2014). Our data indicate that mitochondrial redox status,
specifically dictated by PRX3, is a requirement for MM tumor survival, regulates MM
tumor metabolism, and is a highly relevant chemotherapeutic target. Our data also
support the requirement of metabolic adaptations that occur in cancer (Cairns et al., 2011)
and the sensitivity of these networks to perturbations in redox status.
Taken together we have identified compounds that perturb mitochondrial
function, alone or in combination, and elicit MM tumor cell death. We show that these
compounds have in vivo efficacy by reducing tumor volume in a xenoplant model of
MM. Recovery of the TS:PRX3 complex from tumor tissue indicates the mechanism of
action in vivo is identical to that in vitro. Further analysis is required to determine if the
presence of the TS:PRX3 complex in vivo is a prognostic indicator of efficacy. Since our
data indicates combinatorial therapy using gentian violet and thiostrepton is the most
promising avenue to reduce tumor cell burden, it is imperative to identify the ideal
concentration of each agent and effective delivery methods for translation into human
clinical trials. Furthermore, we have identified a novel signaling axis in which some
aspect of PRX3 function dictates mitochondrial metabolism and function, which
influences FOXM1 expression and cell cycle progression. In conclusion, these studies
support further investigation into identifying unique metabolic signatures in tumor cells
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that may be potential drug targets, and support the rational of pursuing thiostrepton and
gentian violet in the treatment of malignant mesothelioma in clinical trials.
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Appendix

Appendix Figure 1. Differential response of FOXM1 expression to oxidants in LP9m
HM, and HMshPRX3 cells. A) HM and HMshPRX3 cells were treated with 1 mM Nacetyl-L-cysteine (NAC), or menadione (20 and 60 µM) for 18 hrs and immunoblotted
after reducing SDS-PAGE. Note the differential effects of oxidants on on FOXM1
expression between cell lines. B) LP9 mesothelial and HM mesothelioma cell lines were
incubated with increasing concentrations of glucose oxidase for 18 hrs and immunblotted
after reducing SDS-PAGE. Simlar reponses are oberserved with rotenone and menadione.
C) Mitochondrial oxidants in HM and HMshPRX3 cells as analyzed by flow cytometry
after loading with the mitochondrial targeted oxidant probe MitoSOX Red
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Appendix Figure 2. Metabolic alterations in shPRX3 cells compared to wild type
controls. A) Mitochondrial membrane potential in HM and H2373 mesothelioma cells
and their respective shPRX3 couterparts measured in a fluoresecent plate reader with
tetramethylrhodamine ethyl ester (TMRE), a dye that accumulates in energized
mitochondria. Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) is a proton
ionophore that dissapates mitochondrial membrane potential. (n=4, **p<0.01) B)
Relative ATP levels in indicated cell lines. Cells were treated with 30 µM oligomycin
(Oligo) for 30 mins prior to measuring ATP levels to inhibit ATP synthase and reduce
ATP. (n=4, ***p<0.001) C and D) Basal oxygen consumption rate (OCR) and basal
extracellular acidification rate (ECAR) of indicated cell lines. (n=5, ** p<0.01)
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Appendix Figure 3. Mitochondrial structural and cell cycle abnormalities in
HMshPRX3 cells. A) Indicated cell lines were transfected with mito-dsRED
(mitochondria) and cfp-Lifeact (actin) and imaged by live cell microscopy (scale bar = 10
µm). Note the typical fragmented network in HM cells is a hyperfused reticulum in
shPRX3 cells. B) Quantitative measurement of mitochondrial length and branching
(Form Factor) of HM and HMshPRX3 cells. HM cells incubated with 10 µM of the
fission inhibitor mdivi-1 for 18hrs recapitulate the hyperfused network of HMshPRX3
cells (n=8, **p <0.01, ***p < 0.001) C) Representative cell cycle profile of HM and
HMshPRX3 cells. D) Percent of cells in the G2/M phase of the cell cycle. shPRX3 cells
have a larger percentage of cells in G2/M. Treatment of HM cells with 2.5 µM
thiostrepton (TS) for 18 hrs arrests cells in G2/M and HmshPRX3 cells are resistant to
the TS induced cell cycle block. HM cells incubated with 10 µM mdivi-1 (md1) for 18 hr
mimics the G2/M profile of shPRX3 cells (n = 2, **p <0.01, n.s. = not specific).
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